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“Everything is going to be fine in the end. 
If it’s not fine it’s not the end.” 
 
Oscar Wilde 
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Zusammenfassung 
Unter Endotoxintoleranz versteht man die Toleranzentwicklung in Monozyten und anderen 
Immunzellen gegenüber Lipopolysaccharid (LPS) aufgrund einer vorangegangenen 
Endotoxin-Stimulation, welche in vivo als auch in vitro beobachtet werden kann. Dabei 
zeichnen sich Endotoxin-tolerante Monozyten und Makrophagen durch eine verminderte 
Induktion pro-inflammatorischer Zytokine aus, während Gene, welche für die Phagozytose 
und Wundheilung verantwortlich sind, weiterhin exprimiert werden. LPS-induzierte Toleranz 
kann bis zu mehrere Tage andauern, selbst wenn der auslösende Stimulus nicht mehr 
vorhanden ist. Eine mögliche Erklärung für die vorübergehende Inhibierung pro-
inflammatorischer Gene könnten demnach epigenetische Veränderungen sein. Um diese 
Frage zu beantworten, wurden humane LPS-tolerante Monozyten mittels eines in vitro 
Endotoxintoleranz-Modells auf epigenetische Veränderungen untersucht. 
Der erste Teil der Arbeit konzentrierte sich auf die Analyse individueller, immunrelevanter 
Gene. Die Promotorregionen der pro-inflammatorischen Gene TNF und CXCL10 zeigten in 
toleranten Monozyten eine Verringerung der Transkription einhergehend mit einer 
verminderten Induktion der aktivierenden Histonmodifikationen H3K27ac und H4ac auf. Die 
Expression dieser Gene war in den toleranten Monozyten zudem sehr stark inhibiert, was auf 
eine hohe LPS-Toleranzwirkung schließen lässt (highly tolerizable genes). Demgegenüber 
wiesen Gene wie IL6 und IL1B eine Zunahme an H4ac und H3K27ac auf, während ihre 
Genexpression in widersprüchlicher Weise reduziert war. Die Genexpression von IL6 und 
IL1B war allerdings noch gut nachweisbar, selbst in toleranten Monozyten (intermediately 
tolerizable genes). Darüber hinaus war insbesondere die IL6-Genexpression im Vergleich zu 
den Veränderungen der Histonmodifikationen verstärkt von der Signaltransduktionskapazität 
toleranter Monozyten abhängig, wohingegen die stark tolerisierbaren Gene TNF und 
CXCL10 eine verminderte Induktion aktivierender Histonmarker unabhängig von der 
Signalstärke aufwiesen. Weitere Untersuchungen der DNA-Methylierung und der 
Histonmodifikationen H3K9me2, H3K27me3 und H4K20me3 zeigten, dass diese repressiven 
epigenetischen Marker in pro-inflammatorischen Genen toleranter Monozyten nicht erhöht 
waren. Lediglich konnte in toleranten, re-stimulierten Monozyten vereinzelt eine Zunahme an 
H3K9me2 und H4K20me3 in genomischen Regionen upstream von IL1-verwandten Genen 
(IL1B, IL1A und IL1R1) identifiziert werden, während IL6 – widersprüchlich zur 
Genexpression – eine Verringerung an repressiven H3K27me3 aufzeigte. 
Der zweite Teil befasste sich mit der Analyse globaler epigenetischer Veränderungen von 
Histonmodifikationen und DNA Methylierung im Vergleich zur Gesamt-mRNA-Expression 
unter zur Hilfenahme von Next Generation Sequenzierungen. Hier konnte man eine starke 
Verschiebung von aktivierenden Histonmodifikationen (H4ac, H3K27ac) in naïven 
Monozyten zu repressiven Histonmarkern (H3K9me2, H3K27me3, H4K20me3) in toleranten, 
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re-stimulierten Zellen beobachten. Insbesondere zeigten intergenische Genomregionen 
einen verstärkten Anstieg an repressiven Histonmodifikationen, was auf eine mögliche 
regulatorische Funktion dieser Bereiche in der Endotoxintoleranz schließen lässt. Weiterhin 
wurden die differentiell regulierten Regionen auf Transkriptionsfaktor-Bindestellen 
untersucht. Genomische Bereiche, die eine Anreicherung an repressiven H3K9me2 und 
H4K20me3 in toleranten Monozyten zeigten, wiesen verstärkt das Bindungsmotiv für SMAD3 
auf. Zudem ergaben funktionale Gene Ontology (GO)-Analysen dieser Regionen eine 
Überrepräsentation von Genen, welche an Signalwegen und der Transkription beteiligt sind. 
Dies impliziert eine mögliche Rolle von TGFβ in der SMAD3-vermittelten Induktion 
repressiver Histonmodifikationen in intergenischen Regionen und Genen, welche für die 
Signalkaskade/Transktiptionsmaschinerie wichtig sind. Im Gegensatz dazu zeigten tolerante 
Monozyten eine Reduzierung in der DNA Methylierung auf, welche auch nicht mit den 
beschriebenen Veränderungen der Histonmodifikationen korrelierte. Auffallend war, dass 
mehrere tausend genomische Regionen (> 10 000) Veränderungen in den untersuchten 
Histonmodifkationen und der DNA-Methylierung aufwiesen, allerdings insgesamt nur 3638 
Gene differentiell exprimiert waren. Korrelationsuntersuchungen der identifizierten 
epigenetischen Veränderungen mit der globalen mRNA Expression in toleranten Monozyten 
zeigten, dass etwa 27 % der differentiell exprimierten Gene eine epigenetische Signatur 
aufwiesen, welche im Einklang mit dem Histon-Code steht, während Veränderungen der 
DNA-Methylierung keinen Einfluss auf die Genexpression zu haben schien. 
Die vorliegenden Daten zeigen, dass die epigenetische Umgebung von Monozyten stark von 
der Endotoxintoleranz beeinträchtigt wird. Es existiert jedoch kein gemeinsames 
epigenetisches Muster, welches die Toleranzinduktion einzelner pro-inflammatorischer 
Zytokine erklären könnte. Vielmehr scheint es, dass verschiedene Mechanismen direkt oder 
indirekt zusammenwirken und somit zur veränderten Genexpression der Monozyten 
beitragen, die schlussendlich charakteristisch für Endotoxintoleranz sind. Ein tiefgreifendes 
Verständnis der globalen epigenetischen Veränderungen in der Endotoxintoleranz kann 
zudem die Grundlage für neue Behandlungsstrategien von Sepsispatienten liefern. Hier führt 
eine systemische Immuntoleranz (auch als ‚Immunparalyse‘ bezeichnet) gegenüber 
eindringender Erreger und deren Bestandteile zu einer erhöhten Sterblichkeitsrate. 
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Summary 
The phenomenon by which monocytes and other immune cells become tolerant in vivo as 
well as in vivo after repetitive exposure to lipopolysaccharide (LPS) is known as endotoxin 
tolerance. Endotoxin-tolerant monocytes and macrophages are characterized by a 
diminished induction capacity of pro-inflammatory cytokines, whereas genes involved in 
phagocytosis and wound healing are basically unaffected. As LPS tolerance lasts for several 
days, even after the stimulus is cleared, a transient silencing of immune response genes by 
epigenetic changes is very likely. To answer this question, an in vitro endotoxin tolerance 
model with human monocytes was used to analyze alterations in the epigenetic landscape of 
LPS-tolerant cells. 
The first part of the study focused on the analysis of individual immune response genes. The 
promoter regions of the pro-inflammatory genes TNF and CXCL10 showed a reduction in 
transcription-linked histone marks, in particular H4ac and H3K27ac, in tolerant monocytes. 
These genes were also characterized by a high tolerization effect indicated by an abolished 
gene expression in endotoxin tolerance (highly tolerizable genes). In contrast, genes like IL6 
and IL1B showed an increase in H4ac and H3K27ac, while their gene expression was 
paradoxically reduced. Notably, gene expression of IL6 and IL1B was still detectable even in 
tolerant monocytes (intermediately tolerizable genes). Moreover, particularly the IL6 gene 
expression was dependent on signaling strength in tolerant monocytes rather than changes 
in histone modifications, whereas the highly tolerizable genes TNF and CXCL10 possessed 
diminished induction in activating histone modifications independent of signaling 
transduction. Further analysis of H3K9me2, H3K27me3, H4K20me3 and DNA methylation 
indicated that these repressive epigenetic marks were not enhanced in pro-inflammatory 
genes in tolerant monocytes. Solely, enrichment in H3K9me2 and H4K20me3 in the 
upstream regions of IL1-related genomic loci (IL1B, IL1A and IL1R1) could be identified, 
whereas IL6 – conversely to its gene expression – showed a reduction in repressive 
H3K27me3 in tolerant monocytes treated with LPS. 
The second part focused on the analysis of global epigenetic changes in histone marks and 
DNA methylation in comparison to total mRNA expression using next generation sequencing 
approaches. A drastic shift was observed from activating histone modifications (H4ac, 
H3K27ac) in naïve monocytes to repressive ones (H3K9me2, H3K27me3, H4K20me3) in 
tolerant cells treated with LPS. In particular intergenic regions gained repressive histone 
modifications implying a regulatory function in endotoxin tolerance. Analysis of transcription 
factor binding sites within differentially regulated regions identified a significant enrichment 
for the binding motif of SMAD3 in genomic regions enriched for repressive H3K9me2 and 
H4K20me3 in tolerant monocytes. Functional GO enrichment analysis of these regions 
further revealed overrepresentation of genes involved in signaling and transcription.  
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This implies a role of TGFβ in SMAD3-mediated induction of repressive histone modifications 
in intergenic regions and genes important for the signaling transduction/transcription 
machinery. By contrast, DNA methylation was reduced in tolerant monocytes, which did not 
correlate with alterations in histone marks. Strikingly, several thousand genomic regions 
(> 10 000) were differentially regulated by histone modifications and DNA methylation, 
though only 3638 genes in total were differentially expressed. Correlation of the identified 
epigenetic changes with global mRNA expression analysis in tolerant monocytes revealed 
that approximately 27 % of differentially expressed genes showed an epigenetic signature 
consistent with the histone code, while DNA methylation had no impact on gene expression. 
The present data indicate that the epigenetic environment of monocytes is highly affected by 
endotoxin tolerance; however, no common epigenetic pattern exists, which might explain the 
tolerization of specific pro-inflammatory cytokines. It rather demonstrates that different 
mechanisms directly or indirectly act together to downregulate the expression capacity of 
monocytes, which results in the characteristics known for endotoxin tolerance. Hence, 
molecular understanding of these global epigenetic changes in endotoxin tolerance will 
provide the basis for finding novel treatment strategies for sepsis patients, where a systemic 
tolerization of the immune system (so-called ‘immunoparalysis’) to invading pathogens and 
their components increases the patient mortality rate. 
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1. Introduction 
1.1 The Immune System – An Overview 
The immune system is composed of many specialized cell types and soluble factors that use 
a complex array of protective mechanisms to control and eliminate a huge range of potential 
pathogenic organisms and toxic substances. Moreover, it is involved in the anti-tumor 
responses and the regulation of tissue homeostasis, repair and regeneration (Medzhitov 
2008). 
In general, the immune system is didactically divided into two parts: The innate and the 
adaptive immune systems. Innate immunity is an evolutionarily ancient part of host immunity 
and exists in diverse forms in all multicellular organisms – including vertebrates, 
invertebrates and plants. As a first line of host defense against infectious agents and 
dangerous materials, the innate immune response is immediately generated. By contrast, the 
adaptive immune system presumably developed in the jawed fish 500 million years ago and 
is found in the descending vertebrates (Cooper & Alder 2006, Flajnik & Kasahara 2010, 
Murphy et al. 2012b). With a latency of four to seven days, it allows great variability and 
provides the host with a highly specific and individualized immunological memory for 
infections, but also mediates autoimmunity, allergy and allograft rejection (Iwasaki & 
Medzhitov 2010, Janeway 2001, Janeway & Medzhitov 2002, Medzhitov & Janeway 2000). 
Both systems detect structural features of pathogens that mark them as different (non-self) 
from the host (self), and thereby induce a protective immune response to eliminate the 
danger (Medzhitov & Janeway 2002). However, the mechanisms and receptors for host 
defense are distinct: Whereas the innate immune response relies on a limited number of 
germline-encoded receptors that recognize conserved molecular structures shared by many 
pathogens – but not by self-tissues; the adaptive immunity is based on antigen-specific 
receptors, which are assembled by somatic rearrangement of germline gene segments, 
passing a diversification process and providing unique specificity for foreign structures 
(Iwasaki & Medzhitov 2010, Janeway & Medzhitov 2002). 
Initially, invading pathogens are sensed by members of the innate immune system e.g. 
macrophages and dendritic cells, which trigger a fast and robust inflammatory response to 
protect the host (Delves & Roitt 2000, Parkin & Cohen 2001). Inflammation is a complex 
pathophysiological condition that leads to the recruitment of immune cells and clearance of 
infectious agents, but also guides tissue repair and wound healing processes to sites of 
infection (Medzhitov 2008, Takeuchi & Akira 2010). 
Hallmarks of inflammation are pain (dolor), heat (calor), redness (rubor), swelling (tumor) and 
loss of function (functio laesa) (Celsus circa 30 AD, Majno 1975, Nathan 2002, Rather 1971, 
Rock et al. 2010). They result from the increase of blood flow and blood vessel permeability, 
1 
Introduction 
 
release of liquid and inflammatory mediators into the tissue and recruitment of immune cells 
to sites of infection. Inflammation is important as it supports killing of the invading pathogen, 
prevents spreading of infectious agents and promotes tissue repair (Medzhitov 2008, Murphy 
et al. 2012a). 
Additionally, innate immunity plays an essential role in induction and regulation of the 
subsequent adaptive immune response composed of T and B lymphocytes (Iwasaki & 
Medzhitov 2010, Janeway 2001). Activation of dendritic cells by infectious agents results in 
their maturation, induction of co-stimulatory molecules and increased antigen-presentation 
capacity via major histocompatibility complexes (MHCs). Following activation, dendritic cells 
migrate to secondary lymphoid organs e.g. lymph nodes, where they encounter naïve  
T lymphocytes. Within secondary lymphoid organs, dendritic cells function as specialized 
antigen-presenting cells and the interaction of these cells with T lymphocytes mediates 
selection, activation and clonal expansion of T lymphocytes highly specific to antigens 
derived from microbial pathogens. T lymphocytes mediate cell-mediated toxicity of infected 
cells and help to establish humoral immunity by activating specific antibody-producing  
B lymphocytes (Chaplin 2010, Forster et al. 2008, Iwasaki & Medzhitov 2010, Medzhitov & 
Janeway 2002). 
After removal of the inflammatory agent, termination of inflammation and cellular 
homeostasis is achieved by anti-inflammatory mediators and induction of apoptosis in 
immune cells (Foster & Medzhitov 2009, Glass & Saijo 2010, Liew et al. 2005, Serhan 2007, 
Serhan & Savill 2005). 
 
1.2 The Innate Immune Response and Pattern Recognition Receptors 
Initial sensing of invading pathogens like bacteria, viruses or fungi is mediated by  
non-professional immune cells, such as epithelial cells and fibroblasts located at  
host-environment boundaries, as well as by professional cells of the innate immune system. 
Monocytes and macrophages, natural killer (NK) cells and other innate lymphoid cells (Artis 
& Spits 2015), dendritic cells, polymorphonuclear leukocytes like neutrophils, and mast cells 
are implicated as primary effectors during initial inflammation and activation of innate 
immunity (Muralidharan & Mandrekar 2013). The innate immune specificity is genetically 
programmed to detect invariant features of invading microbes. The best-characterized 
microbial sensors of the innate immune system are the so-called pattern recognition 
receptors (PRRs), which detect relatively invariant molecular patterns found in most 
microorganisms. These foreign structures – present only in microbial pathogens among 
entire classes – are referred to as pathogen-associated molecular patterns (PAMPs) (Beutler 
2004, Janeway 1989, Medzhitov & Janeway 2000). 
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Best-known examples of PAMPs include microbial unmethylated DNA, viral double stranded 
RNA and cell wall components of bacteria e.g. lipopolysaccharides (LPS) from gram-
negative bacteria, peptidoglycans and lipoteichoic acids (Beutler 2004, Medzhitov & Janeway 
2000). Moreover, endogenous molecules released from damaged cells by necrosis such as 
high mobility group box 1 (HMGB1), monosodium urate crystals and adenosine triphosphate 
(ATP) can be sensed by PRRs. These immunogenic molecules are termed as damage- or 
danger-associated molecular patterns (DAMPs) (Kaczmarek et al. 2013, Rock et al. 2010, 
Rosin & Okusa 2011). 
The main tasks of PRRs include opsonization, activation of complement and coagulation 
cascades, phagocytosis, induction of apoptosis and activation of inflammatory signaling 
pathways (Janeway & Medzhitov 2002, Medzhitov 2001). PRRs can be broadly categorized 
into three functional classes: Secreted, endocytic and signaling. 
Secreted PRRs (opsonins) bind to microbial cell surfaces and mark pathogens for 
phagocytosis by macrophages and neutrophils. Moreover, some opsonins e.g. C-reactive 
protein (CRP) and mannan-binding lectin (MBL) function as activators of the complement 
system (classical and lectin pathways). Endocytic PRRs such as scavenger receptor and 
mannose receptor are expressed on cell surfaces and mediate recognition and subsequent 
phagocytosis of pathogens without inducing inflammatory mediators (Janeway & Medzhitov 
2002, Jeannin et al. 2008, Medzhitov & Janeway 2000). 
The biggest class of PRRs, including Toll-like receptors (TLRs), RIG-I-like receptors (RLRs) 
and NOD-like receptors (NLRs), activates signaling events. Signaling PRRs are localized in 
membranes – either on cell surfaces or in endosomal/lysosomal organelles (TLRs) – or in the 
cytosol (RLPs, NLPs). After binding to PAMPs or DAMPs, they induce signaling transduction 
cascades leading to activation of different master transcription factors and subsequent 
expression of a variety of immune response genes encoding for pro-inflammatory cytokines, 
type I interferons (IFNs), chemokines, anti-microbial proteins, MHCs and co-stimulatory 
molecules. The transcription factors nuclear factor kappa B (NFκB) and activator protein 1 
(AP1) trigger gene expression of pro-inflammatory cytokines, whereas interferon regulatory 
factors (IRFs) induce production of type I IFNs (Akira et al. 2006, Kawai & Akira 2010, 
Takeuch & Akira 2011). 
 
1.3 LPS Signaling by Toll-like Receptor 4 (TLR4) 
The family of TLRs is among the best-characterized PRRs and plays a key role in pathogen 
recognition and initiation of acute inflammation. In 1996, these PRRs identified in Drosophila 
were discovered to be involved in anti-fungal responses (Lemaitre et al. 1996). One year 
later, the first human homolog for the Toll protein was described (Medzhitov et al. 1997). So 
far, 13 mammalian TLR homologs have been identified, which differ from each other in ligand 
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specificities and localization within the host cell – including 12 in mice (TLR1-9 and  
TLR11-13) and 10 in humans (TLR1-10) (Akira et al. 2006, Beutler 2004, Kawai & Akira 
2010, Murad 2014, Oldenburg et al. 2012, Takeuchi & Akira 2010). 
The host innate immune system recognizes several bacterial virulence factors. Among them 
belong endotoxins from gram-negative bacteria (e.g. LPS, Lipid A) to the most potent 
inflammatory stimulus (Pfeiffer 1892). The glycolipid LPS is the major component of the outer 
membrane of gram-negative bacteria. It consists of a hydrophobic lipid A domain, a core 
polysaccharide, and an O-polysaccharide chain of variable length (Kelly et al. 1991, Nikaido 
1962, Osborn 1963, Raetz & Whitfield 2002). 
The key pattern recognition receptor for detection of gram-negative bacteria and their 
associated endotoxins is TLR4 (Poltorak et al. 1998a, Poltorak et al. 1998b). Together with 
the TLR4 co-receptor cluster of differentiation 14 (CD14) (Wright et al. 1990), endotoxin 
signaling leads to activation of signaling cascades promoting the production of pro-
inflammatory cytokines and IFNs. CD14 is an extrinsic glycosylphosphatidylinositol (GPI)-
anchored membrane protein and was first identified as a marker for monocytes (Goyert et al. 
1986). The 55 kDa glycoprotein CD14 is expressed on the surface of myelomonocytic cells 
or can be secreted in a soluble form (Ulevitch & Tobias 1995). Thus, monocytes and 
macrophages are crucial mediators of inflammation (Zanoni & Granucci 2013). 
The exact signaling pathway of LPS is not completely understood. It is known that a complex 
interaction of several molecules is involved (Fig. 1-1). TLR4 forms a homodimer at the cell 
surface. The LPS-binding protein (LBP) mediates transport of LPS molecules to TLR4 
(Schumann et al. 1990, Tobias et al. 1986). At the plasma membrane, LBP is thought to 
transfer LPS to CD14. For initiation of the transduction pathway, CD14 transfers LPS to the 
myeloid differentiation factor 2 (MD2) that lacks a transmembrane anchor, but is associated 
with TLR4. Once the LPS-TLR4-MD2 complex is formed, the entire complex consisting of 
two blocks of LPS-TLR4-MD2 dimerizes and recruits several cytoplasmic adapter molecules 
through the interaction with the Toll-interleukin-1 receptor (TIR) domain of TLR4. TLR4 is 
unique as it is the only TLR that engages all four adaptors – TIR domain-containing adapter 
protein (TIRAP), myeloid differentiation primary response gene 88 (MyD88), TRIF-related 
adaptor molecule (TRAM) and TIR domain-containing adapter-inducing IFNβ (TRIF). 
Therefore, it is capable of activating both: (1) the TIRAP-MyD88-dependent pathway and (2) 
the TRAM-TRIF-dependent pathway (Akira & Hoshino 2003, Kawai & Akira 2011, Medzhitov 
& Janeway 2000, Murad 2014, Zanoni & Granucci 2013). Notably, CD14 is important for the 
LPS-induced internalization of TLR4 leading to the activation of the MyD88-independent 
(TRIF-dependent) signaling pathway (Zanoni et al. 2011). 
Functionally, MyD88-dependent signaling triggers induction of NFκB and mitogen-activated 
protein (MAP) kinase cascades leading to synergistic production of variable pro-inflammatory 
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genes including tumor necrosis factor (TNF, also known as TNFα1), interleukin-1β (IL-1β),  
IL-6 and CXCL8/IL-8, whereas the MyD88-independent transduction cascade is primary 
involved in expression of type I IFNs e.g. IFNα and IFNβ (Kawai & Akira 2010) (for more 
details see Fig. 1-1). 
 
Fig. 1-1: Simplified diagram of 
LPS signaling through TLR4 
(adapted from Akira et al. 2006, 
Kawai & Akira 2010 and Kawai 
& Akira 2011). LBP coveys LPS 
to CD14 on the cell surface of 
monocytes and macrophages. 
CD14 then transfers LPS to 
MD2 and TLR4, which form a 
complex (homodimer, here 
simplified). TLR4 is capable of 
activating two signaling 
branches by recruitment of 
different adapter combinations. 
(1) TLR4 signaling on the cell 
surface through the TIRAP-
MyD88 signaling pathway 
(MyD88-dependent) leads to the 
first wave of NFκB activation 
(early NFκB) and the production 
of pro-inflammatory cytokines. 
Upon TLR4 activation, MyD88 
recruits several members of the 
IRAK family and TRAF6. 
Following activation, TRAF6 
recruits and interacts with the TAK1 complex, activating it to phosphorylate the IκB kinase (IKK) complex. Once 
activated, the IKK complex can directly phosphorylate IκB, targeting it for degradation and releasing NFκB, which 
translocates into the nucleus and activates the expression of target genes encoding for pro-inflammatory 
cytokines e.g. IL-1β, IL-6 and TNF. Simultaneously, TAK1 initiates the MAP kinase cascade. The MAP kinases 
p38, JNK and ERK1/2 activate CREB and AP1, which target cytokine genes. When IRF5 is activated by TAK1 
(not shown), it translocates into the nucleus and binds to IFN-stimulated response element (ISRE) motifs in the 
promoter regions of cytokines. (2) The ensuing internalization of the entire receptor complex into late endosomes 
initiates the TRAM-TRIF signaling pathway (MyD88-independent), which is hallmarked by late NFκB activation 
and production of type I IFNs. TRIF signaling leads to TRAF3 and TBK1/IKKε activation, both of which are 
required for IRF3 phosphorylation. Dimerized IRF3 molecules translocate into the nucleus and induce type I IFN 
production. Simultaneous activation of TRAF6 by TRIF induces late NFκB activation and MAP kinase cascade 
signaling. Abbreviations: CREB = cAMP response element-binding protein, ERK = extracellular-signal-regulated 
kinase, IκB = inhibitor of kappa B, IRAK = IL-1 receptor-associated kinase, JNK = c-Jun N-terminal kinase,  
NEMO = NFκB essential modifier, p38 = p38 mitogen-activated protein kinase, TAK1 = TGFβ-activated kinase 1, 
TBK1 = TANK-binding kinase 1, TRAF = TNF receptor-associated factor. 
1 http://www.uniprot.org/uniprot/P01375 (as of October 2015) 
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1.4 Cytokines and Chemokines – Mediators of Inflammation 
Cytokines, which include interleukins, interferons, colony-stimulating factors, chemokines, 
and many growth factors, play an essential role in induction and regulation of immune 
responses. Cytokines are produced by many different cell types and often show features of 
functional pleiotropy and redundancy. They act as communication molecules between cells. 
Receptor binding leads to activation of signaling cascades resulting in expression of immune 
relevant genes, changes in metabolism, proliferation or differentiation, migration and 
apoptosis depending on the type and developmental state of the target cells. Moreover, 
extensive crosstalk by cytokines shapes the adaptive immune response (reviewed in Mosser 
& Edwards (2008), Ramnath et al. (2006), Schulte et al. (2013), Striz et al. (2014) and Turner 
et al. (2014)). 
Cytokines can act as activating and pro-inflammatory molecules in immune responses e.g. 
TNF, IL-6, IL-1β and IFNγ; or mediate inhibiting and anti-inflammatory cell functions e.g.  
IL-10 and transforming growth factor β (TGFβ). Additionally, specific types of cytokines 
named chemokines are important for recruitment of immune cells to sites of infection and 
injured tissues e.g. CXCL8/IL-8, CCL3/MIP-1α (macrophage inflammatory protein 1α) and 
CXCL10/IP-10 (IFNγ inducible protein 10). The controlled orchestration of these and other 
cytokines leads to activation of the immune system and clearance of the infectious agents. 
Briefly, at the beginning of an inflammation, the primary master regulators of the immune 
response are TNF and IL-1β, which are produced mainly by monocytes and macrophages. 
Both cytokines act synergistically to activate further immune cells and produce “later” 
cytokines such as IL-6 and CXCL8/IL-8 that potentiate the inflammatory process. IL-6, for 
instance, activates lymphocytes and stimulates production of components of the complement 
system. Moreover, TNF and IL-1β activate the coagulation system and increase the vascular 
permeability of endothelial cells. The latter one facilitates infiltration of leucocytes e.g. 
neutrophils, lymphocytes and monocytes to the inflammatory site, which are attracted by 
chemokines e.g. CXCL8/IL-8 and CXCL10/IP-10. Once the inflammatory agent is removed, 
anti-inflammatory cytokines like IL-10 and TGFβ are important terminators of inflammatory 
processes. They restore the immunological homeostasis by inhibiting the production of pro-
inflammatory cytokines and promoting tissue repair (reviewed in Ramnath et al. (2006) and 
Schulte et al. (2013)). For a more comprehensive overview about each cytokine, see 
Appendix 5.1. 
Although cytokines are critical for host defense, uncontrolled cytokine release – either pro- or 
anti-inflammatory – can have detrimental effects to the host by promoting hyperinflammation 
or immunosuppression. An example for this is sepsis, where systemic activation of the host 
immune system leads to an imbalance in cytokine production affecting the whole body by 
damaging body tissues and organs (Biswas & Lopez-Collazo 2009). 
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1.5 Sepsis: A Disorder of the Immune System 
In the early 1990s, sepsis was defined as a clinical syndrome that is characterized by a 
systemic inflammatory immune response (SIRS) of a host to a (suspected) severe infection, 
typically of bacterial origin (Bone et al. 1992, Vincent et al. 2013). Criteria for SIRS are based 
on four categories including body temperature, respiratory rate, white blood cell count and 
heart rate (Iskander et al. 2013). 
Development of sepsis arises when local inflammatory processes fail to prevent spreading of 
pathogens via the blood stream and induce a systemic activation of the entire immune 
system (Rittirsch et al. 2008). Sepsis can further develop into severe sepsis characterized by 
acute organ dysfunction of e.g. liver and kidneys, and septic shock with hypotension (low 
blood pressure not responding to any treatment) (Angus & van der Poll 2013). The clinical 
manifestations of sepsis were already known at the time of Hippocrates (Majno 1991, 
Rittirsch et al. 2008) and – still today – sepsis remains a serious public health issue in the 
intensive care units, with about six million deaths worldwide per year. The mortality rate 
ranges from 20 % for sepsis to more than 50 % for septic shock (Angus et al. 2006, 
Monneret et al. 2008). Although the risk of dying from sepsis has declined over the past 
decades, the incidence of sepsis still increases, thus, the number of patients dying each year 
is similar to the number of people dying with acute myocardial infarction (Martin 2012). 
Sepsis was thought to be hallmarked by a biphasic nature, which is characterized by an 
initial phase of overt inflammation (SIRS) that leads to a later immunocompromised phase to 
counterbalance the initial inflammatory response (CARS, compensatory anti-inflammatory 
response syndrome) (Hutchins et al. 2014). Nowadays, it is questioned whether the 
inflammatory amplitude of SIRS controls the extent of CARS or if they start independently 
with the same trigger. Moreover, a mixed antagonist response syndrome (MARS) is 
described, where both conditions – SIRS and CARS – co-exist, either as temporary 
homeostasis during the transition from SIRS to CARS or over the complete course of 
infection (Adib-Conquy & Cavaillon 2009, Bone 1996, Hoflich & Volk 2002, Tang et al. 2010). 
Nevertheless, sepsis basically consists of two distinct but not mutually exclusive phases; 
imbalance of either response can result in host damage caused directly by excessive 
inflammation or indirectly through immune dysfunction (Hotchkiss et al. 2013, Rittirsch et al. 
2008). 
The amplitude of the hyperinflammatory phase (SIRS) can persist for a variable period of 
time depending on patient’s age (Martin et al. 2006), comorbidities, organism virulence and 
other factors including genetic polymorphisms in cytokine genes and PRRs (Cook et al. 
2004, Kumpf & Schumann 2010), affecting both the innate and adaptive immune systems 
(Fig. 1-2) (Hotchkiss & Karl 2003, Hotchkiss et al. 2013, Iskander et al. 2013).  
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Fig. 1-2: The immune response in 
sepsis (adapted from Hotchkiss et al. 
2013). The course and outcome of 
sepsis are determined by many 
factors including pathogen virulence, 
comorbidities and genetic pre-
determinants. (A) Although both pro-
inflammatory (SIRS) and anti-
inflammatory responses (CARS) 
develop rapidly after sepsis, the initial 
response in previously healthy young 
patients who now develop severe 
sepsis is dominated by a cytokine-
driven hyper-inflammation. Mortality in 
this early phase of sepsis is mainly 
mediated by cardiovascular collapse 
and multiple organ dysfunctions. 
(B) However, most of the patients who develop sepsis are elderly with several comorbidities, which impair proper 
immune responses. These patients show a reduced hyperinflammatory phase and rapidly enter a state of chronic 
morbidity and profound severe immunosuppression lasting for days or weeks. The longer the predominantly anti-
inflammatory phase lasts, the higher the risk for the patient to develop secondary infections such as nosocomial 
infections resulting in high mortality. However, appropriate biomarkers are still limited to distinguish the two 
phases. So far, persistent decrease in human leukocyte antigen DR (HLA-DR) expression on monocytes is a 
common feature of the immunedepressive state (Docke et al. 1997a). The usage of biomarkers increases the 
efficacy of treatment, either with anti-inflammatory therapies within the first hyperinflammatory phase or boosting 
treatments for immunity reactivation within the immunocompromised phase (Eichacker et al. 2002). 
Previously healthy young adults who develop sepsis often show a cytokine-driven 
hyperinflammation indicated by shock, high fever and multiple organ failure. Full-blown, 
systemic activation of immune responses occurs due to releases of PAMPs and DAMPs from 
invading microorganisms and damaged host tissue, resulting in an overstimulation of 
immune cells and an imbalanced cytokine response known as ‘cytokine storm’ (Hotchkiss et 
al. 2013, Thomas 1972). High production of pro-inflammatory cytokines e.g. TNF, IL-1β and 
IL-6 – normally beneficial for fighting against pathogens – now converts into an excessive 
damaging inflammation mediating a severe dysregulation of various body systems. An 
unbalanced network of pro-inflammatory mediators leads to vascular leakage of fluid into 
tissues by TNF and IL-1β, and cardiac dysfunction by IL-6. Moreover, activation of 
coagulation cascades results in microvascular thromboses throughout the body and impaired 
perfusion of critical organs, which lead to multi-organ failure and often death due to cytokine 
storm-mediated responses (see Fig. 1-2 A) (reviewed in Hotchkiss & Karl (2003), Hotchkiss 
et al. (2013), Hutchins et al. (2014), Rittirsch et al. (2008) and Sriskandan & Altmann (2008)). 
In contrast, elderly people have a reduced or absent hyperinflammation phase and rapidly 
develop impaired immunity (see Fig. 1-2 B). Sepsis is now increasingly a disease of elderly 
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people older than 65 years (Hotchkiss et al. 2013, Martin et al. 2006). Here, the imbalance of 
a favored immunocompromised status increases the risk of secondary or nosocomial 
infections with weakly virulent or opportunistic organisms followed by a high mortality (Otto et 
al. 2011). Nosocomial or hospital-acquired infections are defined as infections occurring 
during treatment in a healthcare unit which are secondary to the patient’s original condition 
(Rittirsch et al. 2008). Immunosuppression (also known as ‘immunoparalysis’; Docke et al. 
(1997b) and Volk HD et al. (1989)) is mediated by a shift towards anti-inflammatory cytokines 
and unresponsiveness of immune cells. One hallmark of sepsis is the reduced ability of 
monocytes to produce pro-inflammatory cytokines, such as TNF, IL-1β and IL-6, in response 
to bacterial challenges (Ertel et al. 1995, Manjuck et al. 2000, Munoz et al. 1991, Volk et al. 
1991). Moreover, the reduced ability to fight and eliminate the causative agents is due to a 
loss of lymphocytes, dendritic cells and gastrointestinal epithelial cells by apoptosis 
(Hotchkiss et al. 1999, Hotchkiss et al. 2002, Hotchkiss et al. 2001). 
As anti-inflammatory therapeutic strategies were not successful, sepsis and its 
pathophysiological events are now thought to be mainly driven by immune suppression 
resulting in secondary infections. Thus, understanding immunological defects that impair host 
immunity is crucial for treatment of sepsis patients since careful boosting of immune system 
improves survival (Hotchkiss et al. 2013, Hutchins et al. 2014, Marshall 2014). 
 
1.6 Endotoxin Tolerance: A Model for Analyzing ‘Immunoparalysis’ in Sepsis 
Patients 
Some of the unbalanced features of sepsis with gram-negative bacteria have been linked to 
endotoxin tolerance (Biswas & Lopez-Collazo 2009, Lopez-Collazo & Del Fresno 2013). 
Endotoxin tolerance is a phenomenon observed in animals and humans, in which immune 
cells become transiently unresponsive to endotoxin treatment (e.g. LPS) after a first 
exposure to LPS (Beeson 1946, Michalek et al. 1980, Virca et al. 1989, Ziegler-Heitbrock et 
al. 1994). Monocytes and macrophages are the principal cells responsible for the induction of 
endotoxin tolerance in vivo (Freudenberg & Galanos 1988). As tolerance minimizes damage 
caused by a given level of excessive inflammation and immunopathology (Medzhitov et al. 
2012), endotoxin tolerance can be assumed to be a mechanism of host protection (Biswas & 
Lopez-Collazo 2009). 
To analyze the systemic mechanisms occurring during sepsis and endotoxin tolerance, 
several in vivo and in vitro models were established. They are based on the tolerization effect 
of two consecutive treatments of animals or immune cells, in particular monocytes and 
macrophages, with endotoxin mimicking a primary (pro-inflammatory phase) and a 
secondary infection (anti-inflammatory phase) in sepsis (Lopez-Collazo & Del Fresno 2013). 
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An in vitro endotoxin model with monocytes demonstrated that a first exposure to endotoxin 
for only one hour is sufficient to develop tolerance. However, exposure with LPS for six to 
eight hours is more effective in inducing a tolerant status in monocytes lasting for up to five 
days (del Fresno et al. 2009). 
Characteristically, LPS tolerant cells are refractory to induce inflammatory cytokine and 
chemokine expression, such as TNF, IL-6, IL-1β, CCL3/MIP-1α, and CXCL10/IP-10 (the 
encoding genes are referred to as ‘tolerizable genes’), and show impaired antigen 
presentation capacity. By contrast, secretion of anti-inflammatory cytokines like the IL-1 
receptor antagonist (IL-1RA), IL-10 and TGFβ, and production of anti-microbial PRRs like the 
macrophage receptor with collagenous structure (MARCO) and the formyl peptide receptor 1 
(FPR1) are unaltered or even enhanced (referred to as ‘non-tolerizable genes’) (Allantaz-
Frager et al. 2013, Biswas & Shalova 2012, Cavaillon & Adib-Conquy 2006, Foster et al. 
2007, McCall et al. 1993, McCall & Yoza 2007, Yoza et al. 2000). Thus, endotoxin tolerance 
is not only a simple downregulation of pro-inflammatory molecules, but rather a 
‘reprogramming’ of monocytes and macrophages. 
Physiologically, this poorly inflammatory, tolerant phenotype is protective in 
hyperinflammation conditions including sepsis as this phenomenon allows for high 
phagocytic activity and bacterial clearance while avoiding the excessive toxicity associated 
with high cytokine production contributing to protection against septic shock (Biswas & 
Lopez-Collazo 2009, Biswas & Shalova 2012, Lopez-Collazo & Del Fresno 2013, Medzhitov 
et al. 2012). However, secondary infections in sepsis-like conditions lead to a high patient 
mortality as the tolerant immune system does not initiate further immune responses against 
new invading pathogens. 
The molecular basis of endotoxin tolerance is still not fully understood. LPS-tolerant cells 
show downregulation of many inflammatory signaling proteins (reviewed in Fan & Cook 
(2004)). However, a loss of LPS signaling can only partly explain the phenomenon of 
endotoxin tolerance. In tolerant cells, LPS stimulation can still induce the expression of 
genes that encode for anti-inflammatory cytokines and anti-microbial mediators, but 
activation of pro-inflammatory genes is refractory. Thus, the differential tolerization effect of 
LPS on monocytes and macrophages rather favors the concept of gene reprogramming than 
an overall downregulation of LPS-induced gene expression (Cavaillon & Adib-Conquy 2006). 
Epigenetic modifications in the chromatin structure of tolerant cells including selective 
changes in histone modifications and nucleosomal rearrangement are emerging as an 
explanation for reprogramming of monocytes and macrophages (Carson et al. 2011, Chan et 
al. 2005, El Gazzar et al. 2009, McCall & Yoza 2007, Medzhitov & Horng 2009, Yoza et al. 
2000). Thus, understanding chromatin modifications in tolerizable and non-tolerizable genes 
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could elucidate the accessibility of gene loci in tolerant monocytes and macrophages leading 
to a better understanding of the progression of endotoxin tolerance and sepsis. 
 
1.7 Epigenetics 
The epigenetic landscape refers to all mechanisms that modulate gene expression without 
changing the underlying DNA sequence. An overview is depicted in Fig. 1-3. 
Traditionally, epigenetic modifications were seen as stable, heritable changes in gene 
expression that are transferred from one cell or organism to their progeny and underlie stable 
differentiation into various cell types and tissues (Kouzarides 2007). 
Moreover, epigenetic changes are now considered to be dynamically regulated and 
reversible to allow chromatin flexibility in response to environmental stimulation. Thus, 
epigenetics are not only important in the development of cell types and organisms, but also 
in immune responses and disease establishment including cancer (Bernstein et al. 2007, 
Carson et al. 2011, Falkenberg & Johnstone 2014, Shakespear et al. 2011). 
Chromatin consists of DNA with associated proteins, mainly histones, which are important for 
packaging and organizing of DNA but also dictate gene transcription. The epigenetic 
landscape, including DNA methylation, histone modifications, nucleosome positioning and 
non-coding RNA, influences gene expression. Chromatin flexibility is mediated mainly by two 
principal mechanisms: DNA methylation and chromatin modifications (see Fig. 1-3). 
Coordinated modifications of DNA and/or associated proteins result in changes within the 
physical accessibility of DNA to transcription factors. These multiple mechanisms lead to 
regulated organization of gene loci into transcriptionally active or silent states (Berger 2007, 
Bernstein et al. 2007). Open or transcriptionally active chromatin (euchromatin) is accessible 
to transcription factors and polymerases, whereas transcriptionally silent chromatin 
(heterochromatin) is densely packed (Bernstein et al. 2007, Carson et al. 2011, Falkenberg & 
Johnstone 2014, Shakespear et al. 2011). 
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Fig. 1-3: Organization of DNA and epigenetic modifications of chromatin (adapted from Bernstein et al. 
(2007)). DNA is hierarchically organized in the eukaryotic nucleus with DNA-associated proteins into higher 
structural units. This structural organization allows it to fit within the small nucleus, but also provides rapid and 
precise access for transcription, replication and repair. A nucleosome is the first structural unit, which consists of 
147 bp DNA wrapped around a histone core containing two copies each of the histone proteins H2A, H2B, H3 
and H4 (Luger et al. 1997). The nucleosomes are connected by the linker histone H1 forming a ‘beads on a 
string’-like structure. Nucleosomes are higher ordered and packaged to a secondary structure referred to as the 
30 nm chromatin fiber (Depken & Schiessel 2009). During mitosis, the chromatin fiber is further packaged into 
dense chromosomal structures (metaphase chromosome). Besides packaging, chromatin plays an important role 
in gene expression. The N-terminal tails of histones can be modified and, thereby, dictate the expression pattern 
of the underlying DNA sequence by influencing the contact between nucleosomes or recruiting other DNA- and 
histone-binding proteins including non-histone proteins like transcription factors. In addition, the DNA molecule 
itself can be modified. DNA methylation occurring at position five of the cytosine ring within 5’-cytosine-guanine-3’ 
dinucleotides (CpGs) is considered to have a repressed chromatin status and shows inhibition of gene 
expression. 
1.7.1 DNA Methylation 
Mammalian DNA methylation of cytosine bases within 5’-cytosine-guanine-3’ dinucleotides 
(CpGs) is associated with a repressed chromatin structure and inhibition of gene expression 
(Bird & Wolffe 1999).  
Several DNA (cytosine-5)-methyltransferases (DNMTs) are known: The de novo 
methyltransferases DNMT3a and DNMT3b are responsible for introducing cytosine 
methylation at previously unmethylated CpG sites, whereas in maintenance the 
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methyltransferase DNMT1 copies pre-existing methylation patterns onto the new DNA strand 
during DNA replication (Klose & Bird 2006). However, there is evidence that this 
classification is too simplistic as DNMT1 also displays de novo activity (Brenner & Fuks 
2007, Jair et al. 2006). Another enzyme closely related to DNMT3a and DNMT3b is the 
DNTM3-like protein (DNMT3L) that does not contain intrinsic DNA methyltransferase activity, 
but physically associates with DNMT3a and DNMT3b and stimulates their methylation 
activity (Goll & Bestor 2005, Klose & Bird 2006). 
Repression of gene expression by DNA modifications is mediated by two possible 
mechanisms: (1) DNA methylation inhibits the association of some DNA-binding factors to 
their DNA loci e.g. transcription factors, or, (2) proteins that recognize methylated CpGs bind 
and recruit co-repressors to form a chromatin remodeling co-repressor complex to silence 
gene expression directly. These DNA-binding proteins are called methyl-CpG-binding 
proteins (MBPs). Moreover, the co-repressor complex can interact with histone deacetylases 
(HDACs) and histone methyltransferases (HMTs), which indirectly induce repression through 
other epigenetic changes like histone modifications (Klose & Bird 2006). 
 
1.7.2 Histone Modifications 
DNA is associated with histone proteins for packaging eukaryotic DNA within the nucleus. 
The basic structure of DNA storage is called a nucleosome, which consists of 147 bp of DNA 
wrapped around an octamer of histone proteins containing of two copies each of the histones 
H2A, H2B, H3 and H4 (Luger et al. 1997). 
Besides their important role in dynamic packaging of genetic material, histones can undergo 
covalent modifications: Post-translational modifications of N-terminal histone tails include 
lysine (K) and arginine (R) methylation, lysine acetylation, serine phosphorylation, lysine 
ubiquiylation and SUMOylation among others (Peterson & Laniel 2004). These modifications 
can direct winding or unwinding of the associated DNA and provide a binding platform for 
transcription factors and chromatin-associated proteins that initiate or repress gene 
transcription (Clapier & Cairns 2009, Smale 2010a). It is believed that the coordinated 
modifications of a given histone, also known as histone code hypothesis or histone code 
theory, can dictate the transcription state of the nearby gene locus (Iizuka & Smith 2003, 
Jenuwein & Allis 2001, Strahl & Allis 2000). The activating or repressing feature of these 
modifications is dependent on the modification itself, but also on the location of the 
modification within the histone tail (see Fig. 1-4) (Carson et al. 2011). 
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Fig. 1-4: Methylations of histone residues 
(adapted from Kooistra & Helin (2012), with 
contributions from Kouzarides (2007) and 
Northrup & Zhao (2011)). Genes and gene-
associated elements need to be accessible 
for different genomic functions like cell 
replication, DNA repair and to respond to 
external stimuli. Histone proteins are not only 
important for packaging and fitting of DNA 
into the nucleus, but modifications of these 
proteins can also orchestrate gene 
expression. Acetylation of lysine within the 
histone tail mediates unfolding of chromatin 
since it neutralizes the basic charge of the 
lysine and thereby is associated with active 
transcription (acetylation is not depicted in 
figure). (A) Methylation at lysines (K) and 
arginines (R) of histone proteins can appear 
in one of three different forms: mono-, di-, or 
trimethyl for lysines and mono- or di- for arginines. Methylation of lysine at position 4 on histone 3 (H3K4), H3K36 
and H3K79 is associated with actively transcribed genes. In particular, mono-, di- and trimethylation of H3K4 is 
highly localized to a few nucleosomes around the promoter region and at the transcription start site (TSS). Within 
the transcribed region of active genes, the following modifications are localized: monomethylation of H2BK5, 
H3K9, H3K27, H4K20 and mono-, di- or trimethylation of H3K79, whereas H3K36me3 peaks at the 3´end of 
transcribed genes. (B) On repressed genes, the methylation marks H3K9me2, H3K9me3 and H4K20me3 are 
relatively homogeneously distributed, whereas H3K27me3 peaks at promoters. 
Actively transcribed genes tend to be associated with multiple ‘activating’ modifications, 
whereas silent genes are associated with only a few ‘repressive’ modifications or are not 
associated with any modifications (Northrup & Zhao 2011). Generally speaking, histone 
acetylation and many methylation events are positively correlated with gene activation, 
whereas histone H3 di- and trimethylation on lysine 27 (H3K27me2, H3K27me3) and lysine 9 
(H3K9me2, H3K9me3), as well as histone H4 trimethylation on lysine 20 (H4K20me3) are 
exceptions that are negatively correlated with gene expression (Barski et al. 2007, Kooistra & 
Helin 2012, Northrup & Zhao 2011, Strahl & Allis 2000). The association of histone 
modifications as activating or repressive is based on their correlation with gene expression. 
For instance, trimethylation of H3K4 (H3K4me3) is found around the transcription start site 
(TSS) of active genes, whereas H3K9me3 indicates heterochromatin and H3K27me3 is 
critical for repression of developmental genes (Bernstein et al. 2007, Kouzarides 2007). For 
an overview about histone modifications and their impact on gene expression see Table 1-1. 
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Table 1-1: Overview of important post-translational modifications of histones at promoters and enhancers 
and their impact on gene expression. A promoter is a genomic region located near the transcription start site 
(TSS), which mediates gene transcription (Northrup & Zhao 2011). Regions of DNA that activate transcription but 
are not located at the TSS are referred to as enhancers. Bivalent modifications of activating and silencing 
(repressive) marks in promoters and enhancers indicate a so-called poised status to keep the underlying gene 
sequence silent but inducible, which allows plasticity in processes including cell differentiation (Kouzarides 2007, 
Shlyueva et al. 2014, Voigt et al. 2013). 
 
   
Transcription Status Kind of Modification at 
 Promoter/Gene Enhancer 
   
Silent / Repressive H3K27me3 (me = methylation) H3K27me3 
 H3K9me2  
 H3K9me3  
 H4K20me3  
   
Poised H3K27me3 H3K27me3 
 H3K4me3 H3K4me1 or H3K4me2 
   
Active H3K4me3 H3K4me1, H3K4me2 
 H3K9ac (ac = acetylation) H3K9ac 
 H3K27ac H3K27ac 
 H3K18ac H3K18ac 
 H4ac (K5, K8, K13, K16) H4ac (K5, K8, K13, K16) 
   
Note: The table does not provide a complete overview. The information included is based on Barski et al. (2007), 
Berger (2007), Northrup & Zhao (2011), Strahl & Allis (2000) and Wang et al. (2008). 
Generally, epigenetic regulations are very dynamic: ‘Epigenetic writers’ such as histone 
acetyltransferases (HATs), histone methyltransferases (HMTs) and DNA methyltransferases 
(DNMTs) lay down epigenetic marks on DNA molecules or histones. These marks are 
recognized by ‘epigenetic readers’, which recruit other chromatin modifiers and remodeling 
proteins to alter chromatin function and structure. ‘Epigenetic erasers’ such as histone 
deacetylases (HDACs) catalyze the removal of epigenetic marks. Addition and removal of 
these post-translational modifications lead to the addition and/or removal of other marks in a 
highly complicated manner. Together, histone and DNA modifications regulate various  
DNA-dependent processes, including transcription, DNA replication and DNA repair 
(reviewed in Berger (2007), Black et al. (2012), Falkenberg & Johnstone (2014) and 
Shakespear et al. (2011)). Moreover, there is a deep cross talk between DNA methylation 
and histone modifications. As already mentioned above (see DNA methylation in Introduction 
section, 1.7.1), DNA methylation signals histone modification, but also vice versa (Kooistra & 
Helin 2012, Kouzarides 2007). For instance, trichostatin A treatment (an HDAC inhibitor) 
causes impaired CpG methylation. Moreover, the histone modification H3K9me3 directly 
affects chromatin silencing and heterochromatin formation by recruiting the heterochromatin 
protein 1 (HP1), which can interact with DNMTs (Brenner & Fuks 2007, Dormann et al. 2006, 
Fuks 2005, Smallwood et al. 2007). 
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1.8 Aims and Objectives 
Epigenetic changes play an important role in regulating inflammatory immune responses. 
Sensing pathogens and danger signals transmits signals to transcription factors and other 
chromatin-modifying proteins, and recruits them to inflammatory gene loci (Stender & Glass 
2013). Thus, inflammatory gene expression is associated with a diversity of additional 
chromatin modifications such as histone acetylation and methylation that open gene loci and 
facilitate transcription (Carson et al. 2011, Ivashkiv 2011).  
In sepsis and endotoxin tolerance, tolerant cells exhibit a selective defect in the induction of a 
subset of genes, encoding pro-inflammatory cytokines (tolerizable, also referred to as class T 
genes), while the expression of other genes encoding for instance for anti-microbial 
mediators is still active (non-tolerizable, also referred to as class NT genes). There is 
evidence that inflammatory processes in sepsis and endotoxin tolerance resulting in 
increases or decreases of gene expression are mediated by epigenetic changes including 
DNA methylation, histone modifications and chromatin remodeling. For instance, Foster and 
her colleagues analyzed murine macrophages in an in vitro endotoxin tolerance model and 
could show that the differential expression patterns of tolerizable and non-tolerizable genes 
were due to different patterns of histone modifications (Foster et al. 2007). Other studies 
indicated that the IL1B and TNF genes displayed an enrichment of the repressive histone 
mark H3K9me2 within their promoter regions in tolerant THP1 cells, a monocytic cell line 
(Chan et al. 2005, El Gazzar et al. 2007). Moreover, the same group showed an increase in 
DNA methylation within the TNF promoter of tolerant THP1 cells (El Gazzar et al. 2008). 
These and other results indicate that epigenetic changes happen in hyperinflammatory 
immune responses such as sepsis and endotoxin tolerance, resulting in an impaired 
expression of genes that regulate key immune activation responses: Therefore, what is 
intended to provide host protection from immunopathology now renders the host more 
susceptible to further infections. However, many of the mentioned studies analyzed 
epigenetic changes in endotoxin tolerance with a focus on murine macrophages, monocytic 
cell lines, or only a limited number of genes. Thus, further understanding and detection of 
these hyperinflammatory-induced epigenetic modifications especially in a human setting 
could lead to early identification of immunocompromised patients allowing more timely 
immune-boosting therapies (Hotchkiss et al. 2013). 
This study aimed to clarify the understanding of epigenetic changes in endotoxin tolerance 
experimentally in the human model. The main question was whether stable non-permissive 
epigenetic changes take place to selectively modify the pro-inflammatory response 
responsible for inflammation-associated pathology, while allowing expression of anti-
inflammatory and anti-microbial mediators in human monocytes during LPS tolerization. 
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Therefore, human primary monocytes were analyzed in an in vitro endotoxin tolerance 
model. The focus included the analysis of particular immune response genes and also the 
identification of genome-wide alterations in the monocytic epigenetic landscape. 
 
The following specific questions were addressed in the first part of the present study: 
♦ Do changes in activating histone modifications allow a discrimination of tolerizable 
(class T) and non-tolerizable genes (class NT) in LPS-tolerant human CD14-positive 
monocytes? 
♦ Are there species-related differences in the positive, transcription-linked histone 
patterns of human monocytes and murine macrophages in endotoxin tolerance? 
♦ Besides activating events, do changes in repressive histone modifications allow a 
classification in tolerizable (class T) and non-tolerizable genes (class NT)? 
♦ Does DNA methylation have an impact on repression of tolerizable genes, in 
particular, the genes encoding for the pro-inflammatory cytokines TNF and IL-6? 
The following specific issues were addressed in the second part: 
♦ Are there global changes in histone modifications that affect the whole monocytic 
genome? What might be the underlying mechanism? 
♦ Does endotoxin tolerance have a genome-wide impact on DNA methylation? 
♦ If so, do these global changes in epigenetic modifications have an influence on gene 
expression? 
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2. Results 
2.1 The Impact of LPS Tolerization on Specific Immune Response Genes 
2.1.1 Analysis of Cytokine Profile in Naïve and Tolerant Human Monocytes 
Initially, culture conditions for cultivation of human monocytes were optimized to increase the 
viability of monocytes in vitro for several days, thus ruling out differences in downstream 
assays coming from a high proportion of dead cells. For a detailed overview of the 
optimization process, please go to the Materials & Methods section (4.3.1.d). 
For all following experiments, human CD14+ monocytes were cultured in MPC-treated plates 
with IMDM medium supplemented with human AB serum from PAN-Biotech (Cat. No.:  
P30-2901M, Lot No.: P073305). 
To verify the hypothesis that LPS tolerization differentially affects gene expression of immune 
response genes, human monocytes were subjected to the in vitro endotoxin tolerance model 
(see Fig. 2-1 for a general overview), and cytokine and chemokine secretion patterns of 
naïve and tolerant human monocytes were characterized using the Luminex system from 
Millipore. The Luminex technology is a bead-based multi-analyte panel and provides 
simultaneous measurement of multiple protein targets in a single sample (Multiplex)2. 
 
Fig. 2-1: General experimental design for 
induction of endotoxin tolerance. Human CD14+ 
monocytes were left untreated (Naïve) or treated 
with LPS overnight (Tolerant) for a minimum of 
16 h, washed, given fresh media and stimulated 
with LPS where indicated (Naïve + LPS, 
Tolerant + LPS). 
 
 
The supernatants of unstimulated naïve monocytes (N), naïve cells treated with LPS for a 
maximum of 4 h (N+L), monocytes rendered tolerant with LPS treatment overnight (T) and 
tolerant cells re-stimulated with LPS (T+L) were compared for cytokine secretion. In parallel, 
the induction of intracellular signaling events by LPS stimulation was exemplarily analyzed by 
flow cytometric analysis of the MAP kinase p38 phosphorylation (see Fig. 2-2 for gating 
strategy and Fig. 2-3 A for experimental design). Naïve monocytes stimulated with LPS 
(N+L) showed an increase in p38 signaling, which was abolished in tolerant monocytes re-
stimulated with LPS (T+L, Fig. 2-3 B). Although the signaling was diminished in tolerant cells, 
the production and secretion of cytokines and chemokines showed a heterogeneous 
secretion pattern (Fig. 2-3 D). 
2 https://www.lifetechnologies.com/de/de/home/life-science/protein-biology/protein-assays-analysis/luminex-assays.html (as of October 2015) 
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Fig. 2-2: Signaling analysis in 
monocytes. Gating strategy for 
analysis of p38 phosphorylation 
by flow cytometry. Cells were 
stimulated with LPS for 15 min 
and stained intracellularly for 
p38 activation with the BD 
Phosflow System. 
 
Consistent with previous studies (Allantaz-Frager et al. 2013, Foster et al. 2007), the 
cytokines and chemokines analyzed in tolerant monocytes could be broadly categorized 
according to their induction capacity into two gene classes: Tolerizable (class T) and non-
tolerizable genes (class NT, Fig. 2-3 D and E). Tolerizable genes showed a diminished 
expression upon re-exposure to LPS (T+L/N+L ratio < 1), whereas non-tolerizable genes 
were even more highly expressed in tolerant cells (T+L/N+L ratio > 1; see Fig. 2-3 E). 
Several secreted proteins, including pro-inflammatory cytokines like TNF, IL-6 and IL-1β 
showed decreased induction after re-stimulation with LPS in tolerant human monocytes and, 
thus, were classified into class T genes (Fig. 2-3 D and E). Notably, the experiment was 
performed without additional ATP stimulus; therefore, the expression of IL-1α and IL-1β was 
almost indetectable in the supernatant. The supplementation of ATP is, however, necessary 
as a second signaling stimulus that mediates cleavage and secretion of the mature forms of 
IL-1α and IL-1β (Schroder & Tschopp 2010). A detailed look at the expression pattern of 
these cytokines revealed that the broad classification might be too simplistic. Especially 
within the class T genes, the LPS tolerization effect on individual cytokines was highly 
heterogeneous. One subgroup including TNF, CCL3/MIP-1α, CCL4/MIP-1β and CXCL10/ 
IP-10 was highly produced in naïve monocytes challenged with LPS (N+L), but their 
expression was almost completely lost in tolerant cells (T+L, Fig. 2-3 D, upper panel). 
Another subgroup containing IL-6 and IL-1β showed basic cytokine secretion even in tolerant 
monocytes (Fig. 2-3 D, middle panel). Moreover, CXCL8/IL-8 and probably CXCL1/GRO and 
IL-10 were re-inducible in tolerant cells, although the expression did not completely reach the 
same levels as in naïve cells challenged with LPS (Fig. 2-3 D, middle panel). 
In contrast, G-CSF, CCL2/MCP-1 and CCL7/MCP-3 categorized into class NT genes 
remained inducible despite reduced signaling and were produced in tolerant cells in even 
higher levels compared to naïve monocytes challenged with LPS (Fig. 2-3 D, lower panel). 
Another well-known example for a class NT gene encodes for the receptor FPR1 (Foster et 
al. 2007). Analysis of FPR1 mRNA clearly showed a higher expression profile in tolerant 
monocytes treated with LPS compared to naïve ones (Fig. 2-3 C). Interestingly, IL-1RA, 
which is also considered to belong to the class NT genes, showed only low levels of re-
challenge dependent induction (Fig. 2-3 D, middle panel). 
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Fig. 2-3 Differential gene expression pattern in endotoxin-tolerant human monocytes. (A) Experimental 
design: Human CD14+ monocytes were tolerized overnight with 100 ng/ml LPS (T) or left untreated (N), washed 
and given fresh media the following day and stimulated with 100 ng/ml LPS for the indicated time points (N+L, 
T+L). (B) Summary of p38 signaling in tolerized and naïve human monocytes after 15 min stimulation with 
100 ng/ml LPS. (C) Naïve and tolerized cells were treated for 1 h with 100 ng/ml LPS or left untreated. Cell pellets 
were lysed and mRNA expression of FPR1 was determined from isolated total RNA. (D) Naïve or tolerized 
monocytes were treated with LPS (N+L, T+L) or left untreated (N, T) for 4 h. Supernatants from cell cultures were 
analyzed by Luminex bead-based multiplex analysis panel. (E) The ratios T+L/N+L of the analyzed cytokines and 
chemokines from D are represented as horizontal bar plot: A ratio above 1 (solid line) is considered as  
non-tolerizable (NT) gene and below 1 as tolerizable (T) gene, whereas the dashed lines indicate a potential 
transition zone. Data are shown for 3 independent experiments (mean ± SEM). 
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In summary, despite reduced signaling capacity in tolerant monocytes, the secretion of 
individual cytokines and chemokines was differentially affected and could be roughly 
categorized into class T and NT genes. However, detailed multiplex analyses indicated that 
this broad classification might be too simplistic and that a sub-grouping in a total of three to 
four classes would better describe the expression patterns of immune response genes in 
endotoxin tolerance. For instance, LPS tolerization had a high effect on e.g. TNF and 
CXCL10/IP-10 production in tolerant monocytes (‘highly tolerizable’), whereas pro-
inflammatory cytokines and chemokines like IL-1β, IL-6 and CXCL8/IL-8 were only 
moderately affected (‘intermediately tolerizable’). The latter group could be further sub-
divided into (a) cytokines that showed reduced expression in tolerant monocytes with only 
limited additional induction capacity after LPS re-stimulation (e.g. IL-1β and IL-6) and (b) 
cytokines that could be re-induced in tolerant cells (e.g. CXCL8/IL-8 and CXCL1/GRO). By 
contrast, other chemokines like CCL7/MCP-3 showed an accumulation of expression over 
time and were produced even higher in tolerant monocytes treated with LPS. They showed a 
similar expression profile as the receptor FPR1, which belongs to the class NT genes  
(non-tolerizable). 
 
2.1.2 Potential Role of Histone Modifications in Tolerant Human Monocytes 
LPS tolerization seemed to differentially affect the expression of immune response genes in 
human monocytes. Changes at the chromatin level can have an impact on gene expression 
(Jenuwein & Allis 2001, Strahl & Allis 2000) and Foster et al. (2007), for instance, showed 
that class T and NT genes were differentially regulated by alterations in histone modifications 
in murine macrophages. Therefore, the potential role of histone marks in endotoxin tolerance 
in human monocytes was analyzed by chromatin-immunoprecipitation (ChIP) assays. 
ChIP is a very powerful tool that allows the study of transcriptional regulation by enabling the 
localization of transcription factors and modified histones to specific DNA loci (Gilmour & Lis 
1985, Jackson 1978, Solomon et al. 1988, Solomon & Varshavsky 1985). It is based on the 
preservation of proteins bound to the DNA in vivo by a fixation agent, normally formaldehyde. 
Following chromatin purification and shearing of DNA-protein complexes into short stretches, 
fragmented chromatin is subjected to immunoprecipitation using an antibody directed 
towards a protein of interest, e.g. histone protein bearing a specific modification. After 
specific enrichment of chromatin fragments, the co-captured DNA is purified and 
subsequently analyzed (Caretti et al. 2003, Kuo & Allis 1999, Weinmann & Farnham 2002). 
An overview about the ChIP technique is schematically depicted in Fig. 2-4. 
The enriched DNA can be analyzed by quantitative real-time PCR (ChIP-qPCR). Here, 
primer pairs specific to a genomic region, e.g. promoter region of the TNF gene, are used to 
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detect co-localized DNA fragments. This approach, however, only focuses on specific gene 
regions of interest. A genome-wide analysis of DNA-protein-interactions is achieved by 
sequencing all enriched DNA fragments (ChIP-Seq). Aligning the sequenced reads to the 
human genome generates a binding profile, where high enrichment of DNA sequences (titled 
as ‘peaks’) represents the location of the analyzed DNA-protein interaction. For more details 
see the Materials & Methods section (4.3.5 and 4.3.6). Various bioinformatic tools involving 
peak calling for identification of significant enriched regions (representing interaction sites), 
gene annotations and searching for transcription factor binding sites can be applied for 
down-stream investigations (see below in 2.2.1 in Results section, and also 4.3.7 in Materials 
& Methods section). 
 
Fig. 2-4: Schematic overview of ChIP 
assays used in this study to analyze 
histone modifications in human 
monocytes. (1) CD14+ human monocytes 
were fixed with 1 % formaldehyde for 7.5 min 
on ice. Here, formaldehyde fixation is 
schematically represented by a star. (2) After 
lysis of cell and nucleic membranes, (3) freed 
chromatin was sheared by sonication for  
10 cycles at 4 °C (Bioruptor from Diagenode, 
high power, 30 sec on/off). A small aliquot of 
input DNA representing total DNA (not shown 
in figure) was stored until further use and was 
processed from step 6 on along with the 
ChIP-enriched DNA. Input DNA further served 
as an internal control for the ChIP assay (for 
more details see Materials & Methods, 4.3.5). 
(4) Magnetic Dynabeads were attached to 
ChIP-validated antibodies directed to histone 
modifications and subsequently incubated 
with sheared chromatin. Control 
immunoprecipitation was performed with a 
non-specific IgG. (5) After magnetic sort and 
washing, specifically enriched DNA-protein-
complexes were eluted. (6) Reversal of cross-
linking from formaldehyde fixation was 
performed and (7) DNA was purified by RNA 
and protein digestion following ethanol 
precipitation. (8a) ChIP-enriched DNA was 
either analyzed by quantitative PCR and 
SYBR Green with primer pairs specifically 
designed to detect genes of interest or (8b) 
directed to sequencing for genome-wide 
analysis of DNA-protein interactions. 
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To apply ChIP assays for analyses of epigenetic changes in human monocytes, the 
technique was first established and further optimized empirically according to DNA cross-
linking and shearing. For more details, please go to Materials & Methods section 4.3.5.d. 
Best fragmentation results were achieved by fixation of human monocytes on ice for 7.5 min 
followed by shearing of isolated chromatin for 10 cycles. These conditions were used for all 
subsequent ChIP assays. 
First, changes of gene expression with combined ChIP-qPCR analyses were performed with 
a specific focus on genes involved in endotoxin tolerance. In particular, the histone patterns 
of TNF, IL6 and IL1B (class T genes) were compared to that of FPR1 (class NT gene). The 
promoter regions (transcription start site, TSS ± 1 kb) of these genes were analyzed for 
enrichment of H3K4me3, acetylation of H3K27 (H3K27ac) and global H4 acetylation (H4ac). 
These histone marks are considered to indicate open, transcriptionally active chromatin 
(Bernstein et al. 2005, Santos-Rosa et al. 2002, Schneider et al. 2004). For specific 
localization of primer pairs used, please go to Appendix section 5.2. H3K4me3 and H4ac 
were already analyzed in murine macrophages and showed distinct patterns in LPS-induced 
chromatin modifications (Foster et al. 2007, Yan et al. 2012). Besides, H3K27ac is an 
additional marker for active promoters and enhancers (Creyghton et al. 2010, Hawkins et al. 
2011, Rada-Iglesias et al. 2011). 
The induction of TNF, IL6 and IL1B mRNA expression was diminished in tolerant human 
monocytes stimulated with LPS (T+L), whereas FPR1 showed an even higher mRNA 
expression compared to naïve monocytes treated with LPS (N+L, Fig. 2-5 B). Consistent 
with the expression pattern, the FPR1 gene showed re-acetylation of H4 and an increase in 
H3K4me3 and H3K27ac in tolerant cells re-stimulated with LPS (T+L). Interestingly, the 
histone pattern of the IL6 and IL1B genes resembled that of FPR1. However, the induction of 
activating histone marks in the promoter/TSS regions of IL6 and IL1B did not correlate with 
their reduced gene expression in tolerant cells (Fig. 2-5 C). By contrast, TNF showed a 
different histone pattern in endotoxin tolerance. Most strikingly, TNF showed a reduced re-
acetylation of H4 and H3K27 in tolerant cells re-treated with LPS (in Fig. 2-5 C), which 
mirrored its reduced expression capacity in human tolerant monocytes (in Fig. 2-5 B). 
Additionally to ChIP-qPCR analyses, ChIP-Seq was performed. This approach allowed an 
objective analysis of histone marks without focusing on specific gene regions (e.g. 
promoter/TSS region). Representative binding profiles of H3K27ac and H4ac within the 
FPR1, IL6, IL1B and TNF genes are depicted in Fig. 2-5 D. Analyses by ChIP-Seq confirmed 
that the FPR1 gene showed higher enrichment of particularly H3K27ac in tolerant monocytes 
re-stimulated with LPS (T+L) compared to naïve ones (N). But again, and in contrast to the 
publication of Foster et al. (2007) that demonstrated a distinct chromatin pattern associated 
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with gene silencing in class T genes, the IL6 and IL1B genes were linked with activating 
histone marks even in tolerant monocytes which was best observed by comparison of N with 
T+L. The genomic region of TNF in tolerant cells treated with LPS (T+L), however, was 
associated with restricted acetylation of H3K27 and H4 comparable to naïve monocytes (N). 
 
 
Fig. 2-5: The class T genes IL6 and IL1B possess similar histone patterns like the class NT gene FPR1.  
(A) Human naïve and tolerant monocytes (tolerized with 100 ng/ml LPS) were stimulated with 100 ng/ml LPS for 
the indicated time points. (B) Cells were subjected to mRNA expression analysis. Depicted are mean values ± 
SEM of 3 independent experiments as relative quantification (RQ). (C) ChIP-qPCR analyses were performed at 
3 h (H3K4me3) or 1.5 h (H4ac and H3K27ac). Results are shown as mean ± SEM of ≥ 5 independent 
experiments (statistical analysis between two samples was performed by Wilcoxon matched-pairs signed-rank 
test, *p ≤ 0.05). (D) ChIP-Seq analysis: H3K27ac and H4ac binding profiles within the FPR1, IL6, IL1B and TNF 
genomic regions are displayed in the UCSC Genome Browser. Arrows indicate positions of primer pairs for  
ChIP-qPCR analysis and triangles show transcription direction. 
Taken together, the analyses of the transcription-linked histone modifications H3K4me3, 
H3K27ac and H4ac demonstrated that the reduced mRNA expression capacity of the class T 
genes IL1B, IL6 and TNF were only partially reflected by their histone pattern indicating that 
other mechanisms might be involved in LPS tolerization. 
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2.1.3 Analysis of Tolerant Murine Macrophages by Histone Modifications 
Many endotoxin tolerance studies were investigated in mice. To rule out species-specific 
differences between humans and mice regarding histone modifications, murine macrophages 
were generated from bone marrow cells of C57BL/6 mice and subjected to endotoxin 
tolerance followed by ChIP-qPCR analysis using antibodies directed towards the activating 
histone marks H4ac and H3K4me3 (Fig. 2-6 A). 
 
 
Fig. 2-6: The murine Il6 and Tnf genes possess different histone patterns in endotoxin tolerance 
compared to the human IL6 and TNF genes. (A) Murine macrophages were generated from bone marrow cells 
of C57BL/6 mice by cultivation of cells with murine M-CSF (muM-CSF) for 5 to 7 days. Differentiated 
macrophages were subjected to endotoxin tolerance. Cells were either tolerized with 100 ng/ml LPS overnight or 
left untreated. Subsequently, naïve and tolerant murine macrophages were stimulated with 100 ng/ml LPS for the 
indicated time points. (B) Gating strategy for signaling analysis of p38 activation: Naïve and tolerant macrophages 
were stimulated with 100 ng/ml LPS for 15 min and p38 phosphorylation was analyzed by BD PhosFlow following 
flow cytometric analysis. (C) Summary of p38 signaling in murine macrophages. (D and E) ChIP-qPCR analyses 
of H3K4me3 (D) and H4ac (E). Due to high variation, a general normalization to Gapdh was performed. Data 
represent 3 (H4ac) or 4 (H3K4me3) independent experiments with mean values ± SEM shown. 
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Similar to human monocytes, the signaling capacity was diminished in tolerant murine 
macrophages (Fig. 2-6 B and C). However, the dynamic of histone modifications of murine 
macrophages and human monocytes were partially conflicting between these two species. 
The class T gene Il1b and the class NT gene Fpr1 showed enrichment of H3K4me3 and 
H4ac in tolerant murine macrophages (Fig. 2-6 D and E). In contrast to human monocytes, 
the re-acetylation of H4 within the Il6 promoter in tolerant murine macrophages re-stimulated 
with LPS was diminished. Strikingly, acetylation of the Tnf gene was still inducible in murine 
macrophages (Fig. 2-6 E), which was not observed in human monocytes (Fig. 2-5 C). 
The analyses of human and murine cells by changes in histone modifications indicated that 
differences in the regulation of histone marks exist between the species. This would imply 
that endotoxin tolerance might be partially mediated by different mechanisms in humans 
versus mice. 
 
2.1.4 Analysis of Signaling Strength on Histone Modifications 
The histone pattern observed in human monocytes did not correlate with the expression of 
the analyzed genes. Whereas the TNF gene showed diminished re-acetylation of H4 and 
H3K27 which mirrored its reduced gene expression in tolerant human monocytes, the class T 
genes IL6 and IL1B contradictorily showed an increase in activating histone modifications  
(as seen in Fig. 2-5). 
To investigate the effect of signaling strength on the induction of activating histone 
modifications in endotoxin tolerance, the magnitude of signaling and capability of tolerant 
cells to activate p38 phosphorylation was analyzed in a more defined experimental setup. 
Therefore, human primary monocytes were tolerized overnight by two different dosages of 
LPS before re-stimulation (Fig. 2-7 A). Compared to the naïve control group, tolerization of 
monocytes with low-dose LPS (T1, 1 ng/ml) led only to a slightly reduced, but clearly 
detectable, signaling capacity of tolerant cells, whereas p38 phosphorylation was nearly 
abolished in monocytes tolerized with high-dose LPS (T100, 100 ng/ml; Fig. 2-7 B). 
Monocytes tolerized with different dosages of LPS were subjected to ChIP-qPCR assays for 
analyses of H3K27ac and H4ac in endotoxin tolerance. Parallel gene expression analyses 
showed that the mRNA expression of the class NT gene FPR1 was higher in low- and  
high-dose tolerized monocytes (Fig. 2-7 C), whereas the cytokine production of the class T 
genes encoding for IL-6, IL-1β (intermediately tolerizable), TNF and CXCL10/IP-10 (highly 
tolerizable) was reduced (Fig. 2-7 D). In particular, IL-6 followed a signaling-dependent 
expression, whereas TNF and CXCL10/IP-10 production was basically already tolerized in 
low-dose treated monocytes. Besides, CXCL8/IL-8 was again highly inducible even in  
high-dose tolerized monocytes reaching an expression level similar to naïve cells stimulated 
with LPS (Fig. 2-7 D). 
27 
Results 
 
 
Fig. 2-7: Tolerization of human monocytes with two different LPS dosages distinctly induces activating 
histone modifications in intermediately tolerizable and highly tolerizable genes. (A) Experimental setup: 
Human monocytes were tolerized overnight with 1 ng/ml LPS (T1) or 100 ng/ml LPS (T100). Untreated cells 
served as naïve (N) control. Naïve (N) and tolerant cells (T1, T100) were washed, given fresh media and 
stimulated with 100 ng/ml LPS for the indicated time points. (B) Signaling in monocytes was analyzed by flow 
cytometric analysis of p38 phosphorylation after 15 min stimulation with LPS. Results are shown for 
5 independent experiments. (C) Cells were lysed and mRNA expression of FPR1 was determined from total RNA. 
Data are shown for 3 independent experiments (mean ± SEM). (D) Monocytes (N, T1, T100) were stimulated with 
LPS for 4 h. For analysis of IL-1β secretion, ATP was added 15 min before the end of stimulation. Supernatants 
were collected and analyzed for cytokine secretion by ELISA. (E, F) Cells were subjected to ChIP-qPCR for 
analyses of H3K27ac (E) and H4ac (F). Results are depicted as mean values ± SEM of 4-5 independent 
experiments. 
In comparison to the naïve control group, LPS treatment of low- and high-dose tolerized 
monocytes induced acetylation of H3K27 in the FPR1 gene (class NT gene), but also in IL8, 
IL6 and IL1B (class T genes), with the highest induction in the lower LPS dosage  
(Fig. 2-7 E). Moreover, these genes showed re-acetylation of H4 even in tolerant monocytes 
(Fig. 2-7 F). By contrast, H3K27ac was reduced in TNF and CXCL10 (class T genes) in 
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tolerant monocytes (Fig. 2-7 E). Most strikingly, re-acetylation of H4 in the TNF and CXCL10 
genes was basically lost in high-dose, but also low-dose, tolerized monocytes (Fig. 2-7 F), 
implying either a signaling-independent mechanism or a different sensitivity towards 
signaling strength, where already minimally reduced p38 activation leads to inhibition of TNF 
and CXCL10/IP-10 production. 
The examination of signaling strength and comparative analyses of inductions of activating 
histone modifications in endotoxin tolerance provided a deeper insight into the regulation of 
class T genes. CXCL8/IL-8, which is considered to belong to the class T genes (Allantaz-
Frager et al. 2013), was again highly re-inducible in tolerant monocytes and the encoding 
gene displayed a similar histone pattern compared to the class NT gene FPR1. Moreover,  
IL-6 and presumably IL-1β were signaling-dependently produced and the encoding genes 
showed high enrichment of positive histone modifications even in tolerant monocytes. The 
data indicates a more signaling-mediated tolerization of these genes. The TNF and CXCL10 
genes, however, showed an absence in their re-induction of activating histone marks which 
was mostly independent of p38 signaling strength in tolerant monocytes. The data further 
confirmed the results obtained by multiplexed quantification of cytokines in Fig. 2-3 and the 
sub-grouping of class T genes in endotoxin tolerance. Inhibition of gene expression of highly 
tolerizable genes like TNF and CXCL10 might presumably be driven by epigenetic 
modifications, whereas tolerization of intermediately tolerizable genes like IL6 and probably 
IL1B is signaling-dependent. Notably, as CXCL8/IL-8 production possessed high induction 
capacity even in tolerant monocytes, the question arises as to whether the encoding gene 
might be a sub-group of class NT genes. 
Finally, previous work from a former PhD student showed that tolerization with low-dose LPS 
was mainly mediated by IL-10, as blocking of IL-10 during endotoxin tolerance induction 
could reverse LPS-tolerization. In contrast, tolerization with a high dose of LPS was basically 
mediated by reduction in signaling transduction (Krüger 2009). This implies that tolerization 
of intermediately tolerizable genes might be potentially mediated by signaling events that 
involve IL-10. 
 
2.1.5 Analysis of Endotoxin Tolerance in High-Dose Tolerized Human Monocytes 
Comparative analyses of signaling strength implicated a discriminative role of signaling in the 
tolerization of specific class T genes (Fig. 2-7). To further investigate the possible impact of 
signaling on the limited expression of the class T genes encoding for TNF, IL-6 and IL-1β, 
the capability of LPS to induce p38 phosphorylation in tolerant monocytes was further 
analyzed in detail in high-dose tolerized cells (100 ng/ml LPS). Expression of these  
pro-inflammatory cytokines in comparison to FPR1 was analyzed by flow cytometry.  
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Gating strategies for extracellular analysis of FPR1 and intracellular cytokine production of 
TNF, IL-6 and IL-1β are depicted in Fig. 2-8 A and B, respectively. 
 
 
Fig. 2-8: Gating strategies for analyses of the receptor FPR1 and the cytokines TNF, IL-6 and IL1β by flow 
cytometry. Cells were first gated for singlets (FSC-H vs. FSC-A) followed by the discrimination of live cells from 
dead ones. CD14-positive monocytes were further investigated for (A) FPR1 expression on the cell surface or (B) 
intracellular cytokine production of TNF, IL-6 and IL-1β. 
Human monocytes were subjected to endotoxin tolerance (Fig. 2-9 A) and the samples were 
separated according to their p38 induction in tolerant cells (Fig. 2-9 B-E and Fig. 2-9 F-I, 
respectively). Dependent on the blood donor, high-dose tolerized monocytes (100 ng/ml 
LPS) showed either a complete loss (Fig. 2-9 B) or a diminished induction of p38 
phosphorylation compared to naïve monocytes treated with LPS (Fig. 2-9 F). In parallel, 
production of TNF, IL-6 and IL-1β (class T genes) in relation to FPR1 (class NT gene) was 
analyzed by flow cytometry for the same samples (Fig. 2-9 C-E and Fig. 2-9 G-I, 
respectively). 
Differences in signaling had no effect on FPR1 surface expression (Fig. 2-9 C and G). 
Tolerant monocytes, which were completely incapable of induction of p38 phosphorylation 
(Fig. 2-9 B), showed diminished IL-6 and IL-1β production (Fig. 2-9 D). In contrast, normal 
expression of IL-6 and IL-1β was observed in tolerant cells treated with LPS (Fig. 2-9 H) that 
were able to generate reduced, but detectable, p38 signaling (Fig. 2-9 F). TNF expression, 
however, was almost not inducible in tolerant monocytes independent of signaling strength 
(Fig. 2-9 D and H). Representative dot plots of flow cytometric analysis for each signaling 
condition are depicted in Fig. 2-9 E and I, respectively. 
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Fig. 2-9: Production of IL-6 and IL-1β is dependent on signaling strength in high-dose tolerized human 
monocytes. (A) Human naïve and tolerant monocytes (tolerized with 100 ng/ml LPS overnight) were stimulated 
with LPS for the indicated time points and subjected to parallel investigation of p38 signaling (B and F), FPR1 
surface expression (C and G) and cytokine production (D and H) by flow cytometry. For analysis of intracellular 
cytokine production of TNF, IL-6 and IL-1β, monocytes were treated in the presence of Brefeldin A (BfA). 
Analyses of FPR1, TNF, IL-6 and IL-1β are depicted whether the tolerant monocytes showed either abolished  
(B to E) or reduced signaling in tolerant human monocytes (F to I). (E & I) Representative dot plots for both 
signaling conditions are shown. Depicted are mean values ± SEM of 6 (reduced signaling) or 8 (no signaling) 
independent experiments. Statistical analysis between two groups was performed by Wilcoxon matched-pairs 
signed-rank test (*p ≤ 0.05, **p ≤ 0.01). 
31 
Results 
 
Signaling dependent expression of IL-6 in high-dose tolerized human monocytes was also 
validated by ELISA (Fig. 2-10 A), as detection by flow cytometry was not optimal (see  
Fig. 2-9). Again, reduced production of IL-6 was only observed in LPS tolerant cells, as long 
as p38 signaling was abolished (Fig. 2-10 B and C), whereas detectable signaling in tolerant 
monocytes (Fig. 2-10 D) had no impact on tolerization of IL-6 production (Fig. 2-10 E).  
By contrast, TNF tolerization was independent of signaling (Fig. 2-10 C and E). 
 
 
Fig. 2-10: Analysis of IL-6 and TNF production in high-dose tolerized human monocytes depending on 
signaling strength. (A) Human naïve and tolerant monocytes (tolerized with 100 ng/ml LPS overnight) were 
stimulated with LPS (100 ng/ml) for the indicated time points. (B, D) Signaling of p38 was investigated by flow 
cytometry. (C, E) In parallel, cell supernatant was subjected to ELISA for analysis of IL-6 and TNF production. 
Depicted are mean values ± SEM of 3 (reduced signaling) or 4 (no signaling) independent experiments. 
In summary, analyses of high-dose LPS tolerization on TNF, IL-6 and IL-1β expression 
dependent on signaling strength further implicated that the encoding genes might potentially 
be regulated by different tolerance mechanisms. Whereas TNF tolerization might be more 
strongly regulated by epigenetic changes e.g. differences in activating histone modifications, 
tolerance induction of the IL6 and IL1B genes seemed to be mainly mediated by reduced 
signaling strength in endotoxin tolerance, which is also reflected by their ‘positive’ histone 
pattern (see Fig. 2-5 and Fig. 2-7). 
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2.1.6 Analysis of Repressive Histone Marks in Endotoxin Tolerance 
In the experiments described thus far, epigenetic changes were analyzed by modifications in 
activating histone marks. However, tolerization of class T genes might be instead regulated 
by enrichment in repressive histone marks than by suppressing activating marks. Therefore, 
ChIP assays with a focus on the repressive histone modifications H3K9me2, H3K27me3 and 
H4K20me3 followed by sequencing (ChIP-Seq) were performed (Fig. 2-11 A). This approach 
was chosen as repressive histone marks cover repressed genes relatively homogeneously 
(Kooistra & Helin 2012). 
H3K9me2 was already shown to be enriched in the promoter regions of IL1B and TNF in 
endotoxin-tolerant THP-1 cells (El Gazzar et al. 2009, El Gazzar et al. 2008) and H4K20me3 
seemed to be involved as a repression checkpoint in LPS/TLR4-mediated signaling (Stender 
et al. 2012). Additionally, H3K27me3 is a well characterized repressive mark for down 
regulation of gene transcription and has an important role in cell development and 
differentiation (Barski et al. 2007, Boyer et al. 2006, Bracken et al. 2006). 
Analyses of the histone marks H3K9me2, H3K27me3 and H4K20me3 by ChIP-Seq indicated 
that a general enrichment of these repressive marks in genes of pro-inflammatory cytokines 
was not detected in endotoxin-tolerant human monocytes (Fig. 2-11), which could have 
explained their reduced expression capacity. No significant differences in repressive histone 
marks could be observed for the TNF, IL8 and CXCL10 genes in human monocytes. 
Strikingly, IL6 even displayed a reduction of the repressive mark H3K27me3 in tolerant cells 
(T+L) compared to naïve monocytes treated with LPS (N+L) (Fig. 2-11 B), which is inversely 
correlated with its gene repression. Thus, it has to be further investigated how these 
modifications really affect expression of the analyzed genes or whether other, yet 
unidentified, repressive histone marks play a role e.g. SUMOylation (Berger 2007, Nathan et 
al. 2006, Shiio & Eisenman 2003). 
By contrast, IL1B showed an increase in H3K9me2 circa 7 kb upstream from its TSS in 
tolerant monocytes. Moreover, ChIP-seq analyses revealed an increase in H4K20me3 near 
the TSS of IL1A and IIL1R1 (encodes for the IL-1 receptor type I), which is involved in IL-1α 
and IL-1β signaling (Fig. 2-11 C) (Weber et al. 2010). The induction of these repressive 
marks might have a specific impact on gene silencing of IL1-related genomic regions. 
Again, analyses of repressive histone modifications could not identify a general, inhibiting 
histone pattern that might clarify the phenomenon by which endotoxin tolerance selectively 
tolerizes a specific set of genes (class T), whereas others are still inducible (class NT). 
Genome-wide analyses of ChIP-Seq data are illustrated in the Results section 2.2.1, see 
below. 
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Fig. 2-11: Endotoxin-tolerant monocytes showed no common enrichment in the repressive histone 
modifications H3K9me2, H4K20me3 and H3K27me3 in selected genes. (A) Experimental setup: Human 
monocytes were tolerized overnight with 100 ng/ml LPS (T100). Untreated cells served as the naïve (N) control. 
Naïve (N) and tolerant cells (T100) were washed, given fresh media and stimulated with 100 ng/ml LPS for 1.5 h. 
(B and C) Cells were subjected to ChIP-Seq using antibodies directed towards H3K9me2, H3K27me3 and 
H4K20me3 to identify enrichment in repressive histone marks. Binding profiles of ChIP-Seq data within  
pro-inflammatory gene loci are displayed in the UCSC Genome Browser. Grey shaded boxes indicate significant 
changes in enrichment of repressive histone modifications identified by the peak caller SICER (for more details, 
see the Results section 2.2.1 below). Triangles indicate transcription direction. 
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2.1.7 DNA Methylation Analyses within the Promoter Regions of IL6 and TNF 
Finally, epigenetic repression of gene expression can also occur by methylation of cytosine 
bases at CpGs (Bird & Wolffe 1999). To elucidate a potential role of DNA methylation in 
tolerization of the pro-inflammatory cytokines IL-6 and TNF, the promoter regions of the 
encoding genes were analyzed by bisulfite conversion. Therefore, human monocytes were 
subjected to endotoxin tolerance and genomic DNA was isolated. Subsequent bisulfite 
conversion mediated deamination of unmethylated cytosine to uracil, whereas methylated 
cytosine remained unchanged. Following promoter-specific PCR, uracil was exchanged with 
tyrosine and PCR products were subjected to sequencing. Resulting sequences were 
compared to the original unconverted DNA to reveal the methylation status of the respective 
CpG sites. 
The promoter region of the human IL6 gene from -1200 bp to +27 bp contained 22 CpG 
motifs (Nile et al. 2008) and the TNF promoter region from -360 to +50 bp covered 12 CpGs 
(Campion et al. 2009) (Fig. 2-12). 
 
Fig. 2-12: Schematic representation 
of CpG motifs within the proximal 
promoter regions of the human TNF 
and IL6 genes analyzed by bisulfite 
sequencing (adapted from Campion et 
al. (2009) and Nile et al. (2008)). The 
CpG dinucleotides that can be 
potentially methylated are represented 
by vertical lines with open circles, and 
their location relative to the 
transcription start site is indicated. 
Bisulfite-modified DNA was amplified by PCR following direct sequencing. The upstream region of the IL6 gene 
was split into three amplicon sections of ca. 400 bp that are indicated as IL6_1, IL6_2 and IL6_3. 
The DNA methylation status of the TNF and IL6 promoter regions was compared in human 
monocytes subjected to endotoxin tolerance (Fig. 2-13 A). As illustrated in Fig. 2-13 B  
and C, naïve and tolerant primary monocytes treated with LPS showed no significant 
changes in de novo DNA methylation. Furthermore, no alterations in percentages of total 
DNA methylation could be identified between the different amplicons and conditions  
(Fig. 2-13 D). 
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Fig. 2-13: The DNA methylation status in the TNF and IL6 promoter regions is not altered by endotoxin 
tolerance. (A) Experimental setup: Human monocytes were tolerized overnight with 1 ng/ml LPS (T1) or 
100 ng/ml LPS (T100). Untreated cells served as a naïve (N) control. Naïve (N) and tolerant cells (T1, T100) were 
washed, given fresh media and stimulated with 100 ng/ml LPS for 1.5 h. Isolated genomic DNA was bisulfite-
treated, promoter-specifically amplified and subjected to direct sequencing. (B and C) Percentage of DNA 
methylation at each CpG position within the human TNF (B) and IL6 (C) promoter regions is depicted as mean ± 
SEM of 5 independent experiments. The circle colors depict distinctly methylated regions: Black shows that more 
than 80 % of analyzed CpGs at that position was methylated, grey indicates methylation status between 80 to 5 % 
and white represents rarely methylated CpGs (below 5 %). (D) Comparison of total DNA methylation between the 
different samples and amplicons. The analysis was performed using the BiQ Analyzer HiMod (Becker et al. 2014). 
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The DNA methylation status was further validated by Methyl-Capture Sequencing 
(MethylCap-Seq). MethylCap-Seq is an approach that works similar to ChIP-Seq (Brinkman 
et al. 2010, Serre et al. 2010). Here, fragmented DNA is incubated with the methyl-binding 
domain (MBD) of proteins that can recognize methylated DNA (for more details see 4.3.9 in 
the Materials & Methods section). Enriched DNA is sequenced and binding profiles indicating 
methylated genomic regions can be visualized in a genome browser. MethylCap-Seq allows 
analysis of DNA methylation on a genome-wide scale, but potentially forfeits resolution of 
single methylated CpGs compared to promoter-specific bisulfite-sequencing. 
As shown in Fig. 2-14, gene regions of IL6 and TNF in naïve and tolerant human monocytes 
did not show a specific change in DNA methylation, which could explain the reduced 
expression of these pro-inflammatory cytokines in endotoxin tolerance. Binding profiles 
indicating localization of DNA methylation in the FPR1, IL1B, IL8 and CXCL10 genes can be 
found in the Appendix 5.5. Detailed genome-wide analysis of MethylCap-Seq data is 
performed in 2.2.2 (see Results section below). 
 
 
Fig. 2-14 Analysis of the IL6 and TNF gene regions by MethylCap-Seq shows no change in DNA 
methylation. (A) Experimental setup: Human monocytes were tolerized overnight with 1 ng/ml LPS (T1) or 
100 ng/ml LPS (T100). Untreated cells served as a naïve (N) control. Naïve (N) and tolerant cells (T1, T100) were 
washed, given fresh media and stimulated with 100 ng/ml LPS for 1.5 h. (B) Cells were subjected to  
MethylCap-Seq to identify enrichment in DNA methylation. Binding profiles of MBD-protein indicating methylated 
DNA within the IL6 and TNF gene loci are displayed in the UCSC Genome Browser. 
Taken together, the results obtained by promoter-specific analysis of the IL6 and TNF genes 
demonstrated that repression by DNA methylation might not play a role in endotoxin 
tolerance, which could be further confirmed by MethylCap-Seq. 
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To summarize the first section, analyses of single LPS-induced genes in endotoxin tolerance 
indicated that alterations at the chromatin level by histone modifications played a role in 
regulation of specific genes. However, the impact of these epigenetic changes might be 
different for every individual gene as the histone pattern did not always correlate with gene 
expression. Moreover, analysis of DNA methylation within the IL6 and TNF gene loci could 
not implicate this modification in repression of these genes. Thus, other mechanisms 
involving signaling strength might play a role in endotoxin tolerance. 
 
2.2 Genome-Wide Analysis of Epigenetic Changes in Endotoxin Tolerance 
2.2.1 Global Analyses of Histone Modifications by ChIP-Seq 
2.2.1.a Characterization of Enriched Regions (Peaks) 
ChIP-qPCR provides a limited picture of the regulation of histone modification during LPS 
tolerization as it focuses only on single immune-relevant genes. Therefore, ChIP combined 
with next generation sequencing (ChIP-seq) was performed to provide a global overview of 
changes in histone modifications in endotoxin tolerance throughout the genome allowing the 
identification of histone modifications within other genes such as transcriptional regulators, 
and other mechanisms responsible for endotoxin tolerization. 
Addressing the assumption that tolerant genes remain repressed, ChIP-Seq experiments 
focused on the comparison of the following two conditions: (1) Naïve human monocytes 
treated with LPS (N+L) and (2) high-dose tolerized cells re-stimulated with LPS (T100+L). 
ChIP assays were performed using antibodies directed to the activating histone marks H4ac 
and H3K27ac, and the repressive marks H3K9me2, H3K27me3 and H4K20me3. 
To identify significant peaks, ChIP-Seq assays were analyzed by the peak calling algorithm 
SICER, which was developed to specifically identify enriched genomic regions generated by 
ChIP-seq experiments analyzing histone modifications (Zang et al. 2009). A general 
overview about the significant peaks called by SICER for each histone mark in the two 
experimental conditions (N+L, T100+L) is demonstrated in Fig. 2-15. Enriched regions 
individually identified within the two conditions were termed SinglePeaks (Fig. 2-15 B). 
Moreover, SICER provides an analysis script to identify distinct enriched genome regions by 
comparing one condition with another (here called DiffPeaks), thereby indicating differentially 
regulated genes or regions (Fig. 2-15 C). Of note, both peak classes (SinglePeaks and 
DiffPeaks) can be identified by two separate analysis methods, thus, each peak list can be 
considered separately and used individually for downstream analyses. 
In naïve monocytes treated with LPS (N+L), the majority of genomic regions were associated 
with activating histone marks, whereas tolerant cells re-stimulated with LPS (T100+L) 
showed enrichment in repressive histone marks (SinglePeaks, Fig. 2-15 B). This effect was 
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even more dramatic when considering differentially enriched genomic regions. Most of the 
activating histone modifications, which showed at least a 2-fold change increase between the 
N+L versus T100+L conditions, were counted in naïve cells stimulated with LPS (N+L). This 
indicates that in tolerant cells, the majority of H4ac and/or H3K27ac in these genomic regions 
were reduced or even lost during LPS tolerization. Here, the lack of re-induction in the 
transcription-linked acetylation marks at H4 and H3K27 might be due to the reduced 
signaling capacity in high-dose tolerized human monocytes. Simultaneously, repressive 
histone modifications, in particular H3K9me2 and H4K20me3, were significantly enriched in 
tolerant cells challenged with LPS, indicating a global endotoxin tolerance-induced 
repression of genomic regions (T100+L, Fig. 2-15 C). Notably, the histone mark H3K27me3 
showed the lowest dynamic change in endotoxin tolerance. 
 
Fig. 2-15: Overview of global, histone mark-enriched genomic regions: Endotoxin tolerance induces a 
shift from activating to repressive histone marks. (A) Experimental setup: Naïve and tolerant human 
monocytes (tolerized with a high dose of LPS, 100 ng/ml) were stimulated with LPS (100 ng/ml) for 1.5 h  
(N+L, T+L) and subjected to ChIP-Seq analyses followed by peak calling using SICER. (B) The number of peaks 
with a minimum SICER score of 100 is depicted as pie charts for the activating histone modifications H3K27ac 
and H4ac, and for the repressive histone marks H3K9me2, H3K27me3 and H4K20me3. (C) Total numbers of 
differentially enriched regions (DiffPeaks) with a minimum fold change (FC) of 2 (P value of minimum 1e-6) were 
identified by the comparison of N+L and T100+L. Here, enriched genomic regions (peaks) were counted for one 
of the two conditions. It should be noted that the figure provides an overview of the number of significant peaks 
(enriched regions) identified by SICER independently whether peaks were potentially co-localized by different 
histone modifications. Moreover, the scripts for identification of SinglePeaks and DiffPeaks are distinct from each 
other, thus, peaks identified in one peak list do not necessarily appear in the other peak set. 
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Next, the localization and distribution of identified enriched regions within the given peak sets 
were determined. As an example, the gene body distribution of every histone mark analyzed 
for the condition N+L (SinglePeaks) is shown in Fig. 2-16. The histone modifications 
H3K27ac, H4ac and H3K27me3 were primarily localized in promoter and gene coding 
regions, whereas the repressive marks H3K9me2 and H4K20me3 were highly localized to 
intergenic regions, allowing only limited mapping to a specific gene (Fig. 2-16 A and B). 
 
 
Fig. 2-16: Gene body distribution of analyzed histone modifications in N+L (SinglePeaks): H3K27ac, H4ac 
and H3K27me3 are located within gene-linked regions. (A) Bar plot representing location of peaks within the 
specified genomic regions. Genomic regions were divided into promoter, 5' UTR, 3' UTR, exon, intron or 
intergenic sections. (B) Overview of peak locations divided into genic (G) and intergenic regions (I) presented as 
VennPie plots, with the number in brackets representing the total count of identified regions (from Fig. 2-15 B). 
Peak annotation and location were analyzed by the Bioconductor package ChIPseeker. 
The binding profile of identified ChIP peaks around the transcription start site (TSS) was 
further investigated for the SinglePeak data set (Fig. 2-17). Peaks were mapped to the TSS 
region (± 10 kb) to obtain a binding matrix. The read count frequency around the TSS region 
in Fig. 2-17 A is generated by the binding profile in Fig. 2-17 B. The binding profile 
represents a gene (TSS region) in every line, and only peaks that aligned within the given 
genomic region are displayed. 
Consistent with the gene body distribution, H3K27ac, H4ac and H3K27me3 were mainly 
distributed near the TSS of genes. In particular, H3K27ac and H4ac showed a sharp peak 
around the TSS region. Generally, the frequency of peak binding near the TSS was higher in 
activating histone marks compared to repressive ones (Fig. 2-17 A and B). 
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Fig. 2-17 ChIP peak binding profile of SinglePeaks around the TSS region (± 10 kb) in naïve (N+L) and 
tolerant monocytes stimulated with LPS (T+L): H3K27ac, H4ac and H3K27me3 are localized near to TSS 
regions. (A) Average profile plot. (B) Heat map of ChIP peaks binding to TSS regions. Plots are generated with 
the Bioconductor package ChIPseeker. 
In summary, a general characterization of peaks identified by ChIP-Seq revealed that the 
activating histone marks H3K27ac and H4ac were highly enriched in naïve monocytes 
stimulated with LPS (N+L). The lack of re-enrichment of these histone modifications in 
tolerant monocytes might be due to an overall loss in signaling transduction. By contrast, 
repressive histone modifications, in particular H3K9me2 and H4K20me3, showed enrichment 
in tolerant monocytes re-stimulated with LPS (T100+L). Generally, localization of analyzed 
histone modifications was consistent with the literature (Barski et al. 2007, Bernstein et al. 
2007, Kouzarides 2007). In particular, H3K27ac, H4ac and H3K27me3 were over-
represented near gene-associated regions. 
 
2.2.1.b Analysis of Genomic Regions Differentially Regulated by Histone 
Modifications in LPS-Tolerant Monocytes 
The subsequent analyses focused on the characterization of genomic regions that either 
gained activating or repressive histone marks by a minimum fold change of 2 in tolerant 
monocytes (DiffPeaks, T100+L) compared to naïve cells treated with LPS (DiffPeaks, N+L). 
This approach allowed the identification of differentially regulated regions potentially 
mediated by endotoxin tolerance. 
First, a general overview of the gene body distribution of DiffPeaks in naïve and tolerant 
monocytes clearly showed that LPS tolerization induced enrichment of histone marks mainly 
located within intergenic regions (Fig. 2-18).  
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Fig. 2-18: Gene body distribution of DiffPeaks in naïve (N+L) and tolerant human monocytes treated with 
LPS (T100+L): Endotoxin tolerance induces enrichment of histone marks in intergenic regions. Genomic 
regions were broadly classified in genic (G) and intergenic regions (I) presented as VennPie plots, with the 
numbers representing the total peak counts identified by SICER shown in brackets (from Fig. 2-15 C). Peak 
annotation and locations were analyzed by the Bioconductor package ChIPseeker. 
Next, a hierarchical clustering was performed to get a global overview of the nature of 
differentially regulated peaks and to identify potential gene clusters that were regulated either 
by activating or repressive histone modifications in endotoxin tolerance. As a clustering of 
identified peaks over the complete human genome was not feasible due to limitations in 
computational power, a more simplified approach was used. Therefore, the identified peak 
sets for every histone modification were annotated by HOMER (Hypergeometric Optimization 
of Motif EnRichment, Heinz et al. (2010)) allowing mapping of peaks to the nearest TSS of a 
gene. This resulted in a list of annotated genes with specification of identified peaks and the 
distance to the specific TSS. Subsequently, all genes that belonged to differentially enriched 
regions (DiffPeaks, minimum fold change of 2, P value ≤ 1e-6) identified by comparing naïve 
(N+L) and tolerant monocytes treated with LPS (T100+L) were unified to one gene list. As 
DiffPeaks were counted either for one of the two conditions, the given gene list was 
compared to the SinglePeak data set (with a minimum SICER score of 100) to obtain values 
for both conditions. If multiple regions were associated with a single gene, the region with the 
highest SICER score was used. DiffPeaks showing a minimum fold change of 2, but a 
SICER Score below 100 in the SinglePeak data set, were counted as zero. 
The final gene list indicating differentially bound regions by histone modifications was 
visualized as a heat map representing individual SICER scores of SinglePeaks of the 
annotated genes using unsupervised hierarchical clustering. Notably, the heat map shown in 
Fig. 2-19 A only indicated a broad, simplified overview. It did not take into account that peaks 
called especially in tolerant cells were mainly located intergenically, which might lead to 
partially less specific correlations. However, a heat map generated focusing only on peaks 
localized within the TSS region (± 10 kb) identified similar gene clusters (not shown). 
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The global overview of differentially bound regions in endotoxin tolerance indicated that each 
of the analyzed histone modifications was basically exclusively associated with specific 
genes. Only small sets of genes showed co-localization in histone modifications. Moreover, 
histone modifications in tolerant and naïve monocytes did not cluster together indicating that 
the peaks were strongly diverse (Fig. 2-19 A). Many genes in naïve monocytes stimulated 
with LPS (N+L) were associated with activating histone marks. Here, functional gene 
ontology (GO) enrichment analysis of e.g. H4ac-associated genes by GREAT (Genomic 
Regions Enrichment of Annotations Tool, McLean et al. (2010)) indicated that these genes 
mainly regulate TLR4-mediated immune responses (Fig. 2-19 B). In tolerant cells, however, 
few gene clusters showed specific enrichment in acetylated histone marks and these clusters 
were different to the ones in naïve monocytes stimulated with LPS. 
By contrast, H4K20me3 and H3K9me2 were enriched and partially co-localized in tolerant 
monocytes. Finally, a huge gene cluster in naïve and tolerant monocytes treated with LPS 
was associated with H3K27me3, which potentially regulates cell differentiation and 
development (Bernstein et al. 2007). However, only a small set of genes showed differences 
in H3K27me3, which is already indicated in Fig. 2-15 C. 
 
 
Fig. 2-19: Different gene clusters are affected by changes in histone modifications in endotoxin tolerance. 
(A) Heat map indicating genes that were differentially modified by histone modifications, with peak regions 
annotated to the nearest gene. Genes belonging to differentially regulated regions indicated by a minimum fold 
change of 2 (P value ≤ 1e-6) in DiffPeaks were unified to one gene list, and the given SICER Score of the 
corresponding genes identified as SinglePeaks were clustered using unsupervised hierarchical clustering 
(Euclidean). The heat map shows the SICER scores of differentially modified genomic regions (generated by R). 
(B) Gene Ontology (GO) enrichment analysis of genomic regions (peaks), which showed an increase in the 
activating histone mark H4ac in naïve monocytes treated with LPS (N+L), was performed by GREAT (Genomic 
Regions Enrichment of Annotations Tool). The scores for ‘Biological Process’ (top 15) are expressed as  
-log(P value). 
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LPS tolerization induced global changes in histone modifications ranging from activating 
histone marks in naïve monocytes to adding repressive ones in tolerant cells. Of particular 
interest was the dynamic change in these epigenetic marks occurring in tolerant monocytes. 
Concerning the histone code hypothesis that genes possessing active or transcription-linked 
histone marks are likely expressed, whereas genes associated with repressive histone 
modifications show reduced gene expression (Strahl & Allis 2000), genomic regions that 
were significantly enriched in LPS tolerized monocytes for either activating or repressive 
histone marks were analyzed in detail. Thus, all downstream analyses focused mainly on the 
condition T100+L. This approach allowed for the identification of potential genes that were 
likely expressed in tolerant monocytes contributing to tolerance induction, e.g. transcriptional 
repressors, and parallel detection of gene groups which were repressed. A further goal was 
to identify the potential nature of epigenetic regulation occurring in endotoxin tolerance 
contributing to gene expression on the one hand and mediating gene repression on the other 
hand. 
Generated peak lists that indicated a minimum 2-fold enrichment in at least one of the 
analyzed histone modifications in genomic regions of tolerant monocytes treated with LPS 
compared to naïve cells (DiffPeaks counted for T100+L) were further ‘narrowed’ to histone-
limited DiffPeak data sets. A description of these peak sets can be found in Table 2-1. In 
detail, the DiffPeak lists were filtered for genomic regions, which possessed no parallel 
enrichment in the opposite activating or repressive histone modifications to rule out poised 
(bivalent) statuses in histone marks. A schematic outline of filtering is illustrated in  
Fig. 2-20 A. For instance, DiffPeaks indicating enrichment in the activating histone mark 
H4ac in tolerant monocytes and showing induction (co-enrichment) in one of the repressive 
histone modifications H3K9me2, H3K27me3 or H4K20me3 were excluded in downstream 
analysis (Fig. 2-20 A). In the opposite case, DiffPeaks enriched for example for the 
repressive mark H4K20me3 in tolerant monocytes lacking parallel enrichment in the 
activating histone marks H3K27ac and H4ac were maintained. 
 
Table 2-1: Detailed description of histone-limited DiffPeak data sets 
 Name of data set Description 
   
A
ct
iv
at
in
g 
H3K27ac_T_no_RepX 
H4ac_T_no_RepX 
‘T’ indicates enrichment in tolerant monocytes treated with LPS (T100+L) 
(DiffPeaks, fold change of minimum 2, P value ≤ 1e-6) 
‘no_RepX’ indicates no co-enrichment in repressive histone marks 
R
ep
re
ss
iv
e H3K9me2_T_no_AcX 
H3K27me3_T_no_AcX 
H4K20me3_T_no_AcX 
‘T’ indicates enrichment in tolerant monocytes treated with LPS (T100+L) 
(DiffPeaks, fold change of minimum 2, P value ≤ 1e-6) 
‘no_AcX’ indicates no co-enrichment in activating histone marks 
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Fig. 2-20: Summary of differentially enriched regions (DiffPeaks) showing enrichment exclusively for 
either activating or repressive histone patterns in tolerant monocytes treated with LPS (T100+L).  
(A) Representative schematic overview for the generation of histone-limited DiffPeak data sets depicted for H4ac: 
Only DiffPeaks identified in the condition T100+L, which showed enrichment in an activating histone mark (here 
H4ac), but no co-enrichment in a repressive histone mark (here H3K9me2), were used for downstream analyses. 
(B) Total numbers of differentially enriched regions (DiffPeaks) in tolerant monocytes stimulated with LPS 
(T100+L, short indicated as ‘T’) are presented for each histone mark. DiffPeaks were further filtered for enriched 
regions that were exclusively regulated by differences in either activating (no co-enrichment in repressive marks, 
‘no_RepX’) or repressive histone modifications (no co-enrichment in activating marks, ‘no_AcX’). Moreover, the 
number of peaks located near the gene transcription start site (TSS ± 10 kb) is depicted. (C) Peaks were 
annotated to the nearest gene and the overlap of genes showing co-regulation of either positive or repressive 
histone modification patterns is represented as a VennPie plot using the Bioconductor package ChIPseeker. 
Significant gene overlap was calculated by the Bioconductor package GeneOverlap using the Fisher’s exact test. 
In Fig. 2-20 B, an overview of the generated histone-limited DiffPeak data sets in tolerant 
monocytes treated with LPS is shown. Generally, most of the DiffPeaks (> 90 %) did not  
co-localize with the opposite histone signature (active or repressive, respectively). Moreover, 
the histone-limited DiffPeak data sets were annotated to the nearest gene and potential  
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co-enrichment of either activating (H3K27ac, H4ac) or repressive histone modifications 
(H3K9me2, H3K27me3 and H4K20me3) were represented as VennPlots (Fig. 2-20 C). Only 
a restricted number of annotated genes seemed to be co-regulated by activating or 
repressive histone patterns in tolerant monocytes re-stimulated with LPS. Significant co-
regulation could be identified for H4ac/H3K27ac and H3K9me2/H4K20me3 (Fig. 2-20 C). 
Additionally, only a limited number of the identified histone-limited DiffPeaks in tolerant 
monocytes stimulated with LPS (T100+L) was restricted to the TSS of genes (approximately 
5 to 30 %, as can be seen in Fig. 2-20 B), indicating that most of the peaks were basically 
located intergenically. This implies that in particular regulatory genomic elements like 
enhancers might be modified during endotoxin tolerance. Enhancers are distinct genomic 
regions that contain binding sites for transcription factors and co-repressors, thus influencing 
the expression of its target genes (Banerji et al. 1981). However, these regulatory elements 
seem to act independently of orientation and the distance to their target genes, and may 
function at large distances of several hundred kilobases or even megabases by looping 
(Shlyueva et al. 2014). The properties of enhancers make it difficult to determine their direct 
impact. Therefore, this thesis focused on the characterization of epigenetic events near 
promoter/TSS regions. 
To identify biologically relevant differences, genes that showed a significant enrichment near 
the TSS (± 10 kb) in either activating (H4ac, H3K27ac) or repressive histone marks 
(H3K9me2, H3K27me3 or H4K20me3) in tolerant monocytes treated with LPS were 
considered for functional GO enrichment analyses using DAVID (Database for Annotation, 
Visualization and Integrated Discovery) (Huang et al. 2009a, b). This approach allows to 
identify genes which are significantly over-represented in a given gene set. An overview of 
GO clusters found is presented in Fig. 2-21. A complete list of over-represented genes found 
by DAVID is provided in the Appendix section 5.7. 
Genes associated with enrichment in the activating histone marks H4ac and H3K27ac in 
tolerant monocytes were preferentially involved in ion binding (Fig. 2-21, upper panel). A 
detailed look at the gene lists provided by DAVID indicates that H4ac and H3K27ac were 
found, for instance, in genes encoding for metallothioneins (MTs), which are important for 
regulation of oxidative stress responses (Kumari et al. 1998). 
Genomic sites linked to an increase in the repressive histone mark H3K9me2 were also 
involved in ion binding. Moreover, most of the genes belonged to DNA binding proteins like 
zinc-finger transcription factors. Enrichment of H4K20me3 in tolerant monocytes was 
associated with genes involved in apoptosis. Furthermore, H3K27me3 was mainly enhanced 
in genes that mediate cell shape and movements dependent on actin filaments (Fig. 2-21, 
lower panel). DAVID analyses of genes associated with H3K9me2 and H4K20me3 also 
displayed hits in cell/organism developmental stages like reproduction, which partially makes 
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sense as these histone modifications are repressive marks indicating a developmental 
repression of these genes in monocytes. As, however, the focus of the analyses was 
narrowed to differentially regulated regions, these false positive results were excluded from 
further considerations. 
 
 
Fig. 2-21: Genes linked to activating histone marks in LPS-tolerant cells are involved in ion binding, 
whereas genes associated with repressive marks are implicated in transcription, apoptosis and filament 
formation. Annotated genes obtained from histone-limited DiffPeak data sets (TSS ± 10 kb) were used for 
functional gene ontology (GO) enrichment analysis using Database for Annotation, Visualization and Integrated 
Discovery (DAVID). The numbers of genes found significantly over-represented in the given gene set is shown in 
brackets. Only GO enrichment scores with a P value (pVal) below 0.05 were considered and are expressed as  
-log(P value). 
Examples of differentially enriched regions for either activating or repressive histone 
modifications in tolerant human monocytes treated with LPS (T100+L) identified by SICER 
are depicted in Fig. 2-22 A and B. 
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Gene expression of selected genes was further analyzed by qRT-PCR to determine whether 
the observed histone pattern identified by SICER was responsible for regulating the gene 
expression changes associated with endotoxin tolerance. Consistent with the histone code 
hypothesis, MT1F and MT1L mRNA expression (increase in activating histone modifications) 
were enhanced in tolerant monocytes (Fig. 2-22 C). The zinc finger transcription factors 
ZSCAN18 and ZNF316 (increase in repressive histone modifications), however, showed LPS 
signaling-dependent expression and exhibited higher expression in T100+L compared to 
N+L. Notably, the mRNAs of these transcription factors were generally expressed in very low 
concentrations (Fig. 2-22 D). 
 
 
Fig. 2-22: Examples of differentially histone mark-enriched genomic regions in endotoxin tolerance 
identified by SICER. (A & B) Binding profiles indicating interactions of histone modifications within the genome 
are displayed in the UCSC Genome Browser. Significant peaks (fold change ≥ 2, P value ≤ 1e-6) identified by the 
peak caller SICER are shaded in grey. (A) Enrichment of activating histone marks. (B) Enrichment of repressive 
histone marks. (C & D) Expression analysis (mRNA) of selected genes showing enrichment in either activating 
(C) or repressive histone modifications (D) in T100+L (mean ± SEM of 3 independent experiments). 
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Next, the histone-limited DiffPeak sets were analyzed for transcription factor binding sites 
(TFBSs) to identify the transcription network within the genomic regions that showed either 
enrichment in activating or repressive histone modifications in endotoxin-tolerant monocytes 
treated with LPS. Here, all identified peaks without limitation in TSS regions were used to 
allow a genome-wide analysis. 
TFBS analysis of DNA regions enriched for repressive H3K9me2 and H4K20me3 revealed a 
significant increase in the binding site for the transcription factor YY1 (ying-yang 1)  
(Fig. 2-23, left panel). However, most of the regions were potentially associated with SCL 
(stem cell leukemia) and SMAD3 (mothers against decapentaplegic homolog 3) binding 
motifs (Fig. 2-23, right panel). A combinational analysis of genomic regions co-localized by 
H3K9me2 and H4K20me3 indicated again an enrichment in SMAD binding sites (Fig. 2-23, 
lower part). Because of the low number of peak regions (DiffPeaks, see Fig. 2-20 B) 
identified for enrichment of H4ac, H3K27ac and H3K27me3 in tolerant monocytes, no 
reliable assumptions for these marks could be assumed. A complete list of TFBSs found is 
provided in Appendix 5.6. 
 
 
Fig. 2-23: Genomic regions linked to repressive H3K9me2 and H4K20me3 are enriched for YY1 and SMAD 
binding sites. Histone-limited DiffPeak data sets identified in tolerant monocytes treated with LPS (T100+L) were 
analyzed for transcription factor binding sites (TFBSs) by HOMER. Motifs identified in genomic regions showing 
significant enrichment in the repressive histone marks H3K9me2 and H4K20me3 (no co-enrichment in activating 
histone marks) are depicted either by P value (left hand side) or by percentage (right hand side). 
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Taken together, TFBSs for e.g. SMAD and YY1 were potentially enriched in genomic 
regions, which showed parallel increases in the repressive histone marks H3K9me2 and 
H4K20me3 in LPS-tolerant monocytes. This implies that these transcription factors might 
partially be the basis for the repressive histone pattern observed in endotoxin tolerance. 
 
2.2.2 Global Analysis of DNA Methylation by MethylCap-Seq 
Besides histone modifications, endotoxin-induced tolerization could be regulated by 
epigenetic changes in DNA methylation, which indicates repression (Bird & Wolffe 1999). 
Global changes in DNA methylation induced by endotoxin tolerance were analyzed by 
Methyl-Capture Sequencing (MethylCap-Seq). MethylCap-Seq is based on the in vitro 
enrichment of methylated DNA fragments by the methyl-CpG binding domains (MBD) and 
subsequent massively parallel sequencing. This technique was already introduced in 2.1.7 
(for more details see 4.3.9 in Materials & Methods). Of note, only preliminary data are 
presented here as replication of this approach is currently in process. 
For better comparison between analyses of histone modifications by ChIP-Seq and DNA 
methylation by MethylCap-Seq, naïve monocytes stimulated with LPS (N+L) were compared 
with high-dose LPS-tolerized monocytes re-treated with LPS (T100+L) (Fig. 2-24 A). 
Differentially methylated genomic regions were identified using the Bioconductor package 
MEDIPS (Lienhard et al. 2014) and significant changes were indicated by a minimum fold 
change of 2 (P value ≤ 0.01). Subsequently, genomic regions were annotated to the nearest 
gene. In total, 13 807 differentially methylated regions could be identified, from which 3756 
regions were linked to TSS regions (± 10 kb, Fig. 2-24 B). 
LPS-tolerant human monocytes (T100+L) compared to naïve cells treated with LPS (N+L) 
showed an overall reduction in DNA methylation (Fig. 2-24 C). Only 577 unique genes could 
be identified showing significant enrichments of DNA methylation by a minimum 2-fold 
change in tolerant monocytes (T100+L). Functional GO enrichment analysis of this gene data 
set revealed that most of the genes were mapped to phosphate metabolism and RNA 
binding (Fig. 2-24 C, for a complete overview of GO results please go to Appendix  
section 5.7). Selected examples of genes or gene regions, which showed significant 
enrichment in DNA methylation in tolerant monocytes treated with LPS, are depicted in  
Fig. 2-24 D. 
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Fig. 2-24: Endotoxin tolerance induces a global loss in DNA methylation. (A) Naïve and tolerant human 
monocytes were subjected to MethylCap-Seq. (B) Overview of significant differentially methylated genomic 
regions identified by comparison of N+L with T100+L. Genes were annotated by the Bioconductor package 
MEDIPS. (C) Genes showing enrichment in DNA methylation in tolerant monocytes treated with LPS (T100+L) 
were analyzed for functional GO enrichment using DAVID. The numbers of genes found significantly over-
represented in the given gene set is shown in brackets. (D) Representative binding profiles indicating enrichment 
in DNA methylation in T100+L for selected genes are displayed in the UCSC Genome Browser. Differentially 
methylated regions (fold change ≥ 2, P value ≤ 0.01) identified by the Bioconductor package MEDIPS are shaded 
in grey. 
Moreover, DNA methylation and histone marks can “communicate” with each other as both 
modifications provide binding platforms for various DNA- and histone-modifying proteins 
(Reviewed in Fuks (2005) and Brenner & Fuks (2007)). Therefore, identified genes showing 
enrichment in DNA methylation (near TSS up to 10 kb) in endotoxin-tolerant monocytes 
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treated with LPS (T100+L) were compared to the gene lists obtained by ChIP-Seq/SICER 
analysis, which indicated an increase in the repressive histone marks H3K9me2 and 
H4K20me3 but no co-enrichment in activating marks near the TSS of genes (Fig. 2-25). 
 
 
Fig. 2-25: Genomic regions showing enrichment in repressive histone modifications do not co-localize 
with DNA methylation. (A) Comparison of gene lists obtained by MethylCap-Seq/MEDIPS with ChIP-Seq/SICER 
data: Genes showing enrichment in DNA methylation in tolerant monocytes treated with LPS were compared to 
genes with significant enrichment in H3K9me2 and H4K20me3, but no co-enrichment in activating histone marks 
(histone-limited DiffPeak data sets, Fig. 2-20 B). Only gene regions up to 10 kb from TSS were considered for 
analysis. (B) Binding profiles indicating enrichment in DNA methylation are compared to genes showing 
enrichment in the repressive histone modifications H3K9me2 and H4K20me3 in tolerant monocytes treated with 
LPS (T100+L) identified by SICER (from Fig. 2-22 B). Binding profiles are depicted in the UCSC Genome 
Browser. Grey shaded boxes indicate significant differentially regulated regions identified by SICER or MEDIPS, 
respectively. 
As indicated in Fig. 2-25 A, no direct association could be found between DNA methylation 
and repressive histone modifications. Only six genes in total showed potential co-localization 
(± 10 kb of TSS) of both epigenetic markers (Fig. 2-25 A). However, genes identified by 
SICER, which gained repressive histone modifications during tolerance inductions (from  
Fig. 2-22 B), often showed parallel enrichment in DNA methylation (no significant result,  
Fig. 2-25 B). 
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Taken together, in contrast to the observed histone pattern, endotoxin tolerance mediated a 
global loss in repressive DNA methylation, which might be due to the first overnight LPS 
stimulus. Only a small proportion of genomic regions gained significant enrichment in DNA 
methylation in tolerant monocytes treated with LPS. Moreover, a direct interaction of DNA 
methylation with repressive histone modifications could not be confirmed by bioinformatical 
analyses. 
 
2.2.3 Validation of Epigenetic Changes by Global mRNA Expression  
As indicated by analyses of histone modifications and DNA methylation, endotoxin tolerance 
seemed to have a dramatic impact on the epigenetic landscape of human monocytes. 
However, whether the observed epigenetic changes were responsible for the characteristic 
gene expression in tolerant monocytes compared to naïve ones remains to be validated. 
Therefore, human monocytes were subjected to the in vitro endotoxin tolerance model and 
extracted RNA was subjected to total mRNA-Sequencing (mRNA-Seq) to analyze the 
genome-wide expression pattern of naïve (N+L) and high-dose tolerized, human monocytes 
stimulated with LPS (T100+L) (see Fig. 2-26 A). 
Comparative analysis in global gene expression identified 3638 genes differentially 
expressed with a minimum fold change of 2 (P value ≤ 0.05); of these, 1758 genes were 
down regulated and 1880 genes were up regulated in high-dose tolerized monocytes 
stimulated with LPS (Fig. 2-26 B). GO analyses of differentially expressed genes revealed 
that tolerant monocytes treated with LPS (T100+L) showed a prominence in phagocytosis- 
and metabolism-related processes, whereas mechanisms involved in gene expression, 
particularly RNA metabolism and translation, and immune responses were reduced  
(Fig. 2-26 C). This gene expression pattern clearly demonstrated a profound gene 
reprogramming in endotoxin tolerance towards an immunosuppressive phenotype. 
Finally, the identified gene sets were correlated with genes that underwent an epigenetic 
change in tolerant monocytes (within TSS ± 10 kb). Approximately 1000 of the differentially 
expressed genes (27 %) showed a transcriptional level and an epigenetic pattern consistent 
with the histone code theory (Strahl & Allis 2000). In particular, changes in activating histone 
modifications (H3K27ac, H4ac) – either enrichment or reduction in tolerant monocytes 
treated with LPS (T100+L) – correlated with genes expression (Fig. 2-26 D). No significant 
correlation could be observed between changes in DNA methylation and transcriptional level 
(Fig. 2-26 F), further confirming that DNA methylation plays only a minor role in endotoxin 
tolerance. 
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Fig. 2-26: Approximately 1000 differentially expressed genes show an expression pattern consistent with 
the histone code theory. (A) Naïve and high-dose tolerized monocytes were treated with LPS and subjected to 
mRNA-Seq analysis. (B) Overview of differentially expressed genes: Volcano plot (left) represents the relationship 
between significance and fold change (FC) illustrated using the Bioconductor package cummeRbund. 
Differentially expressed genes showing a minimum fold change of 2 in RPKM expression values are depicted as 
heat map (right). Heat map was built using R (Euclidean clustering, unsupervised). Three replicates per condition 
were used for expression analysis. (C) GO enrichment analysis of identified differentially expressed genes was 
performed using DAVID, with the count of genes found significantly over-represented in the given dataset is 
shown in brackets. (D and E) Differentially expressed genes were analyzed for potential gene overlap with genes 
identified showing either differences in histone modifications (D) or DNA methylation (E) within the TSS region 
using the Bioconductor package GeneOverlap. Significance was tested using Fisher’s exact test (N.S. = not 
significant). 
In summary, global transcriptomic analysis identified a clear reprogramming of gene 
expression in tolerant human monocytes. Correlation of transcription with specific epigenetic 
signatures demonstrated that gene expression was partially associated with histone 
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modifications representing active or repressive transcription. The analyzed changes in 
histone modifications (but not DNA methylation) indicate how a physiological condition of 
tolerant monocytes is mediated by promoting oxidative stress responses, while global 
repression of transcription and signaling-linked molecules is induced. 
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3. Discussion 
Exposure of monocytes and macrophages to LPS results in expression of several genes 
encoding for pro-inflammatory and anti-inflammatory cytokines, chemokines and anti-
microbial peptides and proteins. Moreover, LPS stimulation leads to tolerance induction and 
reprogramming of gene expression with transient silencing of a specific set of LPS-induced 
genes. This phenomenon known as endotoxin tolerance can be observed in vivo in humans 
and animals as well as in vitro in cell culture (Favorite & Morgan 1942, Fraker et al. 1988, 
Randow et al. 1995). Nowadays, it is common knowledge that LPS-inducible genes can be 
broadly classified into two distinct classes (Biswas & Lopez-Collazo 2009, Biswas & Shalova 
2012, Cavaillon & Adib-Conquy 2006, Seeley & Ghosh 2014). Upon repeated exposure to 
LPS, one group of genes is transiently silenced to prevent excessive inflammation and 
immunopathology. These genes encode for pro-inflammatory cytokines, like TNF and IL-1β, 
and are termed class T genes or tolerizable genes. The tolerization effect on class T genes 
appears within different magnitudes (Erroi et al. 1993), whereas TNF is probably the best 
marker for endotoxin tolerance as assessed by its dramatically reduced production following 
LPS tolerization (Mathison et al. 1990). The second class of genes also termed  
non-tolerizable genes (class NT) contains antimicrobial mediators and effectors that remain 
inducible to maintain a basic antimicrobial host defense against invading pathogens without 
the destructive force of inflammation (Allantaz-Frager et al. 2013, Foster et al. 2007, Lehner 
et al. 2001, Rayhane et al. 2000, Wheeler et al. 2008). 
Both classes of genes are induced by the same receptor named TLR4. Initial LPS stimulation 
induces a temporary downregulation of TLR4 cell surface expression and reduction of 
downstream signaling by e.g. decoupling of TLR4 from the signaling adapter MyD88 
(Medvedev et al. 2002). But downregulation of major signaling pathways including NFκB and 
MAP kinase cascade activation would affect all LPS-induced genes. Thus, it is questioned 
how this differential gene regulation is mediated and how class NT – but not class T – genes 
remain highly inducible. There is increasing evidence that silencing one class of genes 
occurs by gene-specific rather than signal-specific mechanisms, through chromatin 
modifications at the level of individual promoters (Carson et al. 2011, Chan et al. 2005, El 
Gazzar et al. 2007, Foster et al. 2007, Foster & Medzhitov 2009, McCall & Yoza 2007, 
Neagos et al. 2015, Ramirez-Carrozzi et al. 2006). Moreover, sustained unresponsiveness of 
inflammatory reactions in endotoxin tolerance persists for several days (in vitro) and weeks 
(in vivo) even if the original source of inflammation is resolved (Kox et al. 2011) or when the 
transduction of major signaling pathways is recovered (Krüger 2006). Moreover, activation of 
monocytes and macrophages and subsequent restoration of endotoxin tolerance by IFNγ 
(Docke et al. 1997a) or IFNα2 treatment (Shi et al. 2015) seems to be mediated by 
recruitment of transcriptional activators and chromatin remodeling proteins without significant 
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alterations in TLR4 signaling defects (Chen & Ivashkiv 2010, Shi et al. 2015). These 
examples imply some kind of memory generation. As changes in epigenetic marks appear 
more stable than simple alterations in signaling molecules, it is very likely that the initial LPS 
stimulation remodels the epigenetic landscape to a transiently more tolerant phenotype. 
The aim of this study was to elucidate the changes in the epigenetic landscape occurring 
during tolerance induction in a human experimental setup, thus providing new insights in the 
tolerance mechanisms leading to repression of individual genes. 
 
3.1 Individual Class T Genes are Differentially Affected by Epigenetic Changes 
and Signaling Events in Endotoxin Tolerance 
The first part of the study focused on the analysis of differences in transcription-linked 
histone modifications compared to repressive marks with a specific focus on immune-
relevant genes that play an important role in endotoxin tolerance. 
A common pattern to distinguish class NT genes from class T genes could not be identified 
in human monocytes. The study rather provided a detailed classification of class T genes in 
intermediately tolerizable and highly tolerizable. Comparative analysis of activating histone 
modifications and signaling strength in LPS-tolerant monocytes showed that the IL6 and IL1B 
genes possessed activating H3K27ac and H4ac even in tolerant monocytes. Moreover, 
production of IL-6 and presumably IL-1β was signaling-dependent (intermediately 
tolerizable). In contrast, the TNF and CXCL10 genes showed diminished induction of 
activating histone marks independent of signaling strength of tolerant cells (highly 
tolerizable). This type of discrimination seemed to be human-specific, as analysis of murine 
macrophages demonstrated diminished re-acetylation of H4 within the Il6 gene, while the Tnf 
gene showed H4 re-acetylation in tolerant cells. 
Further analysis of repressive histone modifications in human monocytes identified selective 
enrichment of repressive H3K9me2 and H4K20me3 in IL1-related genomic loci, whereas the 
IL6 gene showed reduction in H3K27me3 in tolerant monocytes re-stimulated with LPS. 
Lastly, endotoxin tolerance had no impact in the DNA methylation status of the IL6 and TNF 
genes. 
 
3.1.1 The Role of Activating Events in Individual Genes 
First, characterization of cytokine and chemokine secretion in human tolerant monocytes was 
performed to assure that the experimental setup used in this study followed the expression 
behavior described for endotoxin tolerance. Consistent with previous studies (Allantaz-Frager 
et al. 2013, Foster et al. 2007), a subset of LPS-inducible genes encoding for TNF, 
CXCL10/IP-10, CXCL8/IL-8, IL-6, IL1-RA and IL-1β was selectively reduced upon repetitive 
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exposure to LPS (class T). However, the tolerization behavior of these cytokines was quite 
diverse, demonstrating a high tolerization effect on TNF and CXCL10/IP-10 production, 
whereas IL-6 and IL-1β were only moderately tolerized by LPS treatment. Moreover, 
CXCL8/IL-8 showed a clear re-induction in tolerant monocytes reaching almost the same 
expression level as naïve monocytes treated with LPS. By contrast, expression of other 
chemokines like CCL2/MCP-1 and CCL7/MCP-3 was unaffected or even enhanced. 
Likewise, the mRNA expression of FPR1 was clearly increased in tolerant monocytes 
compared to naïve ones (class NT). The expression of the genes mentioned is somewhat 
controversially discussed in the literature. Especially for CXCL8/IL-8, IL-1RA, IL-1β, 
CCL2/MCP-1 and CCL7/MCP-3, conflicting studies exist showing either 
enhanced/unaffected or reduced expression depending on the model and cell type used for 
analysis of endotoxin tolerance (reviewed in Biswas & Lopez-Collazo (2009), Cavaillon & 
Adib-Conquy (2006), Lopez-Collazo & Del Fresno (2013) and Nahid et al. (2011)).This 
implies that endotoxin tolerance is a very complex phenomenon and that cytokines do not all 
behave the same. Thus, interpretation of endotoxin tolerance and the resulting 
consequences must take into account the diverse nature of cells and the environmental and 
experimental setup. 
To relate the differences in gene expression to potential changes in epigenetic modifications, 
the expression behavior of specific genes affected by endotoxin tolerance was analyzed by 
epigenetic changes. Primarily, the induction of histone modifications indicating 
transcriptionally active chromatin (H3K4me3, H3K27ac and H4ac) was characterized near 
the transcription start sites (TSS ± 1 kb) of TNF, CXCL10, IL8, IL6 and IL1B (class T genes) 
compared to FPR1 (class NT gene). 
ChIP assays of tolerant monocytes challenged with a high dose of LPS (T100+L) compared 
to naïve cells (N+L) demonstrated that highly tolerant genes like TNF and CXCL10 (class T 
genes) showed a diminished re-induction in activating histone modifications, in particular 
acetylation marks, which mirrored their reduced gene expression in endotoxin tolerance. By 
contrast, the TSS regions of IL1B, IL6 and IL8 (class T genes) were associated with a similar 
or even higher levels of activating histone modifications in tolerant cells stimulated with LPS. 
The histone pattern of these genes resembled that of the class NT gene FPR1. However, 
whereas the kinetics of induction of transcription-linked histone marks within the FPR1 gene 
reflected its enhanced gene expression in tolerant monocytes, the positive histone patterns 
of IL1B and IL6 were contrary to their reduced gene expression in endotoxin tolerance. 
Moreover, species-specific differences in histone patterns of class T genes seem to exist. In 
particular, the promoter regions of IL6 and TNF were differentially modified in human 
monocytes compared to murine macrophages. Whereas the human IL6 gene still possessed 
the positive histone mark H3K4me3 and showed re-induction of H4ac in tolerant human 
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monocytes, the re-acetylation of H4 was reduced in murine macrophages. The diminished 
H4 acetylation in the murine Il6 gene has also been shown in a publication by Foster et al. 
(2007). In contrast, H4ac was inducible in the murine Tnf gene while being inhibited in 
human monocytes. This further demonstrates that the mechanisms leading to gene 
repression in endotoxin tolerance might be different and likely depend on the experimental 
setup. 
The variation in tolerance induction of the human cytokines TNF and CXCL10/IP-10 
compared to IL-1β, IL-6 and CXCL8/IL-8 could be partially explained by differences in 
sensitivity towards LPS-signaling strength. For instance, signaling-dependent analyses of 
gene expression combined by histone modification assays revealed that the production of 
CXCL8/IL-8, IL-6 and presumably IL-1β were more sensitive to signaling strength. 
Monocytes tolerized by a low dose of LPS (1 ng/ml) showed a reduced but still clearly 
detectable signaling induction compared to cells treated with a high dose of LPS (100 ng/ml) 
as shown for e.g. the induction of MAP kinase p38 phosphorylation. The remaining signaling 
strength in low-dose tolerized monocytes was sufficient to induce CXCL8/IL-8, IL-6 and IL-1β 
expression, though the production level of particular IL-6 and IL-1β was not as high as in 
naïve monocytes stimulated with LPS. The parallel analysis of the transcription-linked 
histone modifications H3K27ac and H4ac revealed that the corresponding IL8, IL6 and IL1B 
genes showed high induction in these activating histone marks during low-dose LPS 
treatment. Again, the histone patterns were very similar to the epigenetic signature of the 
class NT gene FPR1, which was even more highly expressed in low- and high-dose treated 
monocytes. It is not clear, why especially the IL6 and IL1B genes still possessed high 
enrichment in activating histone marks in tolerant human monocytes while showing reduced 
gene expression capacity. It could be hypothesized that these genes were modified within 
their promoters to a more active, positive histone pattern indicating a kind of ‘stand-by status’ 
for transcription during endotoxin tolerance, meaning that if the signaling level is strong 
enough, these genes will be transcribed. But nevertheless, the production of IL-6 and IL-1β in 
low-dose tolerized cells (1 ng/ml LPS) did not reach the same expression level as in naïve 
monocytes treated with LPS, indicating that additional repressive mechanisms besides 
signaling strength might exist to reduce their expression capacity. Moreover, signaling 
analysis was exclusively performed with a focus on p38 phosphorylation; it cannot be ruled 
out that other signaling mechanisms have an impact on the expression of these genes. For 
instance, a detailed study of TNF tolerance implied that low-dose TNF tolerance is mediated 
by glycogen synthase kinase 3, whereas high-dose tolerance is regulated by A20/glycogen 
synthase kinase 3- and protein phosphatase 1-dependent mechanisms (Gunther et al. 2014). 
Perhaps, this discriminative mechanism is also important in high and low-dose LPS 
tolerization. 
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By contrast, the promoter regions of TNF and CXCL10 showed low acetylation status of 
H3K27 and H4 during low- and high-dose LPS tolerization, without regard to signaling 
strength. In particular, H4ac induction was completely diminished independently of the 
signaling capacity in low- and high-dose treated cells, indicating that the repression of these 
genes is likely mediated by the involvement of histone modifying enzymes e.g. histone 
deacetylases (HDACs) (Castellucci et al. 2015). Moreover, the discrimination described 
seems to be independent of so-called primary and secondary response genes in endotoxin 
tolerance. Primary or early response genes (PRG) e.g. TNF and IL1B are supposed to be 
kept in an open chromatin state in naïve monocytes and macrophages, whereas secondary 
or late response genes (SRG) like IL6 need initial recruitment of the transcription machinery 
after stimulation (Ghisletti et al. 2009, Hargreaves et al. 2009, Ramirez-Carrozzi et al. 2006). 
As IL6 (SRG) and IL1B (PRG) in this study behaved very similarly regarding their epigenetic 
changes, it is likely that the mechanisms involved in LPS tolerization are different than for 
transcription of PRGs and SRGs after initial LPS stimulation. 
 
3.1.2 The Role of Repressive Events in Individual Genes 
Besides changes in positive histone modification, it could be hypothesized that tolerizable 
genes were repressed by gaining repressive histone modifications rather than the loss of 
activating ones. For instance, Stender et al. reported that the repressive H4K20me3 served 
as a checkpoint for expression of TLR4 target genes and that NFκB-dependent erasure of 
H4K20me3 was necessary for gene expression (Stender et al. 2012). Moreover, H3K9me2 
hypermethylation in tolerant monocytic THP1 cells within the promoter regions of TNF and 
IL1B was reported by other studies (Chan et al. 2005, El Gazzar et al. 2007). Thus, a 
selective enrichment in repressive histone modifications in class T genes might be very 
likely. However, analyses of H3K9me2, H3K27me3 and H4K20me3 by ChIP-Seq could only 
partially support an involvement of these repressive histone marks in endotoxin tolerance. 
The IL1B locus, for example, showed an increase in H3K9me2 in tolerant monocytes circa 
7 kb upstream from its TSS. Moreover, ChIP-seq analyses revealed an increase in 
H4K20me3 near the TSS of IL1A and IL1R1, which are both involved in IL-1 signaling. 
However, no differences in repressive histone marks could be observed for the TNF, 
CXCL10 and IL8 genes in human monocytes. Strikingly, IL6 displayed a reduction of the 
repressive mark H3K27me3 in tolerant cells compared to naïve monocytes treated with LPS, 
which negatively correlates with its gene repression. 
Again, a common pattern in repressive histone modifications could not be observed in class 
T genes. Notably, not every known repressive histone mark was analyzed in the present 
study, and many have not yet been identified. Thus, it has to be further investigated  
how these modifications really affect gene expression in endotoxin tolerance.  
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Moreover, individual differences by using primary cells (here human monocytes) cannot be 
ruled out and might result in distinct results than using a cell line like THP-1. 
To elucidate other epigenetic mechanisms (besides histone modifications) involved in 
tolerization of TNF and IL-6 production in primary human monocytes, the promoter regions of 
the encoding genes were investigated for de novo DNA methylation – an epigenetic marker 
for gene regression (Bird & Wolffe 1999). PCR-based bisulfite sequencing (BS-Seq) revealed 
no significant changes in DNA methylation in the promoter regions of human TNF and IL6 in 
naïve and tolerant monocytes treated with LPS. The analysis of BS-Seq data in the present 
work only focused on canonical CpGs. Certainly, recent advances in the field of DNA 
methylation demonstrate that there is a higher diversity in DNA modifications than expected 
(reviewed in Breiling & Lyko (2015)). However, gene-covered analysis of TNF and IL6 by 
MethylCap-Seq, which is a technique in which methylated DNA is indirectly analyzed, 
revealed no significant differences between naïve and tolerant monocytes, further confirming 
that DNA methylation might not play a prominent role in LPS tolerization. This is in contrast 
to previous reports. Detailed analyses of the TNF promoter in THP1 cells demonstrated that 
its repression by DNA methylation was mediated by a complex interplay of several 
molecules: Binding of the NFκB family member RelB and high-mobility group protein 1 
(HMGB1) in tolerant THP1 cells within the TNF promoter led to recruitment of the histone 
H3K9 methyltransferase G9a, which induced the repressive mark H3K9me2. H3K9me2 in 
turn mediated DNA methylation by HP1-dependent recruitment of the DNA methylase 
DNMT3a/b at the TNF promoter (El Gazzar et al. 2009, El Gazzar et al. 2008). The 
discrepancy between the present study and the publications from El Gazzar et al. might arise 
because primary human monocytes may behave differentially than a monocytic cell line as 
discussed above. Moreover, the time frame of DNA methylation analysis might not be 
optimal in the present study. The establishment of DNA methylation is potentially different 
from those of histone modifications and may differ between cell type and species. 
Generally, several defects in signaling events have been reported in endotoxin tolerance 
including suppressed phosphorylation of p38 and reduced degradation of the NFκB inhibitor 
molecule IκBα. LPS stimulation induces a negative feedback loop by parallel activation of 
several negative regulators of TLR4 signaling. These are induced by the same NFκB and 
MAP kinase pathways, and mediate termination of input signaling. LPS-induced inhibitors of 
signaling include: IL-1 receptor associated kinase M (IRAKM, which inhibits TRAF6 complex 
formation), A20 (which prevents ubiquitinylation of the signaling molecule TRAF6), A20-
binding inhibitors of NFκB activation 3 (ABIN-3, which inhibits NFκB activation), and dual 
specificity phosphatase 1 (DUSP1, which dephosphorylates p38). Of note, not all of the 
mechanisms mentioned have been validated in humans (reviewed in Biswas & Shalova 
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(2012), Cavaillon & Adib-Conquy (2006), Grutz (2005), Medzhitov & Horng (2009) and 
Seeley & Ghosh (2014)). However, these mechanisms are basically not selective in that they 
prefer the expression of one subset of genes, while another one is inhibited. The signaling 
inhibitors mentioned act proximally to TLR4 and thus block gene expression in a global 
fashion (Medzhitov & Horng 2009). 
Discrimination in gene expression can be mediated on the chromatin level by e.g. 
transcriptional repressors. LPS signaling increases expression of inactive p50/p50 
homodimers of NFκB, which compete with active p65/p50 heterodimers for binding to the 
gene targets. Moreover, detailed analyses in tolerant, monocytic THP-1 cells revealed that 
repression within the promoter regions of TNF and IL1B relied on a change in the 
composition of the transcription factor NFκB from activating p65-p50 to repressive RelB-p50 
complexes (Chan et al. 2005, El Gazzar et al. 2007). RelB-binding within the Il1b promoter 
has also been demonstrated in murine microglia subjected to LPS preconditioning 
(Schaafsma et al. 2015). 
Active repression can be further mediated by induction of anti-inflammatory cytokine 
expression e.g. IL-10 and TGFβ, which downregulates the activation of immune cells 
including monocytes and macrophages and induces expression of transcriptional regulators. 
For instance, IL-10 influences TNF gene expression by blocking transcription elongation in 
human primary macrophages (Smallie et al. 2010). Moreover, upregulated IL-10 expression 
in murine macrophages activates B cell lymphoma 3 (BCL3) production that negatively 
regulates NFκB signaling by inhibiting p65/p50 binding to its promoter sites (Kuwata et al. 
2003). This negative mechanism, however, is selective for the murine Tnf gene and has no 
influence on Il6 expression, although both cytokine-encoding genes belong to class T genes. 
By contrast, another IL10-inducible molecule called IκBNS limits murine Il6 expression 
(Hirotani et al. 2005, Kuwata et al. 2006). These examples indicate that LPS-induced 
transcriptional regulators act on individual class T genes and limit their expression in a gene-
specific manner (Medzhitov & Horng 2009). Thus, a combinational effect of several 
transcriptional repressors can potentially lead to the discriminative gene expression in 
endotoxin tolerance. 
Yan and colleagues (2012) further demonstrated that binding motifs for NFκB were 
significantly enhanced in promoters of class T genes, but not in class NT genes in murine 
macrophages. Additionally, repressive p50 binding was essential for generating LPS 
tolerance by induction of a stable repressor complex containing the nuclear receptor  
co-repressor 1 (NCoR). Thus, the selective use of an NFκB binding site in promoters of  
pro-inflammatory (class T genes) but not antimicrobial genes (class NT genes) could further 
explain selective down regulation of destructive immune responses (Yan et al. 2012). Yet, 
the finding described in Yan et al. (2012) does not explain why the TNF and CXCL10/IP-10 
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production were highly tolerizable compared to IL-6 and CXCL8/IL-8 in human monocytes in 
this study, if tolerization of class T genes is in general dictated by NFκB binding sites. It 
should be interesting to investigate whether specific transcription factor binding motifs are 
differentially enriched within class T genes in human monocytes. 
Moreover, it could be demonstrated that several transcriptional regulators interact with 
chromatin modifying molecules. NCoR, for instance, was shown to interact with the histone 
deacetylase HDAC3 within the Tnf promoter in murine macrophages (Yan et al. 2012).  
The transcriptional regulator RelB seemed to bind the methyltransferase G9a, which 
methylates H3K9 in the TNF and IL1B genes of THP-1 cells (Chan et al. 2005, El Gazzar et 
al. 2008, El Gazzar et al. 2007, Schaafsma et al. 2015). In the present work, enrichment of 
H3K9me2 could only be confirmed for the IL1B gene in human monocytes as demonstrated 
by ChIP-Seq analysis (discussed above). Another transcriptional regulator is ATF3, which 
has been shown to negatively regulate gene expression of e.g. Il6 and Il12 in an HDAC1-
dependent manner in murine macrophages (Gilchrist et al. 2006). 
To investigate the potential role of histone modifying enzymes and repressor complexes 
leading to distinct chromatin patterns, ChIP assays identifying NCoR and HDAC3 recruitment 
to the promoter regions of human TNF, IL6, IL1B and FPR1 were performed. However, no 
enrichment of these repressive mediators in individual genes could be observed (data not 
shown) implying that the specific mechanism by NCoR-HDAC3 might not be involved in 
human monocytes. However, it cannot be ruled out that other HDACs not analyzed in this 
study such as HDAC1 have an impact in deacetylation of particular genes e.g. TNF and 
CXCL10, as LPS stimulation leads to an increase in the production of several HDACs (Aung 
et al. 2006). 
Taken together, the experimental results determined in this study and by others clearly show 
that endotoxin tolerance has a very complex interplay, which cannot be explained by one 
single mechanism. The combined effect of changes in signaling and epigenetic remodeling 
affects LPS-induced genes by different extents, which may lead to the discriminative 
expression pattern known for endotoxin tolerance. 
3.1.3 Summary 
The analyses of specific class T and NT genes by histone modifications in human monocytes 
showed that the histone patterns were inconsistently affected by LPS tolerization and that the 
modifications only partially reflected their gene expressions in endotoxin tolerance. After 
examining the class T genes encoding for the cytokines and chemokines TNF, CXCL10/ 
IP-10, IL-1β, IL-6 and CXCL8/IL-8 indicated that a common, selective histone pattern, which 
discriminates the class T genes from the class NT genes, unlikely exists. The present study 
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further showed that selective repression of specific genes is potentially a combined effect of 
several molecular mechanisms including epigenetic changes and signaling effects, which 
jointly contribute to the phenomenon known as endotoxin tolerance. 
An earlier study from Foster et al. (2007) introduced the concept of non-heritable 
transcriptional memory based on epigenetic mechanisms in endotoxin tolerance. The authors 
analyzed murine macrophages in an in vitro endotoxin tolerance model and identified two 
distinct histone patterns discriminated by selective changes in H3K4me3 and H4ac, which 
contributed to the opposing gene expression manner of class T and NT genes. They 
demonstrated that H3K4me3 and H4ac persisted and were more highly induced in class NT 
genes, whereas these activating histone marks were lost in class T genes (Foster et al. 
2007). 
The present work suggests a more complex nature of endotoxin tolerance showing that 
tolerization in itself seems to be very discriminative. It is known that endotoxin tolerance 
leads to downregulation of signaling pathways, however the effect on gene expression is 
quite diverse. The data obtained suggest that initial LPS signaling induces chromatin 
remodeling, which combined with a complex interplay of signaling duration, has an impact on 
gene transcription in the tolerized state. Class NT genes probably undergo chromatin 
remodeling so that even reduced signaling is enough for their gene expression (Medzhitov & 
Horng 2009, Seeley & Ghosh 2014), whereas tolerization of class T genes occurs by 
signaling and epigenetic changes. 
This study could identify different levels of regulation: First, the class T genes analyzed 
possessed different patterns in transcription-linked histone modifications. Whereas IL6 and 
IL1B showed enrichment in activating histone marks, the re-induction in H4ac and H3K27ac 
was diminished in the promoter regions of TNF and CXCL10 in tolerant monocytes. Second, 
IL-6 and presumably IL-1β production showed higher sensitivity towards LPS signaling 
compared to TNF and CXCL10/IP-10. Third, tolerization of the genes analyzed was not 
mediated by a specific enrichment in the repressive histone modifications investigated. This 
leads to a more detailed classification of class T genes into highly tolerizable and 
intermediate tolerizable genes (see Fig. 3-1 A). For instance, TNF and CXCL10/IP-10 were 
highly affected by endotoxin tolerance showing only low production in tolerant monocytes. 
The encoding genes were mainly regulated by chromatin changes affecting gene expression 
(highly tolerizable, epigenetic-driven). By contrast, IL-6 and IL-1β showed reduced 
expression in tolerant cells, which was mainly dependent on diminished signaling strength 
(intermediately tolerizable, signaling-driven). Moreover, the IL8 gene possessed a similar 
histone pattern like the IL6, IL1B and FPR1 genes and was highly inducible even in tolerant 
monocytes. Thus, it should be questioned whether IL8 belongs to class NT genes  
(non-tolerizable) or is a subgroup of intermediately tolerizable genes (see Fig. 3-1 A and B). 
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Fig. 3-1: Detailed classification of class T genes based on changes in signaling and histone modification 
(A) Class T genes can be further subdivided into genes that show reduced expression in tolerant human 
monocytes (intermediately tolerizable) and genes that show an almost complete loss in gene expression (highly 
tolerizable). As CXCL8/IL-8 shows high induction capacity even in low-dose tolerized monocytes reaching almost 
the same expression level than naïve cells stimulated with LPS, it is a matter of debate whether the encoding IL8 
gene belongs to the intermediately tolerizable or non-tolerizable gene class. (B) In endotoxin-tolerant human 
monocytes, FPR1 and IL8 show an activating histone pattern and are expressed mainly independently of 
signaling strength (non-tolerizable). In contrast, production of IL-6 and presumably IL-1β is dictated by the 
signaling capacity of tolerant cells (intermediately tolerizable), whereas the TNF and CXCL10 genes possess a 
‘negative’ histone pattern indicated by diminished re-enrichment in activating histone modifications, which 
potentially limits their gene expression (highly tolerizable). 
3.2 Endotoxin Tolerance Alters Genome-Wide the Epigenetic Signature of 
Human Monocytes 
Within the second part of the study, a genome-wide approach was used to investigate global 
epigenetic changes including histone modifications and DNA methylation induced by LPS 
tolerization in human monocytes. 
Genome-wide analysis in histone modifications identified a shift from activating histone 
modifications in naïve human monocytes to repressive histone marks in endotoxin-tolerant 
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cells re-stimulated with LPS. The alterations in histone modifications affected mainly distinct 
gene cluster showing only limited co-regulations in histone marks. In naïve monocytes 
treated with LPS, most of the genes involved in immune responses were associated with 
activating histone modifications, which was reduced in tolerant cells. By contrast, genomic 
regions gaining enrichment particularly in repressive H3K9me2 and H4K20me3 were 
observed in tolerant monocytes. These regions were mainly found in intergenic loci and 
genes involved in signaling and transcription pathways. Analysis of transcription factor 
binding sites within these regions revealed a potential enrichment in the binding motifs for 
YY1 and SMAD3. 
Moreover, endotoxin tolerance induced a global loss in DNA methylation. The identified 
changes in DNA methylation did not co-localized with alterations in repressive histone 
modifications. Finally, correlation of epigenetic changes with the gene expression pattern of 
tolerant monocytes identified approximately 27 % of differentially expressed genes that 
showed a histone pattern consistent with the histone code, while DNA methylation seemed to 
have no impact. 
 
3.2.1 Global Analysis of Histone Modifications 
Focusing on single genes in human monocytes provides only a glimpse into the epigenetic 
mechanisms involved in LPS tolerization. Therefore, genome-wide approaches using next 
generation techniques were applied to analyze the global changes occurring in endotoxin 
tolerance.   
First, analyses of positive (H3K27ac, H4ac) and repressive histone marks (H3K9me2, 
H3K27me3 and H4K20me3) revealed a genome-wide change of differentially regulated 
genomic regions from a more activating histone signature in naïve human monocytes 
stimulated with LPS to a repressive one in LPS-tolerized cells. The identified gene clusters 
were characterized by an almost mutually exclusive possession of either activating (H4ac 
and H3K27ac) or repressive histone marks (H3K9me2, H3K27me3 and H4K20me3), 
implying that these epigenetic signatures do not act cooperatively in regulating gene 
expression of these distinct sets of genes. Comparative analyses revealed that naïve 
monocytes treated with LPS showed enrichment in positive histone marks, especially H4ac, 
in a huge gene cluster, which was lost in tolerant monocytes, probably due to the reduced 
signaling capacity of tolerant monocytes affecting e.g. NFκB and MAP kinase cascades.  
GO analysis of this gene cluster showed a dominance of immune response-related 
mechanisms. This implies that LPS tolerization minimizes the induction capacity of positive 
acetylation markers in genes important for immune defense processes. 
In particular, intergenic sections gained an increase in repressive histone modifications 
implying a regulatory role of these regions in endotoxin tolerance. However, the remote 
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distance to potentially gene-coding regions makes it quite difficult to interpret their specific 
impact on LPS tolerization. Thus, genomic regions that showed differentially regulated 
histone modifications within the TSS ± 10 kb were further analyzed assessing a potential 
biological role in endotoxin tolerance. Regions that showed an increase in activating histone 
modifications in tolerant monocytes treated with LPS were particularly involved in metal 
binding and oxidative stress responses by e.g. metallothioneins as illustrated by GO 
enrichment analysis (Ruttkay-Nedecky et al. 2013). Indeed, mRNA expression analysis 
confirmed a positive correlation of MT1L and MT1F expression with enrichment in activating 
histone modifications in tolerant monocytes. In contrast, genomic regions that gained an 
increase in repressive histone marks, especially H3K9me2 and H4K20me3, during LPS 
tolerization were linked to transcription-involved molecules like zinc finger proteins. This 
implies that endotoxin tolerance might affect the gene transcription machinery in a global 
manner, which results in reduced gene expression. However, mRNA expression analysis of 
selected ZNFs in naïve and tolerant monocytes stimulated with LPS indicated that these 
transcription factors were expressed predominantly independently of their repressive histone 
pattern. Thus, the impact of enrichment in repressive histone marks needs to be validated in 
future studies. The induced changes may be important for the cell itself, but difficult to fully 
understand at the moment due to their complexity. Moreover, the present work focused on 
the analysis of genome-wide changes by comparing of naïve monocytes treated with LPS 
(N+L) with high-dose tolerized cells stimulated with LPS (T100+L). It cannot be ruled out, 
however, that the additional treatment of tolerant monocytes with LPS already changed the 
epigenetic signature of tolerant monocytes. Additionally, high-dose tolerization compared to 
low-dose treatment may differentially affect the epigenetic landscape. Thus, expanded 
analyses of the epigenetic profile of human monocytes using several tolerization conditions 
with or without LPS re-stimulation are required to answer this question. 
Next, the differentially regulated genomic regions were analyzed for transcription factor 
binding sites to identify the transcription factor network associated within these genomic 
elements possibly leading to the observed histone patterns. The potential binding motifs in 
regions that were associated with an enrichment in H3K27ac and H4ac in tolerant monocytes 
can only be hypothesized due to the fact that only a limited number of genomic elements 
significantly gained activating histone modifications in tolerant monocytes treated with LPS. 
Regions that were co-localized by H3K27ac and H4ac most likely showed enrichment for the 
binding motif of AP1, implying a MAP kinase signaling-dependent mechanism of positive 
regulation of these genomic regions (see Appendix 5.6). 
Regions that showed enrichment in the repressive marks H3K9me2 and H4K20me3 in 
tolerant monocytes treated with LPS were significantly enhanced for the binding motif of YY1 
and SMAD3, among others. Notably, the significance values obtained by HOMER were quite 
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low compared to the amount of peaks analyzed. Thus, only assumptions can be made 
regarding the possible transcription network in endotoxin tolerance. 
The transcription factor YY1 can act as a transcriptional activator or repressor depending on 
interaction partners. In endotoxin tolerance, Liu et al. (2014) demonstrated that RelB, YY1 
and the proto-oncogene protein Myc (c-Myc) were selectively recruited to chromatin and 
interacted with the H3K9me2 methyltransferase G9a, which further stabilized the 
repressosomal complex (Liu et al. 2014). Hence, YY1-mediated repression might play an 
important role in endotoxin tolerance. However, only approximately 1 % of genomic regions 
that showed enrichment in H3K9me2 and H4K20me3 in tolerant cells appeared to possess 
the specific binding motif for YY1. Noteably, most of the genomic regions analyzed 
possessed a binding motif for the transcription factor SCL, which is mainly involved in 
monocyte/macrophage differentiation and cell cycle (Dey et al. 2010), and for SMAD3, which 
plays an important role in TGFβ signaling (Li et al. 2006b, Massague 2012). 
Similar to YY1, SMAD3 can act as transcriptional activator or suppressor. As activator, 
SMAD3 can interact with the histone acetyltransferase p300 to foster transcription (Feng et 
al. 1998, Janknecht et al. 1998). Interestingly, SMAD3-mediated activation of transcription 
can be inhibited by YY1, implying a regulatory network of both transcription factors (Kurisaki 
et al. 2003). Here, however, the association of SMAD3 binding motifs in genomic regions 
enriched for repressive histone modifications implies a TGFβ-mediated repression. This 
agrees with the observation that LPS tolerization can be partially mimicked by the 
administration of anti-inflammatory cytokines including IL-10 and TGFβ (Cavaillon et al. 
1994, Randow et al. 1995). Inhibitory activities of TGFβ include inhibition of LPS-induced 
cytokine expression like IL-12, TNF and CCL3/MIP-1α, promotion of MyD88 degradation and 
reduction in CD14 expression, which attenuates TLR4 signaling (Reviewed in Li et al. 
(2006b)). Moreover, overexpression of NFκB p50/p50 homodimers, as shown in endotoxin 
tolerance, triggers gene transcription of IL-10 and TGFβ (Lawrence et al. 2001). 
TGFβ signals through type I and type II receptors (TGFBR1/TGFBR2). Ligand binding brings 
both receptor types in close proximity leading to activation of type I receptors through type II 
receptor-mediated phosphorylation (see Fig. 3-2). Once activated, type I receptor 
phosphorylates SMAD2 and SMAD3, which dimerize and form a complex with SMAD4. The 
whole complex translocates into the nucleus, where it interacts with other transcription 
factors and chromatin-modifying enzymes to control targeted gene expression (Li et al. 
2006b, Massague 2012). SMAD3-mediated inhibition of gene transcription is mediated 
through the binding of transcriptional corepressors. For instance, SMAD3 binds TGFβ-
induced factor homeobox 1 (TGIF), which in turn recruits other repressors like C-terminal-
binding protein (CtBP), and HDAC1 resulting in deacetylation of histone tails (Wotton et al. 
2001, Wotton et al. 1999a, Wotton et al. 1999b). Moreover, SMAD-binding has also been 
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shown to be associated with repressive methylation marks. It was demonstrated that the 
H3K9 methyltransferase Suv39h1 binds to SMAD3, leading to suppression of IL-2 production 
in T cells (Wakabayashi et al. 2011). Additionally, SMAD3 can interact with the histone H3K9 
methyltransferase G9a via the corepressor CtBP (Shi et al. 2003). Hence, H3K9 methylation 
may support silencing of the underlying gene loci. Previous advances highlighted a crucial 
interaction between H3K9 methylation and DNA methylation. For instance, H3K9 methylation 
(H3K9me2 and H3K9me3) can be recognized by adapter proteins like HP1, which can 
interact with DNA methyltransferases (e.g. DNMT3a) to promote genomic silencing. 
Moreover, HP1, but also H3K9 methylation itself, can be a binding platform for other histone 
methyltransferases like the Suv420h methyltransferases to induce repressive H4K20me3 
(reviewed in Fuks (2005)). 
To conclude, the transcription factor network analysis revealed that repressive modification 
of mainly intergenic genomic regions by repressive H3K9me2 and H4K20me3 might be 
potentially mediated by TGFβ/SMAD3-signaling. This provides the molecular basis for the 
observation that SMAD3 and SMAD4 are detrimental for the development of endotoxin 
tolerance (Pan et al. 2010, Werner et al. 2000). Interestingly, a negative feedback loop of 
SMAD3 seems to exist as the SMAD3 gene region itself was associated with enrichment in 
repressive histone marks in tolerant monocytes treated with LPS (see GO analysis in 
Appendix 5.7). Thus, this study provides a mechanistic picture in which endotoxin tolerance 
mediates epigenetic remodeling of intergenic regions and genes involved in signaling and 
transcription machineries by TGFβ/SMAD3-dependent signaling. These events are likely 
induced during the first LPS treatment (Fig. 3-2). Notably, a direct link between repressive 
histone modifications and DNA methylation remains to be validated (discussed in 3.2.2). 
 
3.2.2 Global Analysis of DNA Methylation 
Genome-wide changes in de novo DNA methylation were analyzed to elucidate its potential 
role in transcriptional repression in endotoxin tolerance. Whereas histone modifications are 
easily reversible, DNA methylation leads to stable long-term repression (Senner 2011). 
Surprisingly, tolerant human monocytes treated with LPS showed a general reduction in DNA 
methylation implying a global facilitation of gene expression. The observed decline in DNA 
methylation might be induced by the first LPS stimulus and its biological function needs to be 
analyzed in future studies. 
Only a small set of genomic loci (approximately 570) near the TSS regions showed 
significant enrichment in DNA methylation. GO enrichment analysis indicated an over-
representation of genes involved in ribonucleotide-binding, indicating a negative impact of 
endotoxin tolerance on the transcription machinery by DNA methylation. 
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As mentioned above, recent advances indicate that DNA methylation and repressive histone 
modifications highly cooperate to induce a silenced status in genomic regions and that both 
repressive marks can be dependent on each other (reviewed in Brenner & Fuks (2007), 
Cedar & Bergman (2009) and Rose & Klose (2014)). However, in the present work, no direct 
correlation between methylated DNA and repressive H3K9me2 and H4K20me3 near TSS 
regions could be identified. This suggests that both repressive mechanisms act 
independently of each other in tolerant monocytes or possibly that other histone marks not 
analyzed in the present study like trimethylation of H3K9 (H3K9me3) might appear in 
genomic regions showing parallel enrichment in DNA methylation. Furthermore, not 
identifying potential interactions between repressive histone marks and DNA methylation by 
bioinformatical analyses might be due to either excluding genomic regions by the cut-off 
criteria of a 2-fold change for this study or by not examining more distantly localized regions. 
As already mentioned above in 3.1.2, the timepoint for the establishment of DNA methylation 
might be different from when histone modifications take place (no optimal timing for 
analysis). As only preliminary data was shown, the impact of DNA methylation and its 
interaction with repressive histone marks in endotoxin tolerance needs to be validated in 
future studies. 
 
3.2.3 Epigenetic Changes Partially Correlate with Gene Expression 
The present study illustrates that endotoxin tolerance mediates a global change in the 
epigenetic make-up of human monocytes. This concurs with recent studies demonstrating 
that epigenetic mechanisms have an impact on innate immune cell function. Saeed et al. 
(2014), for instance, analyzed the epigenome and transcriptome of naïve monocytes and 
compared them with naïve, tolerant and trained macrophages. The term ‘trained immunity’ is 
understood as enhanced innate immune responses upon re-stimulation (Netea et al. 2011). 
Saeed and colleagues identified exclusive epigenetic signatures, which classify the different 
cell subsets.  
To further elucidate the impact of the epigenetic changes observed in endotoxin tolerance 
(described above in 3.2.1 and 3.2.2), the mRNA transcriptome in naïve and tolerant 
monocytes treated with LPS was analyzed in the present study. Consistent with the literature 
(Allantaz-Frager et al. 2013, Foster et al. 2007, Pena et al. 2011), endotoxin-tolerant 
monocytes showed increased transcription of genes involved in phagocytosis and wound 
healing (class NT genes) to maintain anti-microbial defense mechanisms, whereas gene 
expression for inflammatory immune responses was inhibited (class T genes). Moreover, the 
gene expression machinery was reduced globally. The observed expression profile was also 
consistent with a recent publication from Shalova et al. (2015), who globally analyzed the 
transcriptome of monocytes from sepsis patients (Shalova et al. 2015). The authors further 
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revealed a hypoxia-inducible factor 1 α (HIF1α)-dependent mechanism in functional 
reprogramming of monocytes to a more immunosuppressive status. HIF1α-mediated 
enhanced phagocytosis and tissue repair, while simultaneously inducing IRAKM, which 
negatively regulated TLR signaling. They also stated that the phenotypes of the monocytes 
analyzed were more complex than a simplified M1 (classical-activated) or M2 polarization 
(alternative-activated) (Shalova et al. 2015). A detrimental role of HIF1α was also 
demonstrated by two other publications from Saeed et al. (2014) and Cheng et al. (2014) in 
trained immunity. The authors showed that trained monocytes changed their energy balance 
from oxidative towards glycolytic metabolism by an mTOR/HIF1α-mediated pathway (Cheng 
et al. 2014, Saeed et al. 2014).  
These publications indicate that HIF1α is a potential master regulator in programming 
monocytes and macrophages towards inflammatory settings. Thus, its role in TGFβ-
mediated induction of repressive histone marks is of high interest in future studies. 
The observed gene expression pattern in tolerant monocytes partially correlated with the 
identified epigenetic changes induced by endotoxin tolerance. Approximately 1000 of 3638 
differentially expressed genes (27 %) showed expression patterns consistent with the histone 
code. Especially alterations in activating H4ac and H3K27ac highly correlated with gene 
transcription. By contrast, no significant correlation could be identified between gene 
expression and DNA methylation. 
Strikingly, several thousand genomic regions (> 10 000) were identified by ChIP-Seq, which 
showed significant enrichment in repressive H3K9me2 and H4K20me3 in endotoxin 
tolerance. However, genes that possessed a reduced expression behavior appeared far less 
with 1758 genes identified. The high abundance of these repressive histone marks without a 
concurrent reduction in expression, especially in intergenic regions, implies a regulatory 
function in endotoxin tolerance. Thus, LPS tolerization may require multiple LPS-related 
enhancer sites for each gene. It further suggests that the given epigenome provides the 
framework and allows higher plasticity in what can potentially be expressed, whereas the 
endotoxin tolerance-induced transcriptional regulators mediate de facto the tolerant 
phenotype of monocytes. This is in agreement with data from the research group of Prof. 
Joachim L. Schultze (Life & Medical Sciences Institute (LIMES), Bonn, Germany), who 
demonstrated that irrespective of gene expression, most genes possessed similar epigenetic 
marks in IFNγ-, IL-4- or TNF+PGE2+P3C (TPP)-treated human macrophages; and that 
basically the master transcription factors in each condition were responsible for the different 
macrophage phenotypes (Xue et al. (2014) and personal communication). However, the 
main question remains as to whether the outcome of these transcriptional regulators is 
affected by epigenetic signatures. Alternatively, regarding the fact that LPS stimulation 
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means cellular stress, these regulatory elements may help to regulate constitutively 
expressed genes, which are critical for the biological setting (Smale 2010b). 
To conclude, only a subset of differentially expressed genes could be linked to a specific 
epigenetic signature in the present work. However, chromatin remodeling by histone 
modifications and DNA methylation is not the only ‘gatekeeper’ for transcriptional activity and 
additional factors are essential for the final regulation of gene transcription. Recent studies 
indicate that the specific network of transcriptional regulators have a crucial impact in the 
macrophage phenotype (Saeed et al. 2014, Xue et al. 2014). A study by Lavin et al. (2014) 
could also show that the local microenvironment has a higher influence in shaping the 
chromatin landscape of macrophages than expected (Lavin et al. 2014). The recent 
advances in macrophage immunity imply that one key protagonist does not solely mediate 
endotoxin tolerance.  
Moreover, processes that go beyond the mechanisms analyzed in this study such as nuclear 
translocation of transcription factors and post-transcriptional regulations could additionally 
regulate gene expression. The MAP kinase p38, for instance, influences stability of mRNA 
transcripts bearing AU-rich elements (ARE) (Dean et al. 2004) and plays a crucial role in 
LPS/TLR4-induced systemic inflammation (Schottelius et al. 2010). Following p38 signaling, 
MAP kinase-activated protein kinase 2 (MK2) activates ARE-binding proteins, which in turn 
binds to AREs of mRNAs and mediates either stabilization or destabilization of target 
transcripts (Barreau et al. 2005). The stability of several cytokine mRNAs, including those of 
TNF, IL6 and IL8, have been reported to be regulated by ARE-binding proteins (reviewed in 
Palanisamy et al. (2012)). For instance, a well-known destabilizer of TNF-mRNA-transcripts 
is tristetraproline (TTP, also known as ZFP36) (Carballo et al. 1998), whereas work from our 
group showed that Tis11d (ZFP36L2), another member of the TTP family, has a more 
stabilizing effect on TNF-mRNA-transcripts compared to TTP (Bossmann 2009). 
Furthermore, post-transcriptional regulation by microRNAs (miRNAs) resulting in selective 
downregulation of protein expression have been implicated in endotoxin tolerance  
(Nahid et al. 2011, Seeley & Ghosh 2014). MiRNAs are short non-coding RNAs, which 
regulate gene expression by complementary gene interference resulting in degradation of 
targeted mRNA or inhibition of translation. For instance, miR-221, miR-579 and miR-125b 
are involved in TNF transcript degradation, which may explain the strong 
hyporesponsiveness of TNF (El Gazzar & McCall 2010). Additionally, miRNA-146a,  
miRNA-155 and miRNA-12 are thought to downregulate LPS/TLR signaling (Taganov et al. 
2006). Sheedy et al. (2010) demonstrated that miR-21 suppressed NFκB activation and 
transcription of IL6 mRNA, but simultaneously promoted production of IL-10 (Sheedy et al. 
2010). 
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Finally, a direct link between epigenetic modifications and miRNAs does exist. Whilst DNA 
methylation and histone modifications influence miRNA expression, miRNAs itself can affect 
epigenetic modifications by targeting chromatin-modifying enzymes (Sato et al. 2011, Wang 
et al. 2015). But again, no single miRNA could be identified, which could completely account 
for the characteristic phenotype of endotoxin tolerance (Seeley & Ghosh 2014). This further 
implies that the phenomenon of LPS tolerance relies on a complex machinery of several 
interaction partners, which together results in the phenotypic characteristics known for 
endotoxin tolerance. 
 
3.2.4 Summary 
The present study provides a detailed description of the epigenetic changes occurring during 
endotoxin tolerance. A bottom-up approach was used by focusing on chromatin alterations 
rather than analyzing transcriptome changes. Site-specific post-translational modifications of 
histone proteins and DNA methylation mediate recruitment of transcription factors and other 
chromatin-modifying proteins, and provide a more stable picture of what occurs during 
tolerization than simple gene expression analyses. These changes may have an impact for a 
longer time period, as transcriptome analyses only provide a snapshot of the current gene 
expression. 
Endotoxin tolerance induced a genome-wide change in the epigenetic make-up of human 
monocytes. As these changes occurred in higher abundance than the actual number of 
differentially expressed genes, the present results imply that global alterations in chromatin 
structure are required for tolerance induction resulting in the characteristic expression 
behavior of tolerant monocytes.  
Treatment of human monocytes with LPS induced a global change from activating, positive 
histone modifications in naïve monocytes to repressive histone marks in tolerant cells. 
Detailed analyses of endotoxin-tolerant human monocytes revealed that a large gene cluster 
including immune response genes showed limited induction capacity in acetylation of H4 and 
H3K27 (probably due to reduced signaling induction in tolerant cells), whereas only a small 
set of genomic regions was associated with an enrichment in activating histone 
modifications. These chromatin changes clearly correlated with gene transcription. Moreover, 
LPS tolerization induced a global enrichment in repressive histone modifications, particularly 
H3K9me2 and H4K20me3, in mainly intergenic regions. The high abundance of these 
repressive marks was mainly independent of gene expression, which implies a regulatory 
function of these regions in induction of endotoxin tolerance. Strikingly, genomic regions 
located near the TSS, which showed induction of repressive H3K9me2 and H4K20me3 in 
endotoxin-tolerant monocytes, were preferentially linked to molecules involved within the 
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transcription and signaling network as indicated by GO analysis. Thus, induction of 
repressive histone modifications by LPS tolerization may influence gene expression in an 
indirect manner by targeting the signaling/transcription framework. 
Transcription factor binding site analyses within genomic regions that showed enrichment in 
the repressive histone marks H3K9me2 and H4K20me3 were potentially enriched for the 
binding motif of SMAD3, implying a TGFβ-dependent mechanism in endotoxin tolerance 
(Fig. 3-2).  
 
 
Fig. 3-2: Model for regulation of endotoxin tolerance by TGFβ signaling. First, LPS treatment leads to 
induction of TGFβ expression as a negative feedback loop to downregulate inflammation. Subsequently, TGFβ 
itself acts on monocytes to establish a repressive histone pattern. Signaling of TGFβ involves two types of 
transmembrane serine/threonine receptors. TGFβ ligands bind first to type II receptors, which recruit and engage 
type I receptors to form a complex. Type II receptors then activate the type I components, which in turn 
phosphorylate intracellular SMAD transcription factors (SMAD2 and SMAD3). These molecules are also called 
receptor-regulated SMAD proteins (R-SMADs). Phosphorylated SMAD2 and SMAD3 dimerize and associate with 
the common SMAD4, also termed Co-SMAD, leading to translocation into the nucleus (Massague 2012). 
Lineage-specific transcription factors (TF) direct SMAD transcription factors to specific genomic regions. In 
endotoxin tolerance, activated SMADs potentially interact with co-repressors (TGIF, CtBP) to induce a repressive 
epigenetic pattern at target regions. TGIF, for instance, can interact with HDACs resulting in deacetylation of 
histone tails. Moreover, CtBP recruits histone methyltransferases (HMTs) like G9a, which induce methylation of 
H3K9. An amplification of repression can be generated by DNA methylation. For instance, the adapter protein 
HP1 can recognize the repressive histone mark H3K9me2 (reviewed in Shinkai (2011)) and recruit DNA 
methyltransferases (DNMTs), but also other HMTs like the H4K20me3 methyltransferase Suv4-20h (reviewed in 
Fuks (2005)). Eventually, induction of a repressive epigenetic signature by TGFβ in intergenic regions and genes 
involved in signaling and transcription may indirectly influence the signaling capacity in tolerant monocytes 
leading to a reduced induction of activating acetylation marks at histone proteins located in immune response 
genes. Notably, a direct link between repressive histone marks and DNA methylation could not be confirmed in 
this work and is shown only to complete the regulatory picture. 
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TGFβ signaling may influence the epigenetic signature towards a more repressive status, 
which impacts intergenic regions and mainly signaling- and transcription-linked molecules. 
By targeting these molecules within the complexity of signaling network, downstream targets 
are affected as well, which leads to a kind of domino effect in tolerization resulting in direct 
and indirect repression, see Fig. 3-2. 
LPS tolerization further influenced DNA methylation in human monocytes in a global fashion. 
In contrast to histone modifications, however, endotoxin tolerance induction led to a global 
decrease in DNA methylation indicating a reduction in gene silencing. Moreover, changes in 
DNA methylation did not directly co-localize with alterations in histone modifications. Thus, its 
impact in induction of endotoxin tolerance has to be the focus of future studies. 
Correlation of the identified epigenetic changes with global mRNA transcriptome analysis 
indicated that not all differentially expressed genes were regulated or affected by the 
epigenetic signature found. This also correlates with results obtained by the detailed analysis 
of individual immune response genes in endotoxin tolerance (TNF & CXCL10 versus IL6 & 
IL1B, see Discussion section 3.1) implying that the specific epigenetic changes and signaling 
events might distinctly affect genes or gene classes. 
 
3.3 Impact of Epigenetic Changes in Endotoxin Tolerance and Sepsis 
Endotoxin tolerance provides a protective mechanism against excessive inflammation, 
however, its incidence also plays a critical role in sepsis. Here, initial tolerance induction 
serves as host protection against uncontrolled inflammation due to tissue damage and 
massive release of pro-inflammatory mediators (‘cytokine storm’). But prolonged 
unresponsiveness of immune cells leads to a higher risk of developing secondary infections, 
which results in the increased mortality of sepsis patients (Biswas & Lopez-Collazo 2009). 
Although endotoxin tolerance does not completely cover the complexity of sepsis, several 
events of sepsis can be mimicked by endotoxin tolerance. Thus, understanding the 
molecular mechanisms in tolerance induction is critical for the development of novel 
treatment strategies in order to activate immunosuppressed immune cells when necessary 
for sepsis patients. 
The results presented here clearly demonstrated that endotoxin tolerance influenced the 
epigenetic signature of human monocytes far beyond the actual gene expression pattern of 
tolerant human monocytes. These findings agree with recent discoveries showing that 
distinct epigenetic programming of innate immunity is shaped by environmental factors 
(Chen et al. 2014, Cheng et al. 2014, Lavin et al. 2014, Saeed et al. 2014). 
Moreover, a publication by Weiterer et al. (2015) showed that global epigenetic changes also 
occur in sepsis patients. The authors demonstrated that sepsis induced a specific change in 
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H3K4me3 and H3K27me3 in distinct promoter regions of immunologically relevant genes 
(Weiterer et al. 2015). Another recent publication further implied that a combinational 
treatment with epigenetic modifiers which affect both histone modifications and DNA 
methylation modulated murine macrophages in endotoxin-induced acute lung injury 
(Thangavel et al. 2015).  
Finally, LPS tolerization can last for several days. This is more profound for sepsis, where 
immunosuppression can persist for weeks or even years as indicated by studies showing a 
reduction in long-term survival of patients who survived sepsis (Iwashyna et al. 2010, Perl et 
al. 1995, Quartin et al. 1997). This implies that even newly generated immune cells from the 
bone marrow may not restore an efficient immune system and that epigenetic changes 
mediated by LPS tolerization occur at the level of hematopoietic stem cells (Carson et al. 
2011). Moreover, bacterial infections generate a heritable change or a kind of fingerprint that 
persists even when the pathogen is eradicated (reviewed in Bierne et al. (2012)).  
Hence, endotoxin tolerance and sepsis are highly complex and multifaceted phenomena, 
which involve changes in signaling events and remodeling of chromatin structure by histone 
modifications and DNA methylation as analyzed in this study, but also post-transcriptional 
control by microRNAs as discussed above. Still, the mechanisms as a whole are not 
completely understood and we are currently starting to elucidate the global changes in the 
epigenetic and transcriptional programs, which directly or indirectly influence the gene re-
programming associated with endotoxin tolerance and sepsis. Thus, controlling these 
genome-wide changes may provide new opportunities in the treatment of sepsis patients. 
 
3.4 Outlook 
The study presented showed that endotoxin tolerance mediated a global change in the 
epigenetic makeup of primary, human monocytes. So far, only genomic regions near the 
TSS of genes were analyzed in detail, but the results clearly illustrate that endotoxin 
tolerance mainly influenced intergenic regions such as enhancers. A general marker for 
enhancers is H3K4me1 (Heintzman et al. 2007). Future analysis of enhancers in endotoxin 
tolerance will be achieved by e.g. performing ChIP-Seq assays directed towards H3K4me1 
or utilizing the sequencing data provided by the Encyclopedia of DNA Elements (ENCODE) 
Project (Consortium 2012). Co-localization analysis with H3K27ac excluding promoter 
regions will give an insight into potentially activated enhancers. Moreover, Ghisletti et al. 
(2010) identified dynamic enhancers in murine macrophages by LPS-inducible binding of the 
acetyltransferase p300 to chromatin exploiting enhancers associated with inducible genes. 
The underlying DNA sequences provide binding for the tissue-restricted transcription factor  
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PU.1 and stimulus-activated transcription factors like NFκB and AP1 (Ghisletti et al. 2010). 
Thus, it will be of huge interest in future studies to determine how this regulatory network will 
work in endotoxin-tolerant cells. 
 
The present results did not show a major role for DNA methylation in endotoxin tolerance, 
however these data are preliminary. Consequently, future studies in DNA methylation, 
probably in combination with other repressive histone marks e.g. H3K9me3, are essential to 
clarify the impact of methylated DNA regions in endotoxin tolerance. 
In addition, transcription factor motif analyses in genomic regions that gained repressive 
H3K9me2 and H4K20me3 in tolerant monocytes treated with LPS revealed a possible role 
for SMAD3. ChIP-Seq assays using antibodies directed towards activated (phosphorylated) 
SMAD3 will be necessary to confirm its role in the regulation of endotoxin tolerance and to 
identify the genomic target regions. 
Finally, regarding the fact that endotoxin tolerance lasts for several days, analysis of the 
observed epigenetic changes in LPS-tolerant monocytes for more than one day will be of 
interest for future research to elucidate the stability and functions of these alterations. 
Additionally, comparing in vitro data to the analysis of epigenetic markers in sepsis patients 
both during and after recovery will provide a detailed insight in the molecular, epigenetic 
processes occurring during sepsis. 
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4. Materials & Methods 
4.1 Software & Programs 
Software/Program Notes 
  
BEDTools Software suite for the comparison, manipulation and annotation of genomic 
features (Quinlan & Hall 2010). 
  
BigWig tools Converts BedGraph file to BigWig file. Part of UCSC’s command line utilities 
(Kent et al. 2010). 
  
Bioconductor project Contains software packages for implementation in R.  
Available online (as of October 2015): http://www.bioconductor.org/. 
(Gentleman et al. 2004, Huber et al. 2015). 
  
BiQ Analyzer HiMod Software for analysis of bisulfite sequencing data (Becker et al. 2014). 
  
BWA Aligner Alignment of NGS data to a reference genome (Li & Durbin 2009). 
  
CellQuest Acquisition of flow cytometry data, BD Biosciences (Franklin Lakes, NJ, USA). 
  
ChIPseeker Tool for analysis and visualization of ChIP-Seq data (Yu et al. 2015). 
  
cummeRbund Bioconductor package for analysis of Cufflinks data (RNA-Seq analysis). 
(Goff et al. 2013) 
  
DAVID Database for Annotation, Visualization and Integrated Discovery, 
GO enrichment analysis (Huang et al. 2009a, b). 
  
FACSDiva Acquisition of flow cytometry data, BD Biosciences (Franklin Lakes, NJ, USA). 
  
FastQC Quality control of fastq files. Available online (as of October 2015): 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ (Andrew 2010). 
  
FlowJo Analysis of flow cytometry data, FlowJo, LLC (Ashland, Oregon, USA). 
  
Galaxy project Platform for NGS data analysis. 
Available online (as of October 2015): http://galaxyproject.org/ . 
(Blankenberg et al. 2010, Giardine et al. 2005, Goecks et al. 2010). 
  
GeneOverlap Bioconductor package for analysis of gene lists (Shen & Sinai 2013). 
  
GraphPad Prism Data analysis tool, GraphPad Software (La Jolla, USA). 
  
GREAT Genomic Regions Enrichment of Annotations Tool for ChIP-Seq data. 
GO enrichment analysis, available online (as of October 2015): 
http://bejerano.stanford.edu/great/public/html/ (McLean et al. 2010). 
  
gplots R tool for plotting data (Warnes et al. 2015). 
  
HOMER Motif discovery and analysis of ChIP-Seq data.  
Available online (as of October 2015): 
http://homer.salk.edu/homer/index.html  (Heinz et al. 2010). 
  
Integrative Genome Viewer 
(IGV) 
Genome browser for visualization of binding profiles. 
Available online (as of October 2015): https://www.broadinstitute.org/igv/. 
(Robinson et al. 2011, Thorvaldsdottir et al. 2013). 
  
MEDIPS Bioconductor package for analysis of differential DNA methylation  
(Lienhard et al. 2014). 
  
R language Statistical computing and graphics. Available online (as of October 2015): 
http://www.R-project.org/. (RCoreTeam 2014). 
  
SAMtools Converts SAM files to BAM files (Li et al. 2009). 
  
SICER Detection of significant DNA-histone protein interactions (Zang et al. 2009). 
  
TopHat / Cufflinks Software tools for analysis of RNA-Seq data. 
(Trapnell et al. 2009, Trapnell et al. 2010) 
  
UCSC Genome Browser Genome browser for visualization of binding profiles. 
Available online (as of Octber 2015): https://genome.ucsc.edu/.  
(Kent et al. 2002). 
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4.2 Materials 
All reagents and substances described in the Methods section 4.3 were purchased from Abcam 
(Cambridge, United Kingdom), Agilent Technologies (Santa Clara, California, USA), Applied 
Biosystems (by Thermo Fisher Scientific; Waltham, Massachusetts, USA), BD Biosciences (Franklin 
Lakes, New Jersey, USA), Biochrom AG (Berlin, Germany), BioLegend (San Diego, California, USA), 
Calbiochem (by Merck Millipore; Billerica, Massachusetts, USA), Carl Roth (Karlsruhe, Germany), 
Diagenode (Seraing (Ougrée), Belgium), eBioscience (by Affymetrix; Santa Clara, California, USA), 
GE Healthcare (Chalfont St Giles, United Kingdom), Gibco (by Thermo Fisher Scientific; Waltham, 
Massachusetts, USA), Invitrogen (by Thermo Fisher Scientific; Waltham, Massachusetts, USA), 
Macherey-Nagel (Dueren, Germany), Merck Millipore (Billerica, Massachusetts, USA), Miltenyi Biotech 
(Bergisch Gladbach, Germany), New England BioLabs (Ipswich, Massachusetts, USA), PAA (by GE 
Healthcare; Chalfont St Giles, United Kingdom), PAN-Biotech (Aidenbach, Germany), Qiagen (Hilden, 
Germany), R&D Systems (Minneapolis, Minnesota, USA), Roche (Basel, Swiss), Sarstedt 
(Nuembrecht, Germany), SERVA Electrophoresis (Heidelberg, Germany), Sigma-Aldrich (St. Louis, 
Missouri, USA) and Thermo Fisher Scientific (Waltham, Massachusetts, USA). 
 
Necessary catalog numbers (Cat. No.) and lot numbers (Lot No.) are indicated within the Methods 
section 4.3. 
 
4.3 Methods 
4.3.1 Cell Culture  
4.3.1.a Human Peripheral Blood Mononuclear Cell (PBMC) Isolation 
Human peripheral blood mononuclear cells (PBMCs) were isolated from buffy coat preparations via 
density gradient (Boyum 1968, Ulmer et al. 1984). In brief, heparinized blood was diluted 1:2 with 
phosphate buffered saline (PBS, Gibco). Thirty-five ml of diluted blood was carefully layered over 
15 ml Ficoll (Biocoll, Biochrom AG, density: 1.077 g/ml) and centrifuged for 20 min at room 
temperature (RT) and 1000 x g (without deceleration). The interface containing PBMCs was 
transferred into fresh tubes and was washed twice with PBS (Gibco). Subsequently, cells were used 
for human CD14+ MACS separation (see 4.3.1.b). 
4.3.1.b Human Monocyte Isolation by Magnetic Cell Separation 
CD14+ human monocytes were isolated from PBMCs using magnetic-activated cell sorting (MACS) 
according to the manufacturer’s protocol (Miltenyi Biotec) with the following modifications: Human 
CD14 MicroBeads (Milteny Biotec, Cat. No. 130-050-201) were added in a ratio of 1:25 (beads:buffer 
volume) to 1 x 107 PBMCs in 80 µl of cold MACS buffer containing PBS (Gibco), 0.5 % low-endotoxin 
fetal calf serum (FCS, Biochrom AG) and 2 mM EDTA (Merck Millipore, sterile-filtered) and incubated 
for 30 min at 4 °C with occasional gentle shaking. Subsequently, cells were washed and isolated using 
a MACS separator. The purity was tested by CD14 labeling and flow cytometric analysis. Generally, a 
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purity of ≥ 90 % of CD14-positive living cells was achieved (see 4.3.2.a for staining). Approximately 
1 x 108 CD14+ monocytes were isolated from 1 x 109 PBMCs generated from buffy coat preparations. 
4.3.1.c Human Monocyte Cultures and the Endotoxin Tolerance Model 
Human CD14+ monocytes were cultured at a density of 2 x 106/ml in IMDM medium (PAA or Biochrom 
AG) supplemented with 10 % human AB serum (PAN-Biotech, Cat. No. P30-2901, Lot No. P073305),  
4 mM L-alanyl-L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (all Biochrom AG) at 37 °C 
and 5 % CO2 in low cell binding multiwell plates (NuncTM, Sigma-Aldrich, Cat. No. Z721050-7EA or 
Z721077-7EA). For a detailed description of the optimization of culture conditions for cultivation of 
human monocytes see 4.3.1.d (below). 
For induction of endotoxin tolerance, CD14+ monocytes were treated with either 1 ng/ml or 100 ng/ml 
LPS (from Escherichia coli, serotype O111:B4, TLRgrade, Enzo Life Sciences, Cat. No. ALX-581-012) 
overnight for 16 to 24 h (tolerant, T). If not otherwise stated, tolerized cells with 100 ng/ml LPS were 
termed either T or T100, whereas tolerized cells with 1 ng/ml were indicated as T1. In parallel, 
unstimulated cells served as control (naïve, N). Subsequently, cells were washed with PBS (Gibco), 
cultured in fresh, complete IMDM medium and challenged with 100 ng/ml LPS for the times indicated 
(termed N+L, T+L, T1+L or T100+L). 
4.3.1.d Optimization of Culture Conditions for Cultivation of Human Monocytes 
Isolated monocytes were cultured in three different types of cell culture plates (tissue culture-, non- 
and MPC-treated), two different media (RPMI 1640 and IMDM) and sera (human AB and FCS). 
Tissue culture-treated plates have a hydrophilic surface promoting cell attachment, whereas non-
treated plates provide a more hydrophobic environment ideal for low cell binding3. Plates covered by 
the polymer MPC (2-methacryroyloxy-ethylphosphorylcholine) (Koike et al. 2005), which mimics cell 
membrane surfaces, offer a very low cell binding platform, therefore, limiting unwanted differentiation 
and providing a better physiological conditions for monocytes4. 
A very popular medium for cultivation of a wide range of immune cells is RPMI 1640 medium 
developed in the Rosewell Park Memorial Institute, which is a modification of MEM medium (Eagle’s 
Minimum Essential Medium). Another common medium also based originally on the MEM medium is 
Iscove's modified Dulbecco's medium (IMDM) that supports cultivation of B and T lymphocytes, 
macrophages and monocytes (Reviewed in Langdon (2004) and Schmitz (2011a)). 
For cell growth and metabolism, the supplementation of culture media with serum is very common. 
The most widely used animal serum is fetal calf serum (FCS). Besides addition of FSC, cultivation of 
cells in species-specific serum, in this case human serum, provides a more physiologically comparable 
environment. For minimizing immunoreactivity, human serum from type AB blood is generally used, 
since it does not contain anti-A and anti-B antibodies against antigens on erythrocytes (reviewed in 
Schmitz (2011b)). 
3 Indicated by distributor: https://www.fishersci.com/shop/products/falcon-tissue-culture-plates/p-154828 (as of October 2015) 
4 Indicated by distributor: http://www.sigmaaldrich.com/catalog/product/sigma/z721050?lang=de&region=DE (as of Occtober 2015) 
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Monocytes isolated from PBMCs following CD14-positive magnetic separation were cultured in either 
tissue culture-, non- or MPC-treated plates in RPMI or IMDM medium supplemented with human AB or 
FCS serum. The viability was determined by flow cytometric analysis (see Material section 4.3.2.a and 
4.3.2.c for staining). Cells were stained with the dye 7AAD to indicate dead cells, and the monocytic 
marker CD14. Viable cells were considered 7AAD-negative and CD14-positive. 
Cells cultured in MPC-treated plates in combination with IMDM medium supplemented with human AB 
serum showed the highest viability (Fig. 4-1 A), whereas cultivation of cells in tissue culture-treated 
plates in RPMI medium and FCS decreased the expression of CD14 by 5 times (Fig. 4-1 B). 
Comparison of all three factors (plates, media and sera) indicated that serum selection had the most 
striking effect on monocyte viability, followed by the type of medium and the cell culture plate. The 
cumulative effect of the optimal serum (human serum), the optimal medium (IMDM) and the optimal 
plate (MPC-treated) offered the highest viability of human monocytes (Fig. 4-1 C and D). 
 
 
Fig. 4-1: Cultivation of human CD14+ monocytes in different culture plates, media and sera. PBMCs were isolated from 
buffy coat preparations followed by CD14-positive isolation by magnetic-cell sorting. Human CD14+ monocytes were cultured for 
one day either in tissue culture-, non- or MPC-treated plates in RPMI or IMDM medium supplemented with human AB or FCS. 
The viability of cells was analyzed by 7AAD and CD14 staining following flow cytometric analysis. (A and B) Gating strategy for 
analysis of cell viability: Living monocytes were considered 7AAD-negative and CD14-positive. (C and D) Cell viability of 
cultured human monocytes (% of 7AAD- CD14+) is depicted dependent on cell culture plates (C) or different kinds of media and 
sera (D). Data represents one experiment out of two. Human AB serum was kindly provided by the research group of Prof. 
Carmen Scheibenbogen (Charité – Institut für Medizinische Immunologie, Berlin, Germany). 
The human AB serum for the initial viability test (see above) was kindly provided by the research 
group of Prof. Carmen Scheibenbogen (Charité – Institut für Medizinische Immunologie, Berlin, 
Germany). To obtain a human AB serum suitable for further use in monocyte cultivation, several 
human sera from different companies and batches were tested for stimulation capacity measured by 
the production of the pro-inflammatory cytokine TNF. 
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From the sera tested (Fig. 4-2 A and B), only one human AB serum from PAN-Biotech (PB-2,  
Fig. 4-2 B) showed similar characteristics compared to the control serum provided by the research 
group of Prof. Carmen Scheibenbogen. Both sera showed low levels of pre-stimulation of untreated 
monocytes indicated by low TNF release into the cell culture supernatant, yet high induction of TNF 
production after LPS stimulation. Notably, the release of TNF after LPS stimulation in PB-2 or control 
serum was lower than for all of the other tested sera, but the overall ratio of LPS-treated monocytes 
compared to untreated ones was similar or even higher than the other sera. 
 
 
Fig. 4-2: Cultivation of human CD14+ monocytes in several human AB sera. Following PBMC and CD14-positive isolation, 
human monocytes were cultured in MPC-treated plates in IMDM medium supplemented with different human AB sera. All sera 
were heat-inactivated and sterile-filtered. (A and B) Cells were cultured in the following sera: from PAA / Cat. No. C05-021 / 
Lot No. C02111-3986 (PAA), Valley Biomedicals / Cat. No. HS1017HI / Lot No. 2A0084 (VB-1), Valley Biomedicals / Cat. No. 
HS1017HI / Lot No. 2C0431 (VB-2), PAN-Biotech / Cat. No. P30-2901M / Lot No. P442000 (PB-1) and PAN-Biotech / Cat. No. 
P30-2901M / Lot No. P073305 (PB-2). Human AB serum kindly provided by the research group from Prof. Carmen 
Scheibenbogen was used as control. Cells were stimulated for 4 h with 100 ng/ml LPS or left untreated (w/o). Supernatants 
were subjected to TNF measurement by ELISA. Data are representative out of 2 independent experiments; shown are mean ± 
standard deviation. (C) Signaling in monocytes: Gating strategy for evaluation of p38 phosphorylation by flow cytometric 
analysis. (D and E) Monocytes cultured for up to 4 days in serum from PAN-Biotech (PB-2) or control (Scheibenbogen) were 
checked every day by flow cytometric analysis for stimulation capacity indicated by p38 phosphorylation after 15 min treatment 
with 100 ng/ml LPS (D) and for viability (E). Data represent one experiment out of two. 
Finally, human CD14+ monocytes were cultured for up to four days in MPC-treated plates and IMDM 
medium supplemented with control or PB-2 serum and checked every day for stimulation capacity and 
viability by flow cytometric analysis. Cultivation of primary human monocytes for experimental 
procedures normally lasted two to three days. 
Signaling capacity (see 4.3.2.d below for staining) was analyzed by induction of intracellular p38 
phosphorylation after LPS stimulation for 15 min compared to untreated cells (Fig. 4-2 C and D). 
Moreover, untreated cells were analyzed for viability by staining monocytes for 7AAD and CD14  
(Fig. 4-2 E). In general, monocytes cultured in PB-2 showed lower p38 MAP kinase signaling induction 
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and lower viability compared to control serum during the four days of cultivation. However, these 
effects were consistent over the time analyzed. Thus, PB-2 from PAN-Biotech (Cat. No.: P30-2901M, 
Lot No.: P073305) was considered as a suitable surrogate for the human AB serum provided by the 
research group of Prof. Carmen Scheibenbogen for the cultivation of human monocytes. 
4.3.1.e Isolation and Cultivation of Murine Bone Marrow-Derived Macrophages 
Bone marrow cells were isolated from mice with a C57BL/6 background and cultured for five to seven 
days in tissue culture treated plates (BD Biosciences) in RPMI-1640 medium (Biochrom AG) 
supplemented with 50 ng/ml murine M-CSF (Miltenyi Biotech), 10 % low-endotoxin FCS,  
2 mM L-alanyl-L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (all Biochrom AG) at 37 °C 
and 5 % CO2. Differentiated murine macrophages were checked for purity by flow cytometry using 
CD11b and F4/80 surface staining, 4.3.2.c, replated at a density of 1 – 2 x 106/ml, and stimulated the 
following day with 100 ng/ml LPS (from Escherichia coli, serotype O111:B4, TLRgrade, Enzo Life 
Sciences, Cat. No. ALX-581-012) for 24 h (tolerant, T). Untreated cells served as a control (naïve, N). 
Subsequently, cells were washed, given fresh media and challenged with 100 ng/ml LPS for the time 
points indicated (N+L, T+L). 
 
4.3.2 Flow Cytometry 
Fluorochrome-labeled antibodies used for flow cytometric analyses are listed in Table 4-1. 
Table 4-1: List of antibodies and staining dyes used for flow cytometric analyses. 
Molecule (Clone) Conjugate Company Cat. No. 
    
Anti-human CD14 (MϕP9) PE BD Biosciences 345785 
Anti-human CD14 (M5E2) BV510 BioLegend 301842 
Anti-human FPR1 (5F1) PE BD Biosciences 556016 
Anti-human IL-1β (JK1B-1) A647 BioLegend 508208 
Anti-human IL-6 (MQ2-13A5) FITC BioLegend 501104 
Anti-human/mouse p38 MAPK (36/p38 (pT180/pY182)) A647 BD Biosciences 612595 
Anti-human TNF (MAb11) A700 BioLegend 502928 
    
Anti-mouse CD11b (M1/70) APC-Cy7 BD Biosciences 557657 
Anti-mouse F4/80 (BM8) A700 BioLegend 123130 
    
Zombie NIR™ Fixable Viability Kit / (APC-Cy7) BioLegend 423105 
Fixable Viability Dye eFluor® 506 / (AmCyan) eBioscience 65-0866 
7AAD / (PerCP) BD Biosciences 559925 
    
 
Flow cytometric analysis of purity/viability and p38 MAPK signaling of human monocytes was 
performed on a BD FACSCalibur device (BD Biosciences) with CellQuest software (version 5.2). A 
minimum of 5 000 monocytes was acquired. Intracellular cytokines and the FPR1 surface expression 
of human monocytes were analyzed on a BD LSRFortessa device (BD Biosciences) using FACSDiva 
software (version 6.2). A minimum of 50 000 human CD14+ cells was acquired. 
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Analysis of murine macrophages was performed on an BD LSRFortessa device with a minimum of 
5 000 murine macrophages acquired. Settings for FACS devices are listed in Appendix 5.3. 
Flow cytometric data were analyzed by FlowJo software (FlowJo LLC, Ashland, OR, USA, version 9). 
4.3.2.a Determination of Purity and Cell Viability with 7AAD  
The viability of human monocytes was determined with 7AAD (BD Biosciences, Cat. No. 559925), 
which stains only dead cells. After extracellular staining of CD14-positive monocytes (PE-conjugate, 
see 4.3.2.c) to check the purity obtained, cell viability staining with 7AAD was performed according to 
the manufacturer’s instructions. 
4.3.2.b Live/Dead Discrimination with a Fixable Dye 
For live/dead discrimination prior to permeabilization, either the Zombie NIR™ Fixable Viability Kit 
(BioLegend, Cat. No. 423105) or the Fixable Viability Dye eFluor® 506 (eBioscience, Cat. No.  
65-0866) were used according to the manufacturer’s instructions. 
4.3.2.c Extracellular Staining of Cell Surface Molecules 
One to two million cells per milliliter were washed twice with staining buffer containing PBS (Gibco) 
supplemented with 2 % serum and 0.1 % sodium azide (SERVA Electrophoresis GmbH) and stained 
for 15 min at 4 °C with antibodies directed towards surface molecules. Antibodies used for surface 
staining were as follows: human anti-CD14 (BV510-conjugate, clone M5E2, or PE-conjugate, clone 
MϕP9), human anti-FPR1 (PE-conjugate, clone 5F1), murine anti-CD11b (APCCy7-conjugate, clone 
M1/70) and murine anti-F4/80 (A700-conjugate, clone BM8). 
4.3.2.d Intracellular Signaling Analysis of p38 MAP Kinase (MAPK) 
Phosphorylation of p38 MAPK was measured using the Phosflow system from BD Biosciences 
according to their protocol. In brief, 2 x 105 cells in 100 µl cell culture medium were stimulated for  
15 min with 100 ng/ml LPS (Enzo Life Sciences, Cat. No. ALX-581-012) and immediately fixed by the 
addition of 2 volumes of Fix Buffer 1 (BD Biosciences, Cat. No. 557870). After incubation for 10 min at 
37 °C, cells were permeabilized in Perm/Wash Buffer I (BD Biosciences, Cat. No. 557885) for 30 min 
at RT and subsequently stained for 20 min at 4 °C with anti-p38 MAPK (A647-conjugate, clone 36/p38 
(pT180/pY182)) and anti-CD14 (PE-conjugate, clone MϕP9) for human monocytes or anti-CD11b 
(APCCy7-conjugate, clone M1/70) and anti-F4/80 (A700-conjugate, clone BM8) for murine 
macrophages. Stained cells were washed and resuspended in staining buffer (see point 4.3.2.c 
above) prior to flow cytometric analysis. 
4.3.2.e Intracellular Cytokine Staining 
For intracellular analysis of cytokine production, naïve or tolerant human monocytes were washed with 
PBS (Gibco), resuspended in fresh medium and stimulated for 6 h with 100 ng/ml LPS (Enzo Life 
Sciences, Cat. No. ALX-581-012) in the presence of Brefeldin A (10 µg/ml, Sigma-Aldrich).  
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After incubation, 1 x 106 cells were stained for the surface molecule CD14, fixed and permeabilizied 
using the Cytofix/Cytoperm kit (BD Biosciences, Cat. No. 554714) as recommended by the 
manufacturer before staining for intracellular cytokines. Antibodies for flow cytometric analysis were as 
follows: human anti-CD14 (BV510-conjugate, clone M5E2), human anti-IL-1β (A647-conjugate, clone 
JK1B-1), human anti-IL-6 (FITC-conjugate, clone MQ2-13A5) and human anti-TNF (A700-conjugate, 
clone MAb11). 
 
4.3.3 ELISA and Multiplex 
Naïve and tolerant monocytes stimulated with either 1 or 100 ng/ml LPS were challenged with 
100 ng/ml LPS (Enzo Life Sciences, Cat. No. ALX-581-012) for the times indicated. After incubation, 
cell culture medium (supernatant) was collected by centrifugation (300 x g for 5 min at 4 °C) and 
stored at -80 °C until use. Cytokines within the supernatant were determined by ELISAs or Multiplex 
Assays according to the manufacturer’s protocols (see Table 4-2). 
 
Table 4-2: List of ELISAs and Multiplex Panel used for cytokine detection in the cell culture supernatant. 
Molecule Company Cat. No. 
   
CXCL8/IL-8 R&D Systems DY208 
CXCL10/IP-10 R&D Systems DY266 
IL-1β eBioscience 88-7010 
IL-6 R&D Systems DY206 
TNF eBioscience 88-7346 
   
MILLIPLEX® MAP Human Cytokine/Chemokine Merck Millipore HCYTOMAG-60K 
   
 
4.3.4 RNA Isolation, cDNA Synthesis and Quantitative Real Time PCR (qRT-
PCR) 
Naïve and tolerant human CD14+ monocytes were stimulated with LPS (Enzo Life Sciences, Cat. No. 
ALX-581-012) for the times indicated. Following stimulation, the expression profiles of several 
inflammatory molecules were evaluated by quantitative real time PCR (qRT-PCR) analysis.  
Total RNA from 1 x 106 monocytes was isolated using the NucleoSpin® RNA Kit (Macherey-Nagel, 
Cat. No. 740955) according to the manufacturer´s protocols. After determination of RNA purity and 
concentration by NanoDrop 2000 spectrophotometer measurement (Thermo Fisher Scientific), RNA 
was reverse-transcribed into cDNA using the QuantiTect Rev. Transcription Kit (Qiagen, Cat. No. 
205311). The generated cDNA was amplified with 1 x TaqMan® Universal PCR Master Mix 
(Invitrogen, Cat. No. 4304437) by qRT-PCR on the 7500 Real Time PCR System (Applied 
Biosystems). 
The specific primers and TaqMan Gene Expression Assays (Invitrogen) used for amplification are 
listed in Table 4-3.  
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Table 4-3: TaqMan Gene Expression Assays and primer pairs used for qRT-PCR. 
Gene   
   
huCXCL10 Assay ID (Invitrogen) Hs01124251_g1 
   
huFPR1 Assay ID (Invitrogen) Hs04235426_s1 
   
huHPRT Forward Primer (5’→3’) AGTCTGGCTTATATCCAACACTTCG (300 nM) 
 Reverse Primer (5’→3’) GACTTTGCTTTCCTTGGTCAGG (300 nM) 
 Probe (5’→3’) Fam-TTTCACCAGCAAGCTTGCGACCTTGA-Tamra (100 µM) 
   
huIL1B Forward Primer (5’→3’) GGCAATGAGGATGACTTGTTCTTT (300 nM) 
 Reverse Primer (5’→3’) GTAGTGGTGGTCGGAGATTCGTAG (300 nM) 
 Probe (5’→3’) Fam-ATGGCCCTAAACAGATGAAGTGCTCCTTCC-Tamra (100 µM) 
   
huIL6 Assay ID (Invitrogen) Hs00985639_m1 
 or  
huIL6 Forward Primer (5’→3’) CCACTCACCTCTTCAGAACGAATT (300 nM) 
 Reverse Primer (5’→3’) AGTGCCTCTTTGCTGCTTTCAC (50 nM) 
 Probe (5’→3’) Fam-ATGTCTCCTTTCTCAGGGCTGAGATGCC-Tamra (100 µM) 
   
huIL8 Assay ID (Invitrogen) Hs00174103_m1 
   
huMT1F Assay ID (Invitrogen) Hs00744661_sH 
   
huMT1L Assay ID (Invitrogen) Hs01591331_g1 
   
huTNF Forward Primer (5’→3’) TCTCGAACCCCGAGTGACAA (50 nM) 
 Reverse Primer (5’→3’) TCAGCACTGGAGCTGCC (900 nM) 
 Probe (5’→3’) Fam-TGTAGCCCATGTTGTAGCAAACCCTCAAGC-Tamra (100 µM) 
   
huZSCAN18 Assay ID (Invitrogen) Hs00225073_m1 
   
huZNF316 Assay ID (Invitrogen) Hs00418202_m1 
   
 
The PCR conditions were as follows: An initial 50 °C (2 min) followed by 95 °C (10 min), 40 cycles of 
95 °C (15 sec) followed by 60 °C (1 min, combined annealing and extension) and a final hold at 4 °C. 
 
The relative mRNA expression level of each target gene was normalized to the expression level of 
human HPRT (2-ΔCT, with CT = cycle threshold). All PCR reactions were carried out in duplicates and 
data analysis was performed using the 7500 System SDS Software (Version 1.4.0, Applied 
Biosystems). 
 
4.3.5 Chromatin Immunoprecipitation (ChIP) 
Interactions between proteins or modified forms of proteins (e.g. histone modifications) and a genomic 
DNA can be identified by chromatin immunoprecipitation (ChIP). 
At first, the ChIP assay requires crosslinking of the chromatin structure with formaldehyde to stabilize 
the interaction between protein factors and DNA. The cross-linked chromatin is further broken down 
into smaller fragments to achieve high resolution. After immunoprecipitation with specific antibodies 
directed towards the target of interest (e.g. histone modifications), the associated DNA is isolated and 
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analyzed by PCR (Northrup & Zhao 2011). For genome-wide resolution, the ChIP DNA is sequenced 
by next generation sequencing techniques (see 4.3.6). 
4.3.5.a Sample Preparation (ChIP) 
ChIP was performed according to a protocol from Dr. Daniel Ibrahim and Dr. Jochen Hecht (MPI for 
Molecular Genetics, Berlin, Germany / Center for Genomic Regulation, Barcelona, Spain), which was 
adapted from a publication by Lee et al. (2006) with following modifications: 
Cell Fixation 
Ten million human monocytes were stimulated for the indicated times (see 4.3.1.c for experimental 
design) and immediately fixed in cell culture medium with 1 % formaldehyde (37 % solution, Sigma-
Aldrich) for 7.5 min at 4 °C with gentle shaking. Formaldehyde fixation was stopped by the addition of 
glycine (125 mM final concentration, SERVA Electrophoresis). Cells were washed twice with ice cold 
PBS (Gibco) and the pellet was frozen at -80 °C until proceeding with cell lysis. 
Cell Lysis and Sonication 
Cell lysis and chromatin isolation was performed by incubating the cell pellet in 2.5 ml Lysis Buffer 1 
(LB1) at 4 °C for 10 min with gentle rotation and subsequent centrifugation at 1350 x g for 5 min at 
4 °C, followed by removal of supernatant and incubation of the pellet in 2.5 ml Lysis Buffer 2 (LB2) for 
10 min at RT. After centrifugation (1350 x g, 5 min, 4 °C), the nuclei pellet was dissolved in 200 µl 
Lysis Buffer 3 (LB3) and transferred to 1.5 ml microtubes (Sarstedt). Freed chromatin was sonicated 
using the Bioruptor from Diagenode (for 10 min with 30 sec pulse on / 30 sec pulse off, set to high 
power) to obtain fragments ranging from 200 to 1000 bp. After sonication, cell debris was removed by 
addition of 1 % Triton X-100 (Sigma-Aldrich) and subsequent centrifugation of samples for 10 min at 
16 000 x g and 4 °C. Supernatant (200 µl) containing sheared chromatin was transferred to fresh 
1.5 ml microtubes. 
Quality Control of Sonicated Chromatin and Determination of DNA Concentration 
From a small aliquot (normally 1/20th of the total volume), DNA was purified for determination of DNA 
fragment size and concentration. Reversal of cross-linking was achieved by incubation of the fixed 
chromatin for 15 min at 95 °C with shaking in the presence of NaCl (for more details see Washing and 
Recovery of DNA below). After RNA and protein digestion, ethanol precipitated DNA was resolved in 
20 µl H2O. DNA concentration was determined by NanoDrop 2000 spectrophotometer measurement 
(Thermo Fisher Scientific) and used for recalculation of DNA concentration in the original chromatin 
sample. Optimal DNA fragment size was checked on a 1.2 % agarose gel by gel electrophoresis  
(see 4.3.5.b). The sonicated DNA should have a fragment range of 200 to 1000 bp with the major 
peak at around 400 to 500 bp. 
Preparation of Magnetic Beads and Immunoprecipitation 
Prior to immunoprecipitation (IP), magnetic protein G beads (Dynabeads® Protein G from Invitrogen, 
Cat. No. 100.04D) were pre-incubated with ChIP antibodies (3 to 5 µg per IP) for a minimum of 3 h at 
4 °C with rotation in the presence of blocking solution (0.5 % BSA in PBS). In general, 20 µl of beads 
were used per IP. 
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Equal amounts of sonicated chromatin (5 to 20 µg) were incubated with antibody-bead complexes 
overnight with constant rotation. ChIP antibodies to H3K4me3 (Cat. No. 07-473), H3K27ac (Cat. No. 
17-683 or 07-360), H3K27me3 (Cat. No. 07-449) and H4ac (Cat. No. 06-866) were purchased from 
Merck Millipore. ChIP-antibodies to H3K9me2 (Cat. No. ab1220) and H4K20me3 (Cat. No. ab9053) 
were purchased from Abcam. Sonicated chromatin incubated with a non-specific IgG antibody (Merck 
Millipore, Cat. No. 12-370) served as a negative control. Ten percent of sonicated total chromatin  
(not immunoprecipitated) was reserved as positive control input DNA and was stored at -20 °C until 
further processing (see below). 
Washing and Recovery of DNA 
Chromatin-antibody-bead-complexes were captured using a magnet and the supernatants were 
discarded. After washing with RIPA Wash Buffer 5 times and a final washing step with TE Buffer, 
protein-DNA complexes were eluted from beads in 110 µl Elution Buffer for 30 min at 65 °C with 
shaking. Beads were spun down for 1 min at 16 000 x g and the supernatants (100 µl) containing 
immunoprecipitated DNA-protein complexes were carefully transferred to fresh microtubes. 
From now on, the input DNA sample representing total DNA was treated the same way as the ChIP 
DNA. For reversal of cross-linking, immunoprecipitated and input DNA were treated with NaCl 
(500 mM final concentration, Sigma-Aldrich) at 65 °C overnight if DNA was subjected to ChIP-Seq 
(see 4.3.6.a), or 95 °C for 15 min if DNA was subjected to qRT-PCR analysis (see 4.3.5.c). RNA and 
protein were removed by RNase A digestion for 30 min at 37 °C (0.4 mg/ml final concentration, Sigma-
Aldrich, Cat. No. R4642), followed by Proteinase K treatment for 1 h at 55 °C (0.4 mg/ml final 
concentration, Sigma-Aldrich, Cat. No. P4850). For analysis of single DNA-protein interactions by 
qRT-PCR (see 4.3.5.c), the resulting DNA was recovered by ethanol precipitation with addition of 
glycogen (Roche, Cat. No. 10901393001) and 3 volumes of cold 100 % ethanol with subsequent 
centrifugation for 30 min at 4 °C, followed by a washing step with 70 % ethanol. Immunoprecipitated 
DNA and input DNA were resolved in 80 to 100 µl H2O. 
For genome-wide resolution of DNA-protein interactions (ChIP-Seq), precipitated DNA was further 
processed and sequenced at the Core Facility for Next Generation Sequencing (NGS) at the Berlin-
Brandenburg Center for Regenerative Therapies (BCRT), Charité – University Medicine Berlin, 
Germany (see 4.3.6.a). 
 
Buffers used for ChIP: 
Lysis Buffer 1 (LB1) Company  Lysis Buffer 2 (LB2) Company 
     
50 mM HEPES-KOH (pH 7.5) Sigma-Aldrich  10 mM Tris-HCl (pH 8.0) Carl Roth 
140 mM NaCl Sigma-Aldrich  200 mM NaCl Sigma-Aldrich 
1 mM EDTA Merck Millipore  1 mM EDTA Merck Millipore 
10 % Glycerin (glycerol)  SERVA   0.5 mM EGTA Merck Millipore 
0.5 % NP-40 Calbiochem    
0.25 % Triton X-100 Sigma-Aldrich    
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Lysis Buffer 3 (LB3) Company  RIPA Wash Buffer (WB) Company 
     
10 mM Tris-HCl (pH 8.0) Carl Roth  50 mM HEPES-KOH (pKa 7.55) Sigma-Aldrich 
100 mM NaCl Sigma-Aldrich  500 mM LiCl Sigma-Aldrich 
1 mM EDTA Merck Millipore  1 mM EDTA Merk Millipore 
0.5 mM EGTA Merck Millipore  1.0 % NP-40 Calbiochem 
0.1 % Na-Deoxycholate Sigma-Aldrich  0.7 % Na-Deoxycholate Sigma-Aldrich 
0.5 % N-Laroylsarcosine Sigma-Aldrich    
     
TE Buffer (TE) Company  Elution Buffer (EB) Company 
     
10 mM Tris-HCl (pH 8.0) Carl Roth  50 mM Tris-HCl (pH 8.0) Carl Roth 
1 mM EDTA Merck Millipore  10 mM EDTA Merck Millipore 
   1.0 % SDS SERVA 
All buffers were sterile-filtered, aliquoted and stored at -20 °C until use. Protease inhibitors 
(1 x cOmplete Protease Inhibitor Tablets, Roche, Cat. No. 11697498001) and 20 mM sodium butyrate 
for analysis of acetylated histones (Sigma-Aldrich, Cat. No. B5887) were freshly added to LB1, LB2, 
LB3, WB and TE just before use. 
4.3.5.b Detection of DNA Fragments by Agarose Gel Electrophoresis 
For detection of correct DNA fragment size after sonication (see 4.3.5.a, Quality Control of Sonicated 
Chromatin and Determination of DNA Concentration), purified DNA was mixed with 6 x Loading Dye 
and analyzed on a 1.2 % agarose gel (SERVA Electrophoresis) with 0.3 µg/ml ethidium bromide (Carl 
Roth) by gel electrophoresis in 1 x TAE buffer with a constant voltage of 100 for 30 min. 
 
1x TAE Buffer Company  6x Loading Dye Company 
     
40 mM Tris Carl Roth  50 % Glycerol SERVA 
0.5 mM EDTA Merck Millipore  1 % SDS SERVA 
Adjusted to pH 7.5   100 mM EDTA Merck Millipore 
(with acetic acid )  Merck Millipore  0.1 % Bromphenol blue  
     
 
4.3.5.c Quantitative Real Time PCR (qRT-PCR) of ChIP DNA 
Immunoprecipitated DNA and input DNA were amplified by qRT-PCR with the gene-specific primer 
pairs listed in Table 4-4. Prior to PCR, input DNA (10 %) was further diluted 1:10 for a final 
concentration of 1 %. The PCR reaction (25 µl) contained 2.5 µl DNA, 12.5 µl of 2x SYBR® Green 
PCR Mastermix (Invitrogen, Cat. No. 4309155) or SYBR® Select Master Mix (Invitrogen, Cat. No. 
4472908) and gene specific forward and reverse primers with the specific concentrations indicated in 
Table 4-4. Samples were analyzed in triplicate. The PCR conditions were as follows: Initial incubation 
at 50 °C (2 min) and 95 °C (10 min), followed by 40 cycles at 95 °C (15 sec) and 60 °C (1 min), with a 
final melting curve for specificity analysis using the 7500 Real Time PCR System (Applied 
Biosystems). ChIP data were calculated as % of input DNA and normalized to IgG control  
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(fold enrichment). All data are presented as fold change relative to enriched DNA from naïve (N) 
untreated cells (relative fold enrichment). 
 
Calculation of enriched ChIP DNA: 
(1) The samples were first adjusted to the total input fraction:  
 What is the CT value of the 1 % input at 100 %? Log2 of 100 = 6.64 
 The raw CT of 1 % input was e.g. 25  
 Adjustment of 1 % to 100 %: 25 – 6.64 = 18.36 (= 100 %) 
 CT of antibody sample was e.g. 23 2 ^ (18,36 – 23) = 0.04 (= 4 %) 
 CT of IgG control was e.g. 28 2 ^ (18,36 – 28) = 0.001 (= 0.1 %) 
(2) Fold enrichment of specific antibody to IgG control:  
 Correlation of specific antibody (in %) to IgG control (in %) 4 % / 0.1 % = 40 (fold enrichment) 
(3) Relative fold enrichment by normalization to naïve (N) control  
 
Table 4-4: Primers used for qRT-PCR analysis of ChIP DNA. 
Gene Concentration Forward primer (5’→3’) Reverse primer (5’→3’) 
    
huCXCL10 300/300 nM ACCCAAATGAGCAATGTTTTCCC GGACTGGCCTGCTTTGACAG 
huFPR1 900/900 nM AGAGGCAAGGGCATCAGCTT CTCATTTCCCCATGACCCATC 
huIL1B 900/900 nM GGCAAACAGGGTGCCAAGTA AGGAAGCCCTTGCAACAACAC 
huIL6 (Park et al. 2011) 900/900 nM ACCCTCACCCTCCAACAAAG GCAGAATGAGCCTCAGACATC 
huIL8 300/300 nM AGAGACAGCAGAGCACACAAGC GCTGCCAAGAGAGCCACGG 
huTNF 300/300 nM CGGGGATGCAGAAAGAGATG GCACCTTCCATGTGCCAGAC 
    
muFpr1 300/300 nM TGCATCCTGCAGATTGGAGA  ACCCAGGCTTTGTGTGTGCT 
muGapdh 300/300 nM CCGCATCTTCTTGTGCAGTG  ACTTCGCACCAGCATCCCTA 
muIl1b 300/300 nM GAGGCCAGAGAGTCCCCAAC  GGGCTTGGGAGTGAAGAGGT 
muIl6 300/300 nM CCCCACCCTCCAACAAAGAT  GTGGGCTCCAGAGCAGAATG 
muTnf 300/300 nM GCCACCACGCTCTTCTGTCT  TTGCCCTCCTAACCCGTTTT 
    
 
 
Binding sites of human primer pairs within the genome are depicted in Appendix 5.2. Data analysis 
was performed using the 7500 System SDS Software (Applied Biosystems, version 1.4.0). 
4.3.5.d Optimization of ChIP 
The fixation and shearing conditions for human monocytes were optimized to gain reliably uniform 
chromatin fragments ranging from 200 to 1000 bp for ChIP assays (Fig. 4-3). A balance between 
fixation temperature and time as well as shearing conditions was needed to avoid over fixation on the 
one hand, but reliable fixed interactions of DNA and proteins on the other hand. Briefly, CD14+ 
monocytes were fixed followed by chromatin isolation. Subsequently, cross-linked chromatin was 
sheared by sonication and DNA was accessed by reversal of cross-linking and purification (for more 
details see 4.3.5.a). To find the optimal ChIP conditions, variations in fixation temperature (Fig. 4-3 B), 
fixation time (Fig. 4-3 C) and shearing time (Fig. 4-3 D) were performed. Proper fragment size of DNA 
was checked by agarose gel electrophoresis (see also 4.3.5.b). 
Optimal DNA fragment size ranging from 200 to 1000 bp was achieved by cell fixation on ice (ca. 4 °C) 
for 7.5 min and shearing for 10 cycles (Fig. 4-3 D). 
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Fig. 4-3: Optimization of fixation and shearing conditions of ChIP assays for human monocytes. (A) Schematic overview 
of determining optimal ChIP fixation and shearing conditions: Human CD14+ monocytes were cross-linked with formaldehyde 
following cell lysis and isolation of fixed chromatin. After shearing of chromatin by sonication, DNA was accessed by reversing 
the cross-linking following DNA purification. Optimal shearing of DNA was analyzed on an agarose gel (1.2 %). (B, C and D) 
Agarose gel with purified DNA: Either fixation temperature (B), fixation time (C) or shearing time (D) was varied. Best results are 
indicated by arrows. M = ladder, RT = room temperature (circa 21 °C). 
 
4.3.6 ChIP-Sequencing (ChIP-Seq) 
For epigenetic characterization of the chromatin status and recovery of all binding sites within a 
genome, ChIP DNA is sequenced and the short sequences called ‘reads’ are aligned to a reference 
genome. As a control for ChIP-Seq data analysis, a library with input DNA (pre-immunoprecipitated 
total DNA) is generated, which allows an accurate estimation of biases produced by sonication of 
chromatin and sequencing. If no input DNA is available, specific enrichment of ChIP DNA is compared 
to different conditions. The generated binding profile of target proteins can be visualized in a genome 
browser. 
Finally, the sequence data are converted to position data by alignment with a reference genome and 
analyzed by peak-calling algorithms to identify ChIP-enriched regions that correspond to histone 
modifications or transcription factor binding sites (Northrup & Zhao 2011). 
4.3.6.a Next Generation Sequencing (NGS) of ChIP DNA 
For genome-wide analysis of histone modifications, the ChIP DNA was subjected to sequencing: 
Ethanol-precipitated DNA from ChIP assays (see 4.3.5.a) was further processed by the BCRT Core 
Facility for Next Generation Sequencing (Jochen Hecht/Ulrike Krüger, Charité-Berlin, Germany). 
In brief, library preparation (ligation of barcoded adapters to DNA fragments) was performed using the 
NEBNext ChIP-seq Library Prep Master Mix for Illumina (New England Biolabs) according to the 
manufacturer’s instructions. A limited PCR amplification was performed for enrichment of ChIP-Seq 
library, followed by size selection of desired DNA fragments ranging from 300 to 450 bp using the 
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BioAnalyzer (Agilent Technologies). Subsequently, DNA samples were sequenced on an Illumina 
Genome Analyzer IIx generating 36 bp single-end reads using TruSeq Cluster Kit and TruSeq SBS Kit 
or on an Illumina HiSeq 1500 generating 50 bp single-end reads using HiSeq Cluster Kit and HiSeq 
SBS Kit (all Illumina). 
As the Illumina technology was used for DNA sequencing, this technique is briefly introduced in this 
section (see Fig. 4-4). The technology basically involves attachment of smaller fragments of DNA to a 
surface followed by massively parallel sequencing. 
 
 
Fig. 4-4: Pipeline of DNA sequencing by Illumina technology. All information and illustrations are adopted from the illumina 
website (online available (as of October 2015): http://www.illumina.com/). 
First, DNA fragments are ligated to barcoded adapters with a known sequence. This allows 
attachment of single-stranded DNA to a solid surface called a ‘flow cell’ and subsequent solid-phase 
bridge amplification of the DNA templates. Here, the DNA molecule bends over and hybridizes to a 
free complementary adapter which functions as a primer allowing synthesis of the complementary 
DNA strand. The amplification results in a flow cell with millions of clusters with the exact number 
depending on the sequencing device used, each containing about 1000 identical copies of the initial 
template in close proximity. Sequencing is mediated in a massively parallel fashion by a ‘DNA 
Sequencing by Synthesis’ approach: First, the DNA strand is denatured leaving the forward DNA 
strand bound to the flow cell and then a sequencing primer complementarily hybridizes to the adapter 
sequence. Subsequently, a single fluorescence-labeled terminator nucleotide is incorporated into the 
nucleic acid chain allowing imaging of a successive nucleotide addition after each sequencing cycle. 
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Finally, enzymatic cleavage of the terminator dye allows the incorporation of the next nucleotide 
starting a new sequencing cycle. 
4.3.6.b Pre-Processing: Quality Filtering and Read Mapping of ChIP-Seq Data 
ChIP experiments followed by NGS produce millions of short read sequences, which are aligned to a 
known reference genome to identify locations of specific DNA-protein interactions. 
The computational analysis starts with so-called fastq files that store the sequence information of all 
reads. The pre-processing pipeline involves quality assessment, mapping to a reference genome, 
duplicate filtering of reads and transformation of the aligned data to coverage vectors. 
(Pipeline was adapted from Dr. Daniel Ibrahim) 
The sequencing data was converted to fastq files and controlled for general quality characteristics 
using FastQC. All reads that had an average Phred-score < 28 were discarded. Subsequently, the 
remaining reads were aligned to the human hg19 genome assembly (Feb. 2009) using the mapping 
algorithm BWA with default parameters allowing two mismatches per reads. The parameters were as 
follows: aln -n=0, aln -o=1, aln -e=1, aln -d=16, aln -i=5, aln -l=-1, aln -k=2, aln -M=3, aln -O=11, aln  
-E=4, aln -R=FALSE, aln -N=FALSE, samse/sampe -n=3, sampe=-N10, sampe -a=500, sampe  
-o=100000, samse/sampe -r=NO. The SAM file created containing aligned read data was used for 
follow-up processing. Reads that repetitively bound within the genome were discarded and only 
uniquely mapped reads were kept for subsequent filtering of duplicates (removal of PCR artifacts by 
the SAMtool rmdup). The final alignment file (BAM file) contained only non-redundant reads. The BAM 
file is the binary and indexed format of the SAM file that stores the final sequence data. 
The quality of the ChIP enriched data was evaluated by calculating the relative strand correlation 
(RSC) and normalized strand correlation (NSC) from the cross-correlation following the ChIP-Seq 
guidelines suggested by the ENCODE consortium (The Encyclopedia of DNA Elements) (Bailey et al. 
2013, Landt et al. 2012). 
The pre-processing was conducted on a server at the Charité (Berlin, Germany) using a locally 
installed version of the Galaxy platform (Blankenberg et al. 2010, Giardine et al. 2005, Goecks et al. 
2010). The infrastructure of the server was set up and maintained by Peter Hansen from the 
Computational Biology Group of Prof. Dr. Peter Robinson. 
 
The ChIP-Seq assays performed are listed in Table 4-5. According to the ChIP-Seq guidelines (Bailey 
et al. 2013, Landt et al. 2012), the sequencing depth should be a minimum of 10 million reads, 
whereas the percentage of uniquely mapped reads should lie above 50 %. The percentage of non-
redundant reads known as non-redundancy fraction (NFR) within the uniquely mapped ones should be 
≥ 80 %. The NSC (≥ 1.05) and the RSC (≥ 0.8) are important indexes for assessing signal-to-noise 
ratios in a ChIP-Seq experiment. 
The quality of the conducted ChIP-Seq experiments was good. Most of the quality criteria, especially 
the most important ones (NSC and RSC), were met by all samples. Solely the NFR was achieved by 
10 of 16 ChIP-Seq analyses. 
 
94 
Materials & Methods 
 
Table 4-5: Overview of performed ChIP-Seq assays. Naïve (N) or tolerant cells (treated with 100 ng/ml LPS 
overnight) were stimulated for 1.5 h with 100 ng/ml LPS (N+L, T100+L) prior to ChIP-Seq analyses. 
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H3K9me2 N+L 1 24990613 24937781 18210519 73.02 13198844 72.48 1.103 5.785 
H3K9me2 N+L 2 30326140 30184109 20672630 68.49 16674211 80.66 1.092 6.554 
H3K9me2 T100+L 1 23940783 23892929 17226306 72.10 11119768 64.55 1.100 4.865 
H3K9me2 T100+L 2 31607282 31447721 22287481 70.87 16640784 74.66 1.090 3.584 
H3K27me3 N+L 1 17952199 17899832 12429386 69.44 8852687 71.22 1.171 2.628 
H3K27me3 N+L 2 39883441 39650973 31657613 79.84 25603692 80.88 1.088 1.919 
H3K27me3 T100+L 1 13360964 13322746 9109428 68.38 6221161 68.29 1.155 2.197 
H3K27me3 T100+L 2 31821055 31616484 22730043 71.89 18853318 82.94 1.099 1.613 
H4K20me3 N+L 1 26648298 26589310 15996756 60.16 13358495 83.51 1.057 1.949 
H4K20me3 N+L 2 35180756 35007444 23065502 65.89 19690983 85.37 1.052 3.052 
H4K20me3 T100+L 1 36067558 35988056 20324041 56.47 15562998 76.57 1.057 1.576 
H4K20me3 T100+L 2 40740966 40524889 25170417 62.11 20489596 81.40 1.054 1.633 
           
H3K27ac N 1 44910266 44693987 34090192 76.27 30042303 88.13 1.055 3.866 
H3K27ac N+L 1 34033741 33846109 25349055 74.90 21698557 85.60 1.069 3.281 
H3K27ac T100+L 1 36474027 36299868 26669802 73.47 22528742 84.47 1.051 3.714 
H4ac N 1 41176243 40953900 32242936 78.73 27712381 85.95 1.084 2.158 
H4ac N+L 1 38083744 37868972 29285769 77.33 24722675 84.42 1.116 1.707 
H4ac T100+L 1 41578935 41369787 31806813 76.88 28126000 88.43 1.051 2.053 
           
H3K9me2 = dimethylation of lysine 9 (K9) at histone 3 (H3), H3K27me3 = trimethylation of K27 at H3, H4K20me3 = 
trimethylation of K20 at histone 4 (H4), H3K27ac = acetylation of K27 at H3, H4ac = pan-acetylation of several lysines  
at H4, RSC = relative strand correlation and NSC = normalized strand correlation. 
 
4.3.6.c Visualization of Binding Profiles 
The final alignment result of the pre-processed analysis is a BAM file including all non-redundant 
reads with an index file (BAI file), which can be displayed in the Integrative Genome Viewer (IGV, 
Broad Institute, version 2.3). For better handling and visualization in the IGV, the alignments within the 
BAM file were converted into bedgraph-files (using BEDTools). 
For visualization within the UCSC Genome Browser from the University of California (Santa Cruz, 
California, USA), read lengths were extended to fragment size and ChIPSeq data was normalized to 
one million aligned sequencing reads. Converted BigWig files were uploaded on a local server from 
the MPI for Molecular Genetics (Berlin, Germany) and displayed in the UCSC Genome Browser (Kent 
et al. 2002). 
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4.3.6.d Peak Calling 
Significant enrichment of regions by ChIP representing DNA-protein interactions known as ‘peaks’ are 
determined by specifically developed algorithms that identify truly enriched ChIP DNA over a given 
background. Here, ChIP samples are either compared with the input DNA or significant differences are 
detected by comparing two conditions. The latter approach was used in this study. As the sequencing 
is performed from the 5’ end (single-end), the alignment of the short sequencing reads results in two 
enrichment profiles, representing one on each strand. Most peak callers, therefore, correct the real 
binding location of the protein of interest by length extractions of reads and shifting the binding sites 
according the 3’ end by one half of the fragment size (Fig. 4-5). The fragment length can be estimated 
based on the size selection during library preparation or computationally by maximizing the cross-
correlation between the sense and anti-sense strand (Kharchenko et al. 2008). 
 
 
Fig. 4-5: Pipeline of the 
central steps in analysis of 
ChIP-Seq data (adapted from 
Liu et al. (2010) and Bardet et 
al. (2012)). For more details 
see text.  
 
 
 
 
 
 
 
 
The peak shape is an important factor in choosing the right peak caller. ChIP-Seq experiments using 
an antibody directed towards a transcription factor (TF) result in sharp peaks because of the binding 
characteristics of TFs to attach to specific DNA sequences (TFBS, transcription factor binding site). By 
contrast, peaks of histone modifications result in broader peaks ranging from 300 bp to several kbs 
depending on the type of histone mark. 
The output file of peak calling is normally a BED file that contains the chromosome name, start point 
and end point of enriched regions. Moreover, it provides a score (normally specific to each peak 
caller), a P value and a false discovery rate (FDR) for evaluation of significantly enriched genomic 
regions indicating specific DNA-protein interactions. 
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4.3.6.e Spatial Clustering Approach for the Identification of ChIP-Enriched 
Regions (SICER) 
(Performed by Carolin Walter) 
SICER (Zang et al. 2009) is a spatial clustering approach to detect large domains of enriched histone 
modifications. The genome is divided into non-overlapping bins of size w (window). For histone 
modifications, a window size of 200 bp representing a nucleosome is normally used. Each bin is 
categorized as ‘eligible’ or ‘ineligible’ based on a Poisson null hypothesis with a fixed λ parameter. 
SICER detects eligible windows (enriched read sequences) that are separated by gaps. A gap of size 
m contains m ineligible windows. A scoring system of detected clusters is delivered together with 
P values and FDRs. The specific SICER score represents the negative logarithm of the probability of 
finding the number of reads observed to be in the current window. The higher the score, the less likely 
the observed interaction occurs by chance (Fischl 2010, Xu et al. 2014, Zang et al. 2009). 
 
For a comprehensive view of SICER peak calling see Fig. 4-6. 
 
 
Fig. 4-6: Peak Calling by SICER. The SICER algorithm identifies enriched regions (peaks) within each condition (N+L, T100+L) 
provided with a score representing the likelihood of the identified interaction (termed as SinglePeak). Moreover, SICER 
compares two ChIP-Seq data sets by treating one condition as a control. The DiffPeak is counted here for the condition N+L. 
The significance is provided by a P value. An IGV snapshot is displayed as representative ChIP-Seq data of the histone 
modification H4ac. Chr = chromosome, N+L = naïve cells treated with LPS, T100+L = tolerant cells (tolerized with 100 ng/ml 
LPS) stimulated with LPS, RefSeq = reference sequence, AQP9 = Aquaporin-9. 
Before peak calling, the two replicates for the repressive histone marks H3K9me2, H3K27me3 and 
H4K20me3 were merged together (see also Table 4-5). The final ten data sets (BAM files) used for 
peak calling consisted of the combination of N+L compared to T100+L for each of the five different 
histone marks; H3K9me2, H3K27me3, H4K20me3, H3K27ac and H4ac. 
Peak calling for each data set was performed using SICER with default parameters applying a window 
(w) size of 200 bp and a gap (g) size of 600 bp (effective human genome length was assumed by 
74.3 %). As no input control data were available, a random E-value threshold of 100 and a random 
background were used to determine the statistical significance of each identified peak (script used: 
SICER-rb.sh). The resulting peak list containing significant genomic regions with a corresponding 
SICER score was titled as ‘SinglePeaks’. 
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Moreover, SICER provides a differential analysis modus: For identification of differential enrichment 
between two ChIP data sets, e.g. the comparison of the condition N+L over T100+L and vice versa for 
a single histone mark, the data sets were analyzed by SICER-df-rb.sh with an FDR of 0.01 (g = 600, 
w = 200). The specific script first identified enriched regions in the two conditions (as above), then 
merged the regions together and identified significantly enriched peaks compared to the defined 
control condition. The output peak lists containing regions with increased or decreased enrichment 
over the control condition were provided with an FDR, P value and fold change (FC). These peak sets 
were termed ‘DiffPeaks’. The data files containing significantly enriched regions were provided in BED 
format. 
4.3.6.f Determining the Final Peak Lists 
(Performed by Carolin Walter) 
Single peak lists called by SICER for each histone mark and every condition were filtered for a 
minimum score of 100 (SinglePeaks). Differential peak lists comparing naïve monocytes treated with 
LPS (N+L) and tolerant cells stimulated with LPS (T100+L) were filtered for a minimum fold change 
(FC) of 2 and a P value of ≤ 1e-6 (DiffPeaks). 
The DiffPeak data sets were further filtered for histone-limited DiffPeak data sets. To identify genomic 
regions with enhanced H4ac-enrichment in tolerant monocytes treated with LPS (T100+L) compared 
to naïve cells (N+L), differentially enriched H4ac in T100+L (DiffPeaks from SICER, 2-fold change) 
were selected and all regions positive for DiffPeaks in repressive histone marks were discarded. The 
same was performed for H3K27ac. 
Moreover, for identifying induction of repressive histone marks in tolerant cells compared to naïve 
ones, specific genomic regions significantly enriched for H3K9me3, H3K27me3 or H4K20me3 
(minimum 2-fold change) in T100+L with a negative correlation in positive histone marks (H3K27ac or 
H4ac) were chosen for down-stream analyses. 
The final peak lists for (1) enrichment of the activating histone marks H4ac or H3K27ac and (2) 
enrichment for the repressive histone modifications H3K9me2, H3K27me3 or H4K20me3 in tolerant 
cells (T100+L) were subjected to down-stream functional analysis. An overview of the final peak lists 
used in this study is given in Table 4-6. 
Table 4-6: Overview of the final ChIP-Seq peak lists used in this thesis. 
SinglePeaks   
Histone/Name Condition Notes 
   
H3K27ac N+L SICER Score ≥ 100 
H3K27ac T100+L SICER Score ≥ 100 
H4ac N+L SICER Score ≥ 100 
H4ac T100+L SICER Score ≥ 100 
H3K9me2 N+L SICER Score ≥ 100 
H3K9me2 T100+L SICER Score ≥ 100 
H3K27me3 N+L SICER Score ≥ 100 
H3K27me3 T100+L SICER Score ≥ 100 
H4K20me3 N+L SICER Score ≥ 100 
H4K20me3 T100+L SICER Score ≥ 100 
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Table 4-6: Overview of the final ChIP-Seq peak lists used in this thesis (continued). 
DiffPeaks   
Histone/Name Counted For Notes 
   
H3K27ac_N N+L FC ≥ 2, P value of minimum 1e-6 
H3K27ac_T T100+L FC ≥ 2, P value of minimum 1e-6 
H4ac_N N+L FC ≥ 2, P value of minimum 1e-6 
H4ac_T T100+L FC ≥ 2, P value of minimum 1e-6 
H3K9me2_N N+L FC ≥ 2, P value of minimum 1e-6 
H3K9me2_T T100+L FC ≥ 2, P value of minimum 1e-6 
H3K27me3_N N+L FC ≥ 2, P value of minimum 1e-6 
H3K27me3_T T100+L FC ≥ 2, P value of minimum 1e-6 
H4K20me3_N N+L FC ≥ 2, P value of minimum 1e-6 
H4K20me3_T T100+L FC ≥ 2, P value of minimum 1e-6 
   
DiffPeaks (Histone-limited) 
Histone/Name Counted For  
   
H3K27ac_T_no_RepX T100+L No overlap with DiffPeaks in repressive histone marks 
H4ac_T_no_RepX T100+L No overlap with DiffPeaks in repressive histone marks 
H3K9me2_T_no_AcX T100+L No overlap with DiffPeaks in activating histone marks 
H3K27me3_T_no_AcX T100+L No overlap with DiffPeaks in activating histone marks 
H4K20me3_T_no_AcX T100+L No overlap with DiffPeaks in activating histone marks 
   
 
4.3.7 Bioinformatical Downstream Analyses of ChIP-Seq Data 
For the identification of potential functional relevance of the DNA-protein interaction, several 
downstream analyses are available including genomic annotation of peaks, discovery of TFBSs within 
the significantly enriched regions and comparison with DNA methylation or RNA expression data. 
The vast majority of downstream analyses were conducted using the open-source R language 
(version 3.1.2) as well as the open-source Bioconductor project (version 3.1), and HOMER (see 4.1 for 
software overview). 
4.3.7.a Gene Annotation and Gene Body Distribution 
(Performed by Carolin Walter) 
Identified peaks (genomic regions) were assigned to the nearest transcription start site (TSS) of a 
gene using Hypergeometric Optimization of Motif EnRichment (HOMER, Heinz et al. (2010)) and 
categorized into following gene body elements: TSS (by default defined from -1 kb to +100 bp), 
transcription termination site (TTS, by default defined from -100 bp to +1 kb), coding DNA sequence 
(CDS Exons), 5' untranslated (UTR) Exons, 3' UTR Exons, Introns and Intergenic regions (Heinz et al. 
2010). 
4.3.7.b Binding Profiles around the Transcription Start Site (TSS) 
Peak binding profiles of ChIP-Seq data to TSS regions were generated by the Bioconductor package 
ChIPseeker (version 1.2.6). Moreover, it supported annotation of ChIP peaks and functional 
visualization (Yu et al. 2015). 
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4.3.7.c Cluster Analysis of Chromatin Signatures (Heat map) 
(In cooperation with Dr. Stephan Schlickeiser) 
Differentially enriched regions were visualized with an unsupervised clustering heat map (Euclidean) 
using R. First, peak sets identified by SICER were annotated to the nearest gene using HOMER. 
DiffPeaks for each histone and every condition (minimum fold change of 2, P value of ≤ 1e-6) were 
unified to a single gene list by discarding duplicates. As DiffPeaks were counted for either one of the 
two conditions, the given gene list was compared to the SinglePeak data set (with a minimum SICER 
score of 100) to obtain values for both conditions. If multiple regions were associated with a single 
gene, the region with the highest SICER score was used. Genes and corresponding SICER scores 
were scaled over the samples and clustered using heatmap.2 (gplot R package, version 2.17.0, 
Warnes et al. (2015)). 
4.3.7.d Analysis of Gene Overlap between Gene Lists 
Significant overlap between gene lists was investigated by the Bioconductor package GeneOverlap 
(version 1.2.0) (Shen & Sinai 2013). 
4.3.7.e Gene Ontology (GO) Enrichment Analysis of ChIP-Seq Data 
Peak lists as BED files were subjected to Genomic Regions Enrichment of Annotations Tool (GREAT, 
version 3) analyses. GREAT not only attributes significant enrichment of genes to specific functional 
processes, it also identifies putative cis-regulatory regions, which is useful for intergenic analyses 
(McLean et al. 2010). 
Moreover, gene ontology analyses of identified gene lists were performed using Database for 
Annotation, Visualization and Integrated Discovery (DAVID, version 6.7) (Huang et al. 2009a, b).  
4.3.7.f Identification of Transcription Factor Binding Sites (TFBSs) 
(Performed by Carolin Walter) 
The enriched genomic regions identified by SICER were analyzed for de novo motif discovery of 
known TFBSs using HOMER (Heinz et al. 2010). 
 
4.3.8 Specific DNA Methylation Analysis of the Human IL6 and TNF Promoter 
Using Short Bisulfite Sequencing (BS-Seq) 
Methylation of DNA molecules is a general marker for repressive gene expression. Methylated 
cytosine can be detected by modification with sodium bisulfite treatment. Here, unmethylated 
cytosines are de-aminated to uracil, whereas methylated cytosines are protected and remain 
unchanged. After sequence-specific PCR, uracil is exchanged with the structural analog tyrosine. PCR 
products can be subjected to sequencing, where formerly methylated cytosine is read as ’C’ while 
unmethylated cytosine is read as ‘T’ in the DNA sequence. The generated sequence data can be 
compared to the original reference DNA (Li & Tollefsbol 2011, Northrup & Zhao 2011). 
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4.3.8.a DNA Preparation and Bisulfite Conversion 
For DNA methylation analysis of the IL6 and TNF promoter regions, DNA was subjected to bisulfite 
treatment followed by PCR and sequencing analysis. 
Genomic DNA was isolated using the QIAamp DNA Mini Kit (Qiagen, Cat. No. 51304) following the 
manufacturer’s instructions. Before elution, columns were dried for additional 10 min and DNA was 
eluted in 200 µl Buffer AE. Bisulfite conversion of isolated DNA was performed with the Epitect 
Bisulfite Kit® (Qiagen, Cat. No. 59194) according to the “Sodium Bisulfite Conversion of Unmethylated 
Cytosines in DNA” protocol. Bisulfite-converted DNA was eluted twice in 25 µl Buffer EB for a final 
volume of 50 µl. DNA was aliquoted and stored at -20 °C until further use. 
4.3.8.b PCR of Target Promoter 
Bisulfite-converted DNA was subjected to sequence-specific PCR. For the human TNF promoter, the 
primers were specifically designed to screen a promoter fragment from -360 to +50 bp containing 12 
CpG doublets surrounding the NFκB binding site at -98 bp (Campion et al. 2009). The human IL6 
promoter region spanning over 1200 bp was subdivided into 3 sections ranging from 350 to 400 bp 
(Nile et al. 2008). The primer sequences are listed in Table 4-7. 
 
Table 4-7: Primer pairs used for promoter-specific PCR of bisulfite-converted DNA. 
Gene/Amplicon Forward primer (5’→3’) Reverse primer (5’→3’) 
   
TNF (Campión et al. 2009) TTAAAAGAAATGGAGGTAATAG CTTCTCTCCCTCTTAACTAATC 
IL6_section1 (Nile et al. 2008) TATTATTTTGAGGGAAGAGGGTTTT TACTCTCCCCACTACCACTAAATCT 
IL6_section2 (Nile et al. 2008) TTTTTTTAAGTGGGTTGAAGTAGGT CAAAAAATAAAACTAAAATCATACA 
IL6_section3 (Nile et al. 2008) TAAAGTGTTGAGTTATTAATAAAAG TCATAACTAAACTCCTAAAAAAAA 
   
 
The specific primer pairs used for promoter amplification already included adapter sequences for 
direct sequencing with Illumina (Adaptor1: 5'-CTACACGACGCTCTTCCGATCT-primer-specific 
sequence-3', Adaptor2: 5'-CAGACGTGTGCTCTTCCGATCT-primer-specific sequence-3'). The PCR 
reactions were performed in 25 µl containing 1 x AmpliTaq Gold Mastermix (Invitrogen, Cat. No. 
4398881), 500 nM of forward and reverse primers and 2.5 µl of bisulfite-converted DNA (circa 100 ng). 
The PCR reaction was carried out as touchdown PCR with the following conditions: Initial denaturation 
at 95 °C (10 min), followed by 10 cycles at 95 °C (30 sec), the sequence-specific annealing 
temperature plus 10 °C for 1 min with decreasing annealing temperature by 1 °C each cycle and 
elongation at 72 °C (1 min), followed by 30 cycles at 95 °C (30 sec), sequence-specific annealing 
temperature (30 sec) and 72 °C (1 min), and a final elongation step at 72 °C (7 min). The specific 
annealing temperatures were as follows: 53 °C (TNF), 58 °C (IL6_section1), 50 °C (IL6_section2) and 
47 °C (IL6_section3). 
Sequences of the promoter regions of TNF and IL6 used for DNA methylation analyses are found in 
the Appendix 5.4. 
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4.3.8.c Purification of PCR Products 
PCR products were purified using the QIAquick PCR Purification Kit (Qiagen, Cat. No. 28104) 
according to the manufacturer’s instructions with the following changes: After DNA binding, columns 
were washed twice with PE Buffer and dried for 10 min to remove residual ethanol. Subsequently, 
DNA was eluted in two serial elution steps, each with 30 µl Elution Buffer. 
4.3.8.d Detection of PCR Products by Gel Electrophoresis 
Purified PCR products were checked on an agarose gel (2 %, SERVA Electrophoresis in 1 x TAE 
buffer) for proper product sizes (see also 4.3.5.b). 
4.3.8.e Restriction Enzyme Digestion for Specificity Analysis of PCR Products 
Specificity of PCR products was further evaluated by restriction enzyme digestion and subsequent gel 
electrophoresis. PCR products were digested with SspI (AATATT) or DraI (TTTAAA) in the enzyme-
corresponding buffer (New England BioLabs). The standard digestion reaction (final volume 10 µl) 
contained 5 µl of purified PCR product, 1 x NEBuffer (No. 2 for SspI, No. 4 for DraI) and 1 µl of 
restriction enzyme. PCR products were digested for 1 h at 37 °C followed by 20 min at 65 °C for heat 
inactivation of the enzyme. Digestion products were checked for correct sizes on a 2 % agarose gel 
(Fig. 4-7). Restriction sites of enzymes are shown in Appendix 5.4. 
 
 
Fig. 4-7: Analysis of restriction enzyme 
digestion of PCR products by gel 
electrophoresis. TNF and IL6 promoter-
specific PCR products of bisulfite-converted 
DNA were digested with the restriction enzymes 
DraI or SspI. Digestion fragments were checked 
for correct sizes on a 2 % agarose gel. The total 
amplicon sizes of the PCR products were as 
follows: TNF = ca. 400 bp (+ 40 bp adapter), 
IL6_1 = ca. 350 bp (+ 40 bp adapter), IL6_2 = 
420 bp (+ 40 bp adapter) and IL6_3 = 370 bp (+ 
40 bp adapter). A, B, C, D and E represent 
different experiments. 
 
4.3.8.f Sequencing of PCR Products 
PCR products were subjected to sequencing. DNA sequencing was carried out on a Illumina MiSeq 
generating 250 bp single-end reads at the BCRT Core Facility for Next Generation Sequencing 
(Jochen Hecht/Ulrike Krüger, Charité-Berlin, Germany). BS-Seq libraries were constructed as 
directional. 
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4.3.8.g Pre-processing and Computational Analysis 
(In cooperation with Peter Hansen) 
The workflow proposed by Krueger et al. was used for data processing (Krueger et al. 2012). After 
trimming of possible adapter sequences, reads were checked for quality by FastQC and reads with a 
Phred-score below 28 were discarded. Fastq files were generated for each amplicon and each 
sample. 
Quality filtered reads were analyzed using BiQ Analyzer HiMod (Becker et al. 2014) and compared 
with reference sequences representing unmethylated, fully C to T converted DNA (reported as % of 
cytosine methylation).  
 
4.3.9 DNA Methylation Analysis by MethylCap-Sequencing (MethylCap-Seq) 
Genome-wide analysis of DNA methylation profiles by NGS-based bisulfite ‘shotgun’ sequencing is 
highly cost-effective. Therefore, alternative strategies focus on the enrichment of sheared, methylated 
DNA by affinity purification using proteins containing methyl-DNA binding domains (MBDs) and 
subsequent analysis of enriched DNA fragments by massive parallel sequencing. One method is 
called MethylCap-Seq that is based on in vitro capture of methylated DNA using the MBD domain of 
MeCP2 (methyl CpG binding protein 2) combined by next generation sequencing of eluted DNA  
(Fig. 4-8) (Brinkman et al. 2010, Serre et al. 2010). 
 
 
Fig. 4-8: Principle of MethylCap. Isolated DNA is fragmented by sonication and subjected to MethylCap. Methylated DNA (Me) 
is enriched by binding to the high affinity H6-GST-MBD fusion protein and subsequent magnetic (M) separation. The protein  
H6-GST-MBD consists of the methyl binding domain (MBD) of human MeCP2 that is fused to glutathione-S-transferase (GST) 
containing an N-terminal His6-tag (H6). GST possesses a high affinity to glutathione (GSH). Isolated DNA can be further 
processed by sequencing analysis. Figure was adapted from the Diagenode website (as of October 2015): 
http://www.diagenode.com/en/catalog/kits-2/dna-methylation-11/product/methylcap-kit-11. 
4.3.9.a Sample Preparation (MethylCap) 
MethylCap-Seq was performed at the BCRT Core Facitlity for Next Generation Sequencing (Jochen 
Hecht/Ulrike Krüger, Charité-Berlin, Germany). Briefly, isolated genomic DNA (from point 4.3.8.a) was 
sheared by sonication and subjected to MethylCap following the instructions of the MethylCap® kit 
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from Diagenode. Elution of captured DNA was performed by a single total elution in High Elution 
Buffer. Sequencing of eluted DNA fragments was performed on an Illumina HiSeq 1500 generating 
50 bp long reads. 
4.3.9.b Pre-Processing and Visualization of MethylCap-Seq Data 
Pre-processing of sequenced data was performed similarly as for ChIP-Seq data, as outlined in 
4.3.6.b. Briefly, sequenced reads were mapped to the human hg19 reference genome (Feb. 2009) 
and filtered for uniquely mapped and non-redundant reads. Aligned reads in BAM files were converted 
to BigWig files and visualized in the UCSC Genome Browser. 
4.3.9.c Identification of Genome-Wide DNA-Methylated Regions 
(Performed in cooperation with Dr. Karsten Jürchott) 
Analysis of enriched DNA fragments representing methylated DNA was performed with the 
Bioconductor package MEDIPS (version 1.16.0) (Lienhard et al. 2014). The workflow provides a 
quality control (QC) followed by differential methylation analysis. 
The QC included saturation analysis, CpG coverage analysis and CpG enrichment calculation. An 
overview of the quality control is shown in Table 4-8. The most important QC parameter is the CpG 
enrichment, which represents the frequency of CpGs observed in the sequenced sample compared to 
the expected frequency in the reference genome (Rodriguez et al. 2012). Samples were generally 
excluded with CpG enrichment values less than 1.4 and saturation values less than 0.5. The samples 
which passed the quality control were further analyzed for differential DNA methylation. 
 
Table 4-8: QC values of MethylCap-Seg data provided by the Bioconductor package MEDIPS. 
Samples Saturation analysis CpG coverage rate CpG enrichment  
   enrichment.score.relH enrichment.score.GoGe 
     
N 0.89 22.60 % 3.73 1.87 
N+L 0.83 23.97 % 3.02 1.68 
T1 0.71 12.96 % 2.65 1.58 
T1+L 0.78 9.95 % 3.76 1.90 
T100 0.81 14.75 % 3.60 1.84 
T100+L 0.78 12.19 % 3.47 1.81 
     
QC parameter: Saturation (library complexity) > 0.05, CpG coverage rate (5x; fraction of CpGs sequenced at least 
five times) > 5 %, CpG enrichment scores (compared to reference genome) > 1.4. 
 
Analysis of differentially methylated genomic regions was performed with default parameters 
(uniq=TRUE, extend=300, shift=0 and ws=100) over the complete human genome 
(“BSgenome.Hsapiens,UCSC.hg19”, chromosome 1 to 22, chromosome X and chromosome Y). 
The analysis was performed by identifying differential methylation between N+L with T100+L 
conditions. As no replicates were available, the differential coverage was calculated by edgeR (p.adj = 
“none”) and differentially methylated regions were identified by a minimum fold change of 2  
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(P value = 0.01). Regions of interest were annotated with the nearest genes (annotation = GENE, 
tssSz =c(-10000,10000)). 
4.3.9.d Gene Ontology (GO) Enrichment Analysis of MethylCap-Seq Data 
GO enrichment analyses of identified gene lists were performed using Database for Annotation, 
Visualization and Integrated Discovery (DAVID, version 6.7) (Huang et al. 2009a, b). 
 
4.3.10 Expression Profiling by mRNA Sequencing (mRNA-Seq) 
4.3.10.a Sample Preparation (mRNA) 
Total isolated RNA from section 4.3.4 was subjected to mRNA-Seq for genome-wide analysis of 
mRNA expression in human monocytes. In total, three replicates per condition (N+L, T100+L) were 
used. Illumina deep sequencing was performed at the genomics core facility of the Center of 
Excellence for Fluorescent Bioanalytics (KFB, University of Regensburg, Germany). 
4.3.10.b Data Processing and Determining of Differentially Expressed Genes 
(Performed in cooperation with Peter Hansen) 
Data preprocessing and analysis were performed on a locally installed version of the Galaxy platform 
(Blankenberg et al. 2010, Giardine et al. 2005, Goecks et al. 2010) at the Charité (Berlin, Germany). 
Data analysis was performed in principle according to the tuxedo workflow proposed by Trapnell et al. 
(Trapnell et al. 2012).  
In brief, mRNA-Seq data was quality controlled using FastQC. Sequenced reads were mapped to the 
reference genome (human hg19) using TopHat (version 2.0.9) (Trapnell et al. 2009) with known gene 
model annotations (human reference .GTF annotation) to disable novel splice discovery. The aligned 
reads were directly tested for differential expression using Cuffdiff (version 2.1.1) (Trapnell et al. 2010) 
with the human reference annotation used as transcript assembly. Geometric normalization was 
applied to normalize between samples and replicates (as proposed by Anders & Huber (2010)). 
Default parameters were used for TopHat and Cuffdiff analysis. Data visualization was performed by 
the Bioconductor package cummeRbund (version 2.8.2) (Goff et al. 2013). 
RNA-Seq analysis results were controlled for normalization and quality (Fig. 4-9). To quantify the 
transcript expression and compare between samples, Cuffdiff determines the reads per kilobase of 
transcripts per million mapped reads (RPKM) for all genes. 
The expression profile for naïve monocytes treated with LPS (N+L) was compared to the 
transcriptome of high-dose tolerized cells stimulated with LPS (T100+L). Differentially expressed 
genes (DEG), which showed at least a 2-fold change and a P value smaller than 0.05, were used for 
downstream analyses.  
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Fig. 4-9: Quality control of mRNA-Seq data. 
Box plot (left) represents proper normalization of 
data. Scatter plot (right) evaluates good quality 
based on low deviation from the dashed line. 
Replicates were combined to one condition. Data 
was visualized by the Bioconductor package 
cummeRbund. 
 
 
 
4.3.10.c Heat map of Differentially Expressed Genes 
A heat map of RPKM expression values of selected genes (DEG) was generated using R. Data matrix 
was scaled over the samples before hierarchical clustering (Euclidean) using heatmap.2 (gplot R 
package, version 2.17.0, Warnes et al. (2015)). 
4.3.10.d GO Enrichment Analysis of mRNA-Seq Data 
GO enrichment analysis of identified genes was performed using DAVID (version 6.7) (Huang et al. 
2009a, b). 
4.3.10.e Analysis of Gene Overlap between Gene Lists 
Significant overlap between gene lists was investigated by the Bioconductor package GeneOverlap 
(version 1.2.0, Shen & Sinai (2013)). 
 
4.4 Statistical Analysis 
Data were analyzed by GraphPad Prism (La Jolla, California, USA, version 5 and 6) and are 
presented as mean ± standard error of the mean (SEM) of more than three independent experiments. 
Statistical analysis was performed for a sample size > 5 and relied on the general comparison of naïve 
cells with tolerant monocytes. Wilcoxon matched-pairs signed-rank test was used to determine 
significant differences between two related groups (non-parametric, for comparison of samples from 
one source with different conditions). P values of < 0.05 were considered statistically significant and 
were displayed in figures as follows: *p ≤ 0.05 and **p ≤ 0.01. 
For analysis of gene overlap between identified gene lists, the Bioconductor package GeneOverlap 
(version 1.2.0) was used (Shen & Sinai 2013). Significance was tested using the Fisher’s exact test. 
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5. Appendix 
5.1 Cytokines and Chemokines – An Overview 
Information about the following cytokines and chemokines is reviewed in Ramnath et al. 
(2006), Schulte et al. (2013) and Turner et al. (2014). 
 
The 17 kDa protein TNF is one of the primary master regulators of inflammation 
(Parameswaran & Patial 2010) and is responsible for the pathophysiological conditions 
associated with sepsis (Carswell et al. 1975). 
The primary function of TNF is the upregulation of multiple pro-inflammatory proteins like 
cytokines, chemokines and adhesion molecules. In local inflammatory responses, TNF is 
important for activation of macrophages and their production from progenitor cells (Fahlman 
et al. 1994, Witsell & Schook 1992). Furthermore, it induces phagocytosis, increases 
vascular permeability, and enhances adhesion molecules on endothelial cells to facilitate 
infiltration of leucocytes to the site of infection and allow clearance of infectious agents 
(Nakae et al. 1996, Shimaoka & Park 2008). TNF is mainly produced by activated immune 
cells like monocytes and macrophages, lymphocytes and polymorphonuclear cells; and by 
non-immune cells like fibroblasts in response to infectious and/or inflammatory stimuli 
(Schulte et al. 2013, Striz et al. 2014, Turner et al. 2014). 
However, once invading pathogens infiltrate the blood stream, TNF is systemically produced 
leading to a dramatic loss of liquid, and vascular occlusion resulting in organ failure and 
sometimes death as seen in sepsis (see 1.5 in Introduction section) (Roman et al. 1993). 
IL-1β was originally identified as an endogenous pyrogen, which can induce fever on its own. 
It is mainly produced by monocytes and macrophages, neutrophils and hepatocytes (Striz et 
al. 2014, Turner et al. 2014). IL-1β activates neutrophils, induces production of cytokines and 
chemokines production like IL-6, CXCL8/IL-8 and TNF (Cavaillon et al. 1994, O'Neill 2008), 
and upregulates adhesion molecules on leukocytes and endothelial cells (Striz et al. 2014, 
Turner et al. 2014). 
The production and secretion of IL-1β and other cytokine family members need two signals. 
First, TLR4 signaling leads to activation of NFκB signaling followed by expression of 
biologically inactive pro-IL-1β. Second, inflammasome-dependent activation of caspase-1 
mediates posttranslational processing of the propeptide into the active IL-1β form and 
subsequent secretion via exocytosis (Kostura et al. 1989, Schroder & Tschopp 2010). 
The IL-1 receptor antagonist (IL-1RA) is a competitive inhibitor of IL-1β signaling (McIntyre 
et al. 1991). It inhibits the function of IL-1β through binding to the IL-1 receptor but fails to 
induce intracellular signaling. It is secreted by neutrophils, monocytes, macrophages and 
hepatocytes as an acute phase protein (Arend & Guthridge 2000). 
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TNF and IL-1β share a remarkable array of biological effects (Elias et al. 1989, Okusawa et 
al. 1988). Both cytokines are main activators of the coagulation system (Schouten et al. 
2008) and operate synergistically to induce a shock-like status characterized by vascular 
permeability, severe pulmonary edema and hemorrhage (Schulte et al. 2013). TNF and IL-1β 
are released within the first 30 to 90 min after exposure to LPS (Creasey et al. 1991, Kuhns 
et al. 1995) and act on other immune cells such as macrophages, endothelial cells and 
neutrophils. Binding to their receptors orchestrates a second level of inflammatory cascades. 
Activation of MAP kinases and the transcription factor NFκB result in the induction of 
downstream immunoregulatory mediators including cytokines like IL-6 and CXCL8/IL-8, and 
lipid mediators (Cohen 2002, Schulte et al. 2013). 
IL-6 is a 21 kDa glycoprotein and is a pleiotropic cytokine with a wide range of functions 
including activation and differentiation of macrophages, dendritic cells, B and T cells. 
However, application of IL-6 alone cannot induce a shock-like status. It can be produced by a 
variety of cells including T and B cells, monocytes and macrophages, dendritic cells, 
fibroblasts and endothelial cells (Schulte et al. 2013, Striz et al. 2014, Turner et al. 2014). 
The key functions of IL-6 are the induction of fever and mediation of the acute phase 
response (Castell et al. 1988, Gauldie et al. 1989, Leon et al. 1998). In an acute infection,  
IL-6 stimulates hepatic synthesis of acute phase proteins such as C-reactive protein and 
complement components, and mediates activation of the coagulation system (fibrinogen, 
ferritin) (Kishimoto 2010). 
A potent activator for monocytes and macrophages is IFNγ, which is preferentially produced 
by activated NK cells, NKT cells and some T cell subtypes including cytotoxic CD8+ T cells 
and T helper 1 cells. Its production is tightly regulated by macrophage-derived cytokines like 
TNF and IL-12 (Schulte et al. 2013). IFNγ induces phagocytic effector functions, activates 
anti-microbial activity and increases antigen processing, thereby promoting antigen 
presentation to lymphocytes through MHCs and activation of adaptive immunity  
(Giacomini et al. 1988, Young & Hardy 1995). Moreover, IFNγ enhances killing of 
intracellular pathogens, e.g. viruses (Muller et al. 1994), Leishmania major (Wang et al. 
1994), Listeria monocytogenes (Huang et al. 1993) and Mycobacteria (Cooper et al. 1993). 
Administration of IFNγ can rescue monocyte function and reverse ‘immunoparalysis’ in 
sepsis (Bozinovski et al. 2002, Docke et al. 1997a, Flohe et al. 2008, Leentjens et al. 2012, 
Schefold et al. 2008, Volk et al. 1996). 
 
The main function of chemokines is chemotaxis, although their role is more complex and 
involves homeostatic and housekeeping functions (Turner et al. 2014). Chemokines are a 
group of small proteins (8-12 kDa), characterized by the presence of three to four conserved 
cysteine residues, subdivided into four families based on the arrangement of the N-terminal 
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residues (Nomiyama et al. 2013). The majority of chemokines belong to the CXC and CC 
subfamily (Striz et al. 2014, Turner et al. 2014). 
Chemokines have an important role within the cytokines as they regulate the recruitment of 
immune cells to sites of infection or injury.  
IL-8 belongs to the CXC subfamily and is also known as CXCL8. The chemokine is a critical 
inflammatory mediator and was originally identified as neutrophilic chemoattractant 
(Baggiolini et al. 1992, Hammond et al. 1995). However, CXCL8/IL-8 also recruits 
monocytes, lymphocytes, basophils and eosinophils to sites of infection (Turner et al. 2014), 
and induces the expression of adhesion molecules (Takami et al. 2002). 
Whereas CXCL8/IL-8 basically regulates the recruitment and phagocytosis activity of 
neutrophils to inflamed tissues, other chemokines like monocyte chemoattractant protein-1 
(MCP-1 also known as CCL2), macrophage inflammatory protein-1α (MIP-1α also known as 
CCL3) and IFN-inducible protein of 10 kDa (IP-10 also known as CXCL10) are important 
regulators for the attraction of mainly monocytes and macrophages but also T cells, NK cells 
and dendritic cells. Thus, early chemokine expression appears in two phases: First, 
recruitment of neutrophils by e.g. IL8/CXCL8 followed by attraction of monocytes, NK cells 
and T cells by CCL2/MCP1, CCL3/MIP1α and CXCL10/IP-10 (Striz et al. 2014). 
 
After clearance of infectious agents, several mechanisms are involved in downregulation of 
effector mechanisms and tissue healing. These processes are also orchestrated by cytokines 
like IL-10 and TGFβ. 
The 35 kDa homodimeric cytokine IL-10 is produced by NK cells, T cells and monocytes.  
IL-10 has mainly immunosuppressive functions and is involved in termination of inflammatory 
processes (Schulte et al. 2013, Striz et al. 2014). For instance, it inhibits the production of 
pro-inflammatory cytokines and chemokines (de Waal Malefyt et al. 1991, Fiorentino et al. 
1991), thereby preventing tissue damage (van der Poll et al. 1997). Moreover, IL-10 reduces 
the antigen-presenting capacity of dendritic cells by downregulation of MHCs and 
costimulatory molecules, leading to inhibition of T lymphocyte activation (O'Keefe et al. 
1999). 
Another anti-inflammatory cytokine is TGFβ, which is widely produced by platelets, 
macrophages, lymphocytes, endothelial and epithelial cells, eosinophils and others. It plays 
an important role in tissue repair and fibrosis (Sporn & Roberts 1989), suppression of TNF 
and IL-1β release (Bogdan & Nathan 1993), and inhibition of T cell function and proliferation 
(Gilbert et al. 1997, Li et al. 2006a). Additionally, TGFβ is an important mediator of sepsis-
induced immunosuppression (Blobe et al. 2000) and mediates tolerance induction of 
monocytes and macrophages to LPS together with IL-10 (Randow et al. 1995). 
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5.2 Binding Sites of Primer Pairs for ChIP-qPCR Analysis of Human Monocytes 
and Murine Macrophages 
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5.3 Cytometer Settings 
BD FACSCalibur 
Laser Detector 1. Pass 2. Pass PMT Fluorochrome 
Blue  
488 nm (15 mW) 
A 560 SP 530/30 BP FL1 FITC, Alexa 488, GFP, CSFE 
B  480/10 BP SSC  
C 640 LP 585/42 BP FL2 PE 
D 640 LP 670 LP FL3 PerCP, PE-Cy5, PE-Cy7, 7AAD 
Red 
640 nm (10 mW) 
C 640 LP 660/20 BP FL4 APC, Alexa 647 
 
BD LSRFortessa 
Laser Detector 1. Pass 2. Pass PMT Fluorochrome 
Blue 
488 nm (100 mW) 
 
A 685 LP 696/40 BP Blue 695/40 PerCP, PerCP-Cy5.5, 7AAD 
B 505 LP 525/50 BP Blue 525/50 FITC, Alexa 488, GFP, CFSE 
C Empty 488/10 BP SSC  
YellowGreen (YG) 
561 nm (100 mW) 
A 750 LP 780/60 BP YG 780/60 PE-Cy7, PE-H7, PE-A750, 
PC7 
B 685 LP 710/50 BP YG 710/50 PE-Cy5.5 
C 635 LP 670/30 BP YG 670/30 PE-Cy5, PC5 
D 600 LP 610/20 BP YG 610/20 PE-TexasRed (ECD), PI, PE-
A610 
E Empty 585/15 BP YG 585/15 PE 
F Empty Empty   
G Empty Empty   
H Empty Empty   
Red 
639 nm (40 mW) 
A 750 LP 780/60 BP Red 780/60 APC-Cy7, APC-A750 
B 685 LP 710/50 BP Red 710/50 Alexa 700, APC-A700 
C Empty 670/14 BP Red 670/14 APC, Alexa 647 
Violet (Vio) 
404 nm (50 mW) 
A 705 780/60 Vio 780/60 Horizon V800, Qdot 800 
B 685 710/50 BP Vio 710/50 Qdot 705, Qdot 700 
C 635 660/20 BP Vio 660/20 Qdot 655 
D 600 610/20 Vio 610/20 Qdot 605 
E 505 525/50 BP Vio 525/50 Amcyan, Horizon V450, Qdot 
525 
F Empty 450/50 BP Vio 450/50 Pacific Blue, Alexa 405, 
Horizon V450 
G Empty Empty   
H Empty Empty   
Ultra-Violet (UV) 
355 nm (60 mW) 
A 505 530/30 UV 530/30 Indo-1 (free Ca2+) 
B Empty 405/20 UV 405/20 Indo-1 (bound Ca2+), DAPI, 
Hoechst 
C Empty Empty   
 
FSC = forward scatter 
LP = long pass 
mW = milliwatts 
PMT = photomultiplier tube with specific band pass filter 
SP = short pass 
SSC = sideward scatter 
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5.4 DNA Methylation Analysis by BS-Seq 
Sequence of untreated and bisulfite-treated DNA (displayed by MethPrimer, Li & Dahiya (2002)) 
 
Explanations:  Upper row:  Original sequence  
Lower row:  Bisulfite modified sequence  
++  CpG site 
::  Non-CpG 'C' converted to 'T' 
>>>>>> Primer position 
DraI / SspI Restriction site for specific enzyme 
 
Human TNF promoter region (Campion 2009) 
    1 CCAAAAGAAATGGAGGCAATAGGTTTTGAGGGGCATGGGGACGGGGTTCAGCCTCCAGGG 
      ::||||||||||||||:||||||||||||||||:|||||||++|||||:||::|::|||| 
    1 TTAAAAGAAATGGAGGTAATAGGTTTTGAGGGGTATGGGGACGGGGTTTAGTTTTTAGGG 
      >>>>>>>>>>>>>>>>>>>>>>> 
   61 TCCTACACACAAATCAGTCAGTGGCCCAGAAGACCCCCCTCGGAATCGGAGCAGGGAGGA 
      |::||:|:|:||||:|||:|||||:::||||||::::::|++||||++|||:|||||||| 
   61 TTTTATATATAAATTAGTTAGTGGTTTAGAAGATTTTTTTCGGAATCGGAGTAGGGAGGA 
                                                                   
  121 TGGGGAGTGTGAGGGGTATCCTTGATGCTTGTGTGTCCCCAACTTTCCAAATCCCCGCCC 
      |||||||||||||||||||::||||||:||||||||::::||:|||::||||:::++::: 
  121 TGGGGAGTGTGAGGGGTATTTTTGATGTTTGTGTGTTTTTAATTTTTTAAATTTTCGTTT 
                                                    DraI 
  181 CCGCGATGGAGAAGAAACCGAGACAGAAGGTGCAGGGCCCACTACCGCTTCCTCCAGATG 
      :++++||||||||||||:++|||:||||||||:||||:::|:||:++:||::|::||||| 
  181 TCGCGATGGAGAAGAAATCGAGATAGAAGGTGTAGGGTTTATTATCGTTTTTTTTAGATG 
                                                                   
  241 AGCTCATGGGTTTCTCCACCAAGGAAGTTTTCCGCTGGTTGAATGATTCTTTCCCCGCCC 
      ||:|:||||||||:|::|::|||||||||||:++:|||||||||||||:|||:::++::: 
  241 AGTTTATGGGTTTTTTTATTAAGGAAGTTTTTCGTTGGTTGAATGATTTTTTTTTCGTTT 
                                                    TSS          
  301 TCCTCTCGCCCCAGGGACATATAAAGGCAGTTGTTGGCACACCCAGCCAGCAGACGCTCC 
      |::|:|++::::|||||:|||||||||:|||||||||:|:|:::||::||:|||++:|:: 
  301 TTTTTTCGTTTTAGGGATATATAAAGGTAGTTGTTGGTATATTTAGTTAGTAGACGTTTT 
 
  361 CTCAGCAAGGACAGCAGAGGACCAGCTAAGAGGGAGAGAAG 
      :|:||:|||||:||:||||||::||:||||||||||||||| 
  361 TTTAGTAAGGATAGTAGAGGATTAGTTAAGAGGGAGAGAAG 
                         <<<<<<<<<<<<<<<<<<<<<< 
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Human IL6 promoter region (Nile 2008) 
    1 CACCATCCTGAGGGAAGAGGGCTTCTGAACCAGCTTGACCCAATAAGAAATTCTTGGGTG 
      :|::||::|||||||||||||:||:||||::||:||||:::|||||||||||:||||||| 
    1 TATTATTTTGAGGGAAGAGGGTTTTTGAATTAGTTTGATTTAATAAGAAATTTTTGGGTG 
   IL6_1 >>>>>>>>>>>>>>>>>>>>>>>>>                                    
   61 CCGACGCGGAAGCAGATTCAGAGCCTAGAGCCGTGCCTGCGTCCGTAGTTTCCTTCTAGC 
      :++|++++||||:|||||:||||::|||||:++||::||++|:++||||||::||:|||: 
   61 TCGACGCGGAAGTAGATTTAGAGTTTAGAGTCGTGTTTGCGTTCGTAGTTTTTTTTTAGT 
                                                                   
  121 TTCTTTTGATTTCAAATCAAGACTTACAGGGAGAGGGAGCGATAAACACAAACTCTGCAA 
      ||:|||||||||:||||:||||:|||:||||||||||||++|||||:|:|||:|:||:|| 
  121 TTTTTTTGATTTTAAATTAAGATTTATAGGGAGAGGGAGCGATAAATATAAATTTTGTAA 
                   DraI                                              
  181 GATGCCACAAGGTCCTCCTTTGACATCCCCAACAAAGAGGTGAGTAGTATTCTCCCCCTT 
      ||||::|:|||||::|::|||||:||::::||:||||||||||||||||||:|:::::|| 
  181 GATGTTATAAGGTTTTTTTTTGATATTTTTAATAAAGAGGTGAGTAGTATTTTTTTTTTT 
                                                                   
  241 TCTGCCCTGAACCAAGTGGGCTTCAGTAATTTCAGGGCTCCAGGAGACCTGGGGCCCATG 
      |:||:::||||::|||||||:||:||||||||:||||:|::||||||::|||||:::||| 
  241 TTTGTTTTGAATTAAGTGGGTTTTAGTAATTTTAGGGTTTTAGGAGATTTGGGGTTTATG 
                                                                   
  301 CAGGTGCCCCAGTGAAACAGTGGTGAAGAGACTCAGTGGCAATGGGGAGAGCACTGGCAG 
      :|||||::::|||||||:|||||||||||||:|:|||||:|||||||||||:|:|||:|| 
  301 TAGGTGTTTTAGTGAAATAGTGGTGAAGAGATTTAGTGGTAATGGGGAGAGTATTGGTAG 
                            IL6_1  <<<<<<<<<<<<<<<<<<<<<<<<<        
  361 CACAAGGCAAACCTCTGGCACAGAGAGCAAAGTCCTCACTGGGAGGATTCCCAAGGGGTC 
      :|:||||:|||::|:|||:|:||||||:|||||::|:|:||||||||||:::|||||||: 
  361 TATAAGGTAAATTTTTGGTATAGAGAGTAAAGTTTTTATTGGGAGGATTTTTAAGGGGTT 
                                                                   
  421 ACTTGGGAGAGGGCAGGGCAGCAGCCAACCTCCTCTAAGTGGGCTGAAGCAGGTGAAGAA 
      |:|||||||||||:||||:||:||::||::|::|:||||||||:|||||:|||||||||| 
  421 ATTTGGGAGAGGGTAGGGTAGTAGTTAATTTTTTTTAAGTGGGTTGAAGTAGGTGAAGAA 
                             IL6_2  >>>>>>>>>>>>>>>>>>>>>>>>>       
  481 AGTGGCAGAAGCCACGCGGTGGCAAAAAGGAGTCACACACTCCACCTGGAGACGCCTTGA 
      |||||:|||||::|++++||||:||||||||||:|:|:|:|::|::||||||++::|||| 
  481 AGTGGTAGAAGTTACGCGGTGGTAAAAAGGAGTTATATATTTTATTTGGAGACGTTTTGA 
                                                                   
  541 AGTAACTGCACGAAATTTGAGGATGGCCAGGCAGTTCTACAACAGCCGCTCACAGGGAGA 
      |||||:||:|++||||||||||||||::|||:||||:||:||:||:++:|:|:||||||| 
  541 AGTAATTGTACGAAATTTGAGGATGGTTAGGTAGTTTTATAATAGTCGTTTATAGGGAGA 
                                                                  
  601 GCCAGAACACAGAAGAACTCAGATGACTGGTAGTATTACCTTCTTCATAATCCCAGGCTT 
      |::||||:|:|||||||:|:||||||:|||||||||||::||:||:|||||:::|||:|| 
  601 GTTAGAATATAGAAGAATTTAGATGATTGGTAGTATTATTTTTTTTATAATTTTAGGTTT 
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  661 GGGGGGCTGCGATGGAGTCAGAGGAAACTCAGTTCAGAACATCTTTGGTTTTTACAAATA 
      ||||||:||++|||||||:||||||||:|:||||:||||:||:|||||||||||:||||| 
  661 GGGGGGTTGCGATGGAGTTAGAGGAAATTTAGTTTAGAATATTTTTGGTTTTTATAAATA 
                                            SssPI                   
  721 CAAATTAACTGGAACGCTAAATTCTAGCCTGTTAATCTGGTCACTGAAAAAAAATTTTTT 
      :|||||||:|||||++:||||||:|||::|||||||:||||:|:|||||||||||||||| 
  721 TAAATTAATTGGAACGTTAAATTTTAGTTTGTTAATTTGGTTATTGAAAAAAAATTTTTT 
                                                                   
  781 TTTTTTCAAAAAACATAGCTTTAGCTTATTTTTTTTCTCTTTGTAAAACTTCGTGCATGA 
      ||||||:||||||:||||:|||||:|||||||||||:|:|||||||||:||++||:|||| 
  781 TTTTTTTAAAAAATATAGTTTTAGTTTATTTTTTTTTTTTTTGTAAAATTTCGTGTATGA 
            DraI                                       IL6_2  <<<<<<< 
  841 CTTCAGCTTTACTCTTTGTCAAGACATGCCAAAGTGCTGAGTCACTAATAAAAGAAAAAA 
      :||:||:||||:|:|||||:||||:|||::||||||:|||||:|:||||||||||||||| 
  841 TTTTAGTTTTATTTTTTGTTAAGATATGTTAAAGTGTTGAGTTATTAATAAAAGAAAAAA 
      <<<<<<<<<<<<<<<<<<     IL6_3  >>>>>>>>>>>>>>>>>>>>>>>>>       
  901 AGAAAGTAAAGGAAGAGTGGTTCTGCTTCTTAGCGCTAGCCTCAATGACGACCTAAGCTG 
      ||||||||||||||||||||||:||:||:||||++:|||::|:|||||++|::||||:|| 
  901 AGAAAGTAAAGGAAGAGTGGTTTTGTTTTTTAGCGTTAGTTTTAATGACGATTTAAGTTG 
                                                                   
  961 CACTTTTCCCCCTAGTTGTGTCTTGCCATGCTAAAGGACGTCACATTGCACAATCTTAAT 
      :|:||||:::::|||||||||:|||::|||:|||||||++|:|:||||:|:|||:||||| 
  961 TATTTTTTTTTTTAGTTGTGTTTTGTTATGTTAAAGGACGTTATATTGTATAATTTTAAT 
                                                                   
 1021 AAGGTTTCCAATCAGCCCCACCCGCTCTGGCCCCACCCTCACCCTCCAACAAAGATTTAT 
      |||||||::|||:||::::|::++:|:|||::::|:::|:|:::|::||:|||||||||| 
 1021 AAGGTTTTTAATTAGTTTTATTCGTTTTGGTTTTATTTTTATTTTTTAATAAAGATTTAT 
                                                                   
 1081 CAAATGTGGGATTTTCCCATGAGTCTCAATATTAGAGTCTCAACCCCCAATAAATATAGG 
      :||||||||||||||:::||||||:|:|||||||||||:|:||:::::|||||||||||| 
 1081 TAAATGTGGGATTTTTTTATGAGTTTTAATATTAGAGTTTTAATTTTTAATAAATATAGG 
                      TSS                  SssPI 
 1141 ACTGGAGATGTCTGAGGCTCATTCTGCCCTCGAGCCCACCGGGAACGAAAGAGAAGCTCT 
      |:|||||||||:|||||:|:|||:||:::|++||:::|:++||||++|||||||||:|:| 
 1141 ATTGGAGATGTTTGAGGTTTATTTTGTTTTCGAGTTTATCGGGAACGAAAGAGAAGTTTT 
                                                                   
 1201 ATCTCCCCTCCAGGAGCCCAGCTATGA 
      ||:|::::|::|||||:::||:||||| 
 1201 ATTTTTTTTTTAGGAGTTTAGTTATGA 
   IL6_3  <<<<<<<<<<<<<<<<<<<<<<<< 
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5.5 MethylCap-Seq Binding Profiles within the FPR1, IL8, IL1B & CXCL10 Genes 
 
 
Naïve (N), low (T1, 1 ng/ml) and high-dose tolerized monocytes (T100, 100 ng/ml) were treated with 100 ng/ml 
LPS for 1.5 h and subjected to MethylCap-Seq. Binding profile of MBD-protein indicating methylated DNA within 
the genomic loci is displayed in the UCSC Genome Browser. 
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5.6 Transcription Factor Binding Sites (TFBSs) Identified by HOMER 
H3K9me2_T_no_AcX (DiffPeak for T100+L, no co-enrichment in activating histone modifications) 
Total Target Sequences = 11 558 
Rank Motif (known) Name P value 
% of Targets 
Sequences 
with Motif 
1 
 
YY1(Zf)/Promoter/Homer 1e-8 0.77% 
2 
 
MyoD(HLH)/Myotube-
MyoD-ChIP-Seq/Homer 1e-7 5.43% 
3 
 
Sp1(Zf)/Promoter/Homer 1e-5 0.81% 
4 
 
AP2gamma(AP2)/MCF7-
TFAP2c-ChIP-Seq/Homer 1e-4 5.64% 
5 
 
MyoG(HLH)/C2C12-
MyoG-ChIP-
Seq(GSE36024)/Homer 
1e-4 7.59% 
6 
 
HNF4a(NR/DR1)/HepG2-
HNF4a-ChIP-Seq/Homer 1e-4 4.38% 
7 
 
Ap4(HLH)/AML-Tfap4-
ChIP-
Seq(GSE45738)/Homer 
1e-4 9.16% 
8 
 
Tcf12(HLH)/GM12878-
Tcf12-ChIP-Seq/Homer 1e-4 6.92% 
9 
 
SCL/HPC7-Scl-ChIP-
Seq/Homer 1e-4 39.50% 
10 
 
MafA(bZIP)/Islet-MafA-
ChIP-
Seq(GSE30298)/Homer 
1e-3 6.17% 
11 
 
FXR(NR/IR1)/Liver-FXR-
ChIP-Seq/Homer 1e-3 3.30% 
12 
 
Myf5(bHLH)/GM-Myf5-
ChIP-
Seq(GSE24852)/Homer 
1e-2 4.96% 
13 
 
HEB?/mES-Nanog-ChIP-
Seq/Homer 1e-2 4.18% 
14 
 
ZBTB33/GM12878-
ZBTB33-ChIP-Seq/Homer 1e-2 0.13% 
15 
 
RUNX2(Runt)/PCa-
RUNX2-ChIP-
Seq(GSE33889)/Homer 
1e-2 8.52% 
16 
 
MafF(bZIP)/HepG2-MafF-
ChIP-
Seq(GSE31477)/Homer 
1e-2 4.26% 
17 
 
Smad3(MAD)/NPC-
Smad3-ChIP-
Seq(GSE36673)/Homer 
1e-2 26.84% 
18 
 
NFY(CCAAT)/Promoter/H
omer 1e-2 8.23% 
19 
 
NFkB-
p65(RHD)/GM12787-p65-
ChIP-Seq/Homer 
1e-2 4.67% 
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Rank Motif (known) Name P value 
% of Targets 
Sequences 
with Motif 
20 
 
Atoh1(bHLH)/Cerebellum-
Atoh1-ChIP-Seq/Homer 1e-2 8.53% 
21 
 
EKLF(Zf)/Erythrocyte-
Klf1-ChIP-
Seq(GSE20478)/Homer 
1e-2 1.81% 
22 
 
GFX(?)/Promoter/Homer 1e-2 0.09% 
23 
 
STAT6/Macrophage-
Stat6-ChIP-Seq/Homer 1e-2 6.09% 
24 
 
STAT6(Stat)/CD4-Stat6-
ChIP-Seq/Homer 1e-2 6.26% 
25 
 
AP-2alpha(AP2)/Hela-
AP2alpha-ChIP-
Seq/Homer 
1e-2 4.77% 
26 
 
Sox3(HMG)/NPC-Sox3-
ChIP-
Seq(GSE33059)/Homer 
1e-2 21.40% 
 
H3K27me3_T_no_meX (DiffPeak for T100+L, no co-enrichment in activating histone modifications) 
Total Target Sequences = 161 
Rank Motif (known) Name P value 
% of Targets 
Sequences 
with Motif 
1 
 
Tcf12(HLH)/GM12878-
Tcf12-ChIP-Seq/Homer 1e-2 13.04% 
2 
 
FOXA1:AR/LNCAP-AR-
ChIP-
Seq(GSE27824)/Homer 
1e-2 3.73% 
3 
 
NF1(CTF)/LNCAP-NF1-
ChIP-Seq/Homer 1e-2 6.83% 
 
H4K20me3_T_no_meX (DiffPeak for T100+L, no co-enrichment in activating histone modifications) 
Total Target Sequences = 2 758 
Rank Motif (known) Name P value 
% of Targets 
Sequences 
with Motif 
1 
 
Tbox:Smad/ESCd5-
Smad2_3-ChIP-
Seq(GSE29422)/Homer 
1e-9 3.30% 
2 
 
YY1(Zf)/Promoter/Homer 1e-8 1.34% 
3 
 
GFY-
Staf/Promoters/Homer 1e-8 0.98% 
4 
 
Foxa2(Forkhead)/Liver-
Foxa2-ChIP-Seq/Homer 1e-6 10.04% 
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Rank Motif (known) Name P value 
% of Targets 
Sequences 
with Motif 
5 
 
Sox3(HMG)/NPC-Sox3-
ChIP-
Seq(GSE33059)/Homer 
1e-5 20.91% 
6 
 
NFY(CCAAT)/Promoter/H
omer 1e-4 8.88% 
7 
 
Fox:Ebox(Forkhead:HLH)/
Panc1-Foxa2-ChIP-
Seq(GSE47459)/Homer 
1e-4 10.98% 
8 
 
HEB?/mES-Nanog-ChIP-
Seq/Homer 1e-3 6.92% 
9 
 
VDR(NR/DR3)/GM10855-
VDR+vitD-ChIP-
Seq/Homer 
1e-3 2.54% 
10 
 
SCL/HPC7-Scl-ChIP-
Seq/Homer 1e-3 46.10% 
11 
 
FOXA1(Forkhead)/MCF7-
FOXA1-ChIP-Seq/Homer 1e-3 12.90% 
12 
 
Sox2(HMG)/mES-Sox2-
ChIP-Seq/Homer 1e-3 9.89% 
13 
 
Smad3(MAD)/NPC-
Smad3-ChIP-
Seq(GSE36673)/Homer 
1e-3 30.81% 
14 
 
RUNX2(Runt)/PCa-
RUNX2-ChIP-
Seq(GSE33889)/Homer 
1e-3 9.53% 
15 
 
Sp1(Zf)/Promoter/Homer 1e-3 1.92% 
16 
 
RUNX-AML(Runt)/CD4+-
PolII-ChIP-Seq/Homer 1e-3 8.23% 
17 
 
NFkB-
p65(RHD)/GM12787-p65-
ChIP-Seq/Homer 
1e-2 5.94% 
18 
 
FOXP1(Forkhead)/H9-
FOXP1-ChIP-
Seq(GSE31006)/Homer 
1e-2 5.11% 
19 
 
AR-halfsite(NR)/LNCaP-
AR-ChIP-
Seq(GSE27824)/Homer 
1e-2 38.46% 
20 
 
RUNX1(Runt)/Jurkat-
RUNX1-ChIP-Seq/Homer 1e-2 11.34% 
21 
 
FOXA1(Forkhead)/LNCA
P-FOXA1-ChIP-
Seq(GSE27824)/Homer 
1e-2 14.90% 
22 
 
NFkB-p65-Rel(RHD)/LPS-
exp(GSE23622)/Homer 1e-2 0.80% 
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H3K27ac_T_no_RepX (DiffPeak for T100+L, no co-enrichment in repressive histone modifications) 
Total Target Sequences = 377 
Rank Motif (known) Name P value 
% of Targets 
Sequences 
with Motif 
1 
 
Atoh1(bHLH)/Cerebellum-
Atoh1-ChIP-Seq/Homer 1e-3 15.92% 
2 
 
CEBP:AP1(bZIP)/ThioMa
c-CEBPb-ChIP-
Seq(GSE21512)/Homer 
1e-2 10.88% 
 
H4ac_T_no_RepX (DiffPeak for T100+L, no co-enrichment in repressive histone modifications) 
Total Target Sequences = 236 
Rank Motif (known) Name P value 
% of Targets 
Sequences 
with Motif 
1 
 
Tcf3(HMG)/mES-Tcf3-
ChIP-Seq/Homer 1e-2 5.08% 
 
 
Overlap in several histone modifications 
 
Combined activating histone modifications in LPS-tolerant monocytes 
H3K27acT_H4acT_no_RepX 
Total Target Sequences = 32 
Rank Motif (known) Name P value 
% of Targets 
Sequences 
with Motif 
1 
 
NFAT:AP1/Jurkat-
NFATC1-ChIP-
Seq/Homer 
1e-2 12.50% 
 
Combined repressive histone modifications in LPS-tolerant monocytes 
H3K9me2T_H4K20me3T_no_AcX 
Total Target Sequences = 350 
Rank Motif (known) Name P value 
% of Targets 
Sequences 
with Motif 
1 
 
Tbox:Smad/ESCd5-
Smad2_3-ChIP-
Seq(GSE29422)/Homer 
1e-2 4.29% 
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5.7 Gene Ontology (GO) Enrichment Analysis by DAVID 
BIOLOGICAL PROCESS (BP)  Histone M
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egions, TSS ± 10 kb): H
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1.07E-14 
2.58E-02 
3.20E-05 
3.80E-04 
1.53E-03 
1.11E-03 
9.80E-04 
4.89E-04 
3.60E-02 
4.63E-02 
P value 
O
PR
M
1, O
R
5D
14, O
R
2T1, O
R
5L1, O
R
5D
16, O
R
5J2, O
R
5L2, LPAR
3, O
R
4C
3, H
C
R
TR
1, O
R
4C
13, O
R
4C
15, O
R
4S2, O
R
4C
12, O
R
4C
11, N
PFFR
2, O
R
5F1, O
R
5AN
1, O
R
2M
7, 
O
R
5P3, O
R
10S1, O
R
5M
11, O
R
10AG
1, O
R
5M
8, O
R
5T3, O
R
51I2, O
R
3A3, O
R
5AK2, O
R
4K15, G
R
M
7, O
R
4K13, O
R
6Q
1, O
R
4C
46 
PC
D
H
B6, C
D
H
18, PC
D
H
B3, PC
D
H
A5, PC
D
H
B4, PC
D
H
A10, PC
D
H
G
A3, C
D
H
23 
O
R
5D
14, O
R
2T1, O
R
5L1, O
R
5D
16, O
R
5J2, O
R
5L2, PR
KG
2, O
R
4C
3, O
R
4C
13, O
R
4C
15, O
R
4S2, O
R
9I1, O
R
8K3, O
R
4C
12, O
R
4C
11, O
R
7C
1, O
R
5F1, O
R
5AN
1, O
R
2M
7, 
O
R
5P3, O
R
10S1, O
R
5M
11, O
R
10AG
1, O
R
5M
8, O
R
5T3, O
R
51I2, O
R
5AK2, O
R
3A3, O
R
4K15, O
R
8J1, O
R
4K13, O
R
8J3, O
R
8H
1, O
R
6Q
1, O
R
8D
4, O
R
4C
46 
G
K2, G
K5 
TR
IO
BP, M
YR
IP, C
ALD
1 
PTG
R
1, AD
H
6, AD
H
1A 
O
R
5D
14, O
R
2T1, O
R
5L1, O
R
5D
16, O
R
5J2, O
R
5L2, O
R
4C
3, O
R
4C
13, O
R
4C
15, O
R
9I1, O
R
4S2, O
R
8K3, O
R
4C
12, O
R
4C
11, O
R
7C
1, O
R
5F1, O
R
5AN
1, O
R
2M
7, O
R
5P3, 
O
R
10S1, O
R
5M
11, O
R
10AG
1, O
R
5M
8, O
R
5T3, O
R
51I2, O
R
5AK2, O
R
3A3, O
R
4K15, O
R
8J1, O
R
4K13, O
R
8J3, O
R
8H
1, O
R
6Q
1, O
R
8D
4, O
R
4C
46 
ZN
F208, ZN
F582, ZN
F17, ZN
F534, ZN
F80, ZN
F155, ZN
F676, ZN
F16, ZN
F578, R
ABG
EF1, R
AR
A, ZN
F732, KD
M
5A, D
ED
D
2, ZN
F43, C
5O
R
F51, ZN
F45, ZN
F547, SP100, 
ZN
F285, ZN
F479, ZN
F354C
, ZN
F812, ZN
F790, ZN
F502, ZFP28, ZN
F549, PR
D
M
8, N
U
C
B1, ZFP82, ZN
F134, ZN
F716, ZSC
AN
18, ZN
F98, ZN
F483, VEN
TXP7, SO
X5, ZN
F35, 
ZN
F660, ZN
F226, ZN
F599, ZN
F569, ZFP3, ZN
F221, ZSC
AN
1, VAV1, PKN
O
X1, ZN
F419, TR
PS1, ZIK1 
ZN
F208, ZN
F582, ZN
F17, ZN
F534, ZN
F80, ZN
F155, ZN
F676, AD
H
1A, ZN
F16, ZN
F578, R
ABG
EF1, R
AR
A, ZN
F732, R
N
F148, KD
M
5A, ZN
F43, ZN
F45, ZN
F547, SP100, 
ZN
F285, AD
AM
TS20, ZN
F479, ZN
F812, ZN
F354C
, ZN
F790, ZN
F502, ZFP28, ZN
F549, PR
D
M
8, ZFP82, M
YR
IP, R
N
F133, PR
D
M
9, N
APEPLD
, ZN
F134, ZN
F716, ZSC
AN
18, 
ZN
F98, ZN
F483, IN
G
4, M
KR
N
9P, AD
H
6, ZN
F35, ZN
F365, ZN
F660, M
TM
R
3, ZN
F226, ZN
F599, TEC
, PTG
R
1, ZN
F569, ZFP3, ZN
F221, ZSC
AN
1, C
R
YZ, U
2AF1L4, VAV1, 
ZN
F585B, TEX13A, ZN
F419, TR
PS1, ZIK1 
ZN
F208, ZN
F582, ZN
F17, ZN
F534, ZN
F80, ZN
F155, ZN
F676, AD
H
1A, ZN
F16, ZN
F578, R
ABG
EF1, R
AR
A, ZN
F732, R
N
F148, KD
M
5A, ZN
F43, ZN
F45, SP100, ZN
F547, 
ZN
F285, AD
AM
TS20, ZN
F479, ZN
F812, ZN
F354C
, ZN
F790, ZN
F502, ZFP28, ZN
F549, PR
D
M
8, ZFP82, PPM
1G
, M
YR
IP, R
N
F133, PR
D
M
9, N
APEPLD
, ZN
F134, ATP2C
1, 
ZN
F716, ZSC
AN
18, ZN
F98, ZN
F483, EN
O
X1, IN
G
4, M
KR
N
9P, AD
H
6, ZN
F35, ZN
F365, ZN
F660, M
TM
R
3, ZN
F226, ZN
F599, TEC
, PTG
R
1, C
YP2C
9, ZN
F569, ID
O
2, ZFP3, 
ZN
F221, ZSC
AN
1, C
R
YZ, U
2AF1L4, VAV1, ZN
F585B, TEX13A, ZN
F419, TR
PS1, ZIK1 
ZN
F208, ZN
F582, SLC
9A8, ZN
F17, ZN
F534, ZAK, ZN
F80, PC
D
H
A5, ZN
F676, ZN
F155, AD
H
1A, ZN
F16, PC
D
H
G
A3, R
ABG
EF1, ZN
F578, TR
PV4, R
AR
A, ZN
F732, KD
M
5A, 
R
N
F148, C
D
H
23, ZN
F43, ZN
F45, SP100, ZN
F547, ZN
F285, PC
D
H
B6, ZN
F479, AD
AM
TS20, ZN
F812, ZN
F354C
, PC
D
H
B3, PC
D
H
B4, ZN
F790, ZN
F502, ZFP28, ZN
F549, 
N
U
C
B1, PR
D
M
8, PITPN
M
1, ZFP82, PPM
1G
, M
YR
IP, R
N
F133, PR
D
M
9, N
APEPLD
, ZN
F134, ATP2C
1, G
R
M
7, ZN
F716, ZSC
AN
18, ZN
F98, ZN
F483, EN
O
X1, IN
G
4, KC
N
A2, 
C
AC
N
B2, AD
H
6, M
KR
N
9P, ZN
F35, ZN
F365, ZN
F660, M
TM
R
3, ZN
F226, PC
D
H
A10, ZN
F599, TEC
, AC
SL5, PTG
R
1, TR
PC
6, C
YP2C
9, ZN
F569, FSC
B, ID
O
2, ZFP3, ZN
F221, 
C
R
YZ, ZSC
AN
1, U
2AF1L4, VAV1, ZN
F585B, TEX13A, ZN
F419, EFH
B, C
D
H
18, TR
PS1, EM
R
3, ZIK1, TSSK6 
ZN
F208, ZN
F582, SLC
9A8, ZN
F17, ZN
F534, ZAK, ZN
F80, PC
D
H
A5, ZN
F676, ZN
F155, AD
H
1A, ZN
F16, PC
D
H
G
A3, R
ABG
EF1, ZN
F578, TR
PV4, R
AR
A, ZN
F732, KD
M
5A, 
R
N
F148, C
D
H
23, ZN
F43, ZN
F45, SP100, ZN
F547, ZN
F285, PC
D
H
B6, ZN
F479, AD
AM
TS20, ZN
F812, ZN
F354C
, PC
D
H
B3, PC
D
H
B4, ZN
F790, ZN
F502, ZFP28, ZN
F549, 
N
U
C
B1, PR
D
M
8, PITPN
M
1, ZFP82, PPM
1G
, M
YR
IP, R
N
F133, PR
D
M
9, N
APEPLD
, ZN
F134, ATP2C
1, G
R
M
7, ZN
F716, ZSC
AN
18, ZN
F98, ZN
F483, EN
O
X1, IN
G
4, KC
N
A2, 
C
AC
N
B2, AD
H
6, M
KR
N
9P, ZN
F35, ZN
F365, ZN
F660, M
TM
R
3, ZN
F226, PC
D
H
A10, ZN
F599, TEC
, AC
SL5, PTG
R
1, TR
PC
6, C
YP2C
9, ZN
F569, FSC
B, ID
O
2, ZFP3, ZN
F221, 
C
R
YZ, ZSC
AN
1, U
2AF1L4, VAV1, ZN
F585B, TEX13A, ZN
F419, EFH
B, C
D
H
18, TR
PS1, EM
R
3, ZIK1, TSSK6 
ZN
F208, ZN
F582, SLC
9A8, ZN
F17, ZN
F534, ZAK, ZN
F80, PC
D
H
A5, ZN
F676, ZN
F155, AD
H
1A, ZN
F16, PC
D
H
G
A3, R
ABG
EF1, ZN
F578, TR
PV4, R
AR
A, ZN
F732, KD
M
5A, 
R
N
F148, C
D
H
23, ZN
F43, G
ABR
G
1, G
ABR
G
2, ZN
F45, SP100, ZN
F547, ZN
F285, PC
D
H
B6, ZN
F479, AD
AM
TS20, ZN
F812, PC
D
H
B3, ZN
F354C
, PC
D
H
B4, ZN
F790, ZN
F502, 
ZFP28, ZN
F549, N
U
C
B1, PR
D
M
8, PITPN
M
1, ZFP82, PPM
1G
, M
YR
IP, R
N
F133, PR
D
M
9, N
APE
PLD
, ZN
F134, ATP2C
1, G
R
M
7, ZN
F716, ZSC
AN
18, ZN
F98, ZN
F483, EN
O
X1, 
IN
G
4, KC
N
A2, C
AC
N
B2, AD
H
6, M
KR
N
9P, ZN
F35, ZN
F365, ZN
F660, M
TM
R
3, ZN
F226, PC
D
H
A10, ZN
F599, TEC
, AC
SL5, PTG
R
1, TR
PC
6, C
YP2C
9, ZN
F569, FSC
B, ID
O
2, 
ZFP3, ZN
F221, C
R
YZ, ZSC
AN
1, U
2AF1L4, VAV1, ZN
F585B, TEX13A, ZN
F419, EFH
B, C
D
H
18, TR
PS1, EM
R
3, ZIK1, TSSK6 
ATP2C
1, PC
D
H
B6, PC
D
H
B3, PC
D
H
B4, C
D
H
23 
G
R
IA1, G
R
M
7, TM
O
D
2, PTN
, IL1B, SH
C
3 
C
D
48, PKN
O
X1, R
PL22, M
S4A1, KIR
2D
S4, VAV1, H
SH
2D
, S
YK 
G
enes 
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PATH
W
AY
 
M
F BIOLOGICAL PROCESS 
 
H
istone M
odifications (A
nnotated G
enom
ic R
egions, TSS ± 10 kb): H
4K
20m
e3_T_no_A
cX (Enrichm
ent in H
4K
20m
e3 in endotoxin tolerant m
onocytes; no co-localization w
ith activating histone m
odifications) 
BIOLOGICAL PROCESS  
H
istone M
odifications (A
nnotated G
enom
ic R
egions, TSS ± 10 kb): H
3K
27m
e3_T_no_A
cX (Enrichm
ent in H
3K
27m
e3 in endotoxin tolerant m
onocytes; no co-localization w
ith activating histone m
odifications) 
 
R
EAC
T_14797:Signaling by G
PC
R
 
hsa04740:O
lfactory transduction 
G
O
:0019899~enzym
e binding 
G
O
:0060179~m
ale m
ating behavior 
G
O
:0007618~m
ating 
G
O
:0019098~reproductive behavior 
G
O
:0007617~m
ating behavior 
G
O
:0042108~positive regulation of cytokine biosynthetic 
process 
G
O
:0017157~regulation of exocytosis 
G
O
:0034976~response to endoplasm
ic reticulum
 stress 
G
O
:0045165~cell fate com
m
itm
ent 
G
O
:0032940~secretion by cell 
G
O
:0001817~regulation of cytokine production 
G
O
:0051046~regulation of secretion 
G
O
:0060341~regulation of cellular localization 
G
O
:0046903~secretion 
G
O
:0006954~inflam
m
atory response 
G
O
:0006952~defense response 
G
O
:0010941~regulation of cell death 
G
O
:0043067~regulation of program
m
ed cell death 
G
O
:0042981~regulation of apoptosis 
Term 
G
O
:0001508~regulation of action potential 
G
O
:0019226~transm
ission of nerve im
pulse 
G
O
:0034330~cell junction organization 
G
O
:0019228~regulation of action potential in neuron 
G
O
:0032231~regulation of actin filam
ent bundle form
ation 
G
O
:0050877~neurological system
 process 
G
O
:0051492~regulation of stress fiber form
ation 
G
O
:0032233~positive regulation of actin filam
ent bundle 
 
Term 
15 
11 
13 
2 3 3 3 4 4 4 6 7 7 8 9 10 11 15 18 18 18 Count 
2 3 2 2 2 6 2 2 Count 
6.33 
4.64 
5.49 
0.84 
1.27 
1.27 
1.27 
1.69 
1.69 
1.69 
2.53 
2.95 
2.95 
3.38 
3.80 
4.22 
4.64 
6.33 
7.59 
7.59 
7.59 
% 6.90 
10.34 
6.90 
6.90 
6.90 
20.69 
6.90 
6.90 
% 
4.12E-02 
4.28E-02 
3.62E-02 
3.77E-02 
4.58E-02 
2.15E-02 
1.32E-02 
2.30E-02 
9.05E-03 
9.05E-03 
3.23E-02 
4.88E-02 
2.81E-02 
1.47E-02 
1.40E-02 
1.46E-02 
8.69E-03 
2.52E-02 
3.04E-02 
2.94E-02 
2.71E-02 
P value 
9.59E-02 
9.34E-02 
8.10E-02 
7.69E-02 
3.06E-02 
2.83E-02 
2.77E-02 
2.05E-02 
P value 
O
PR
M
1, O
R
2B6, O
R
5M
10, O
XT, O
R
1L6, PTH
1R
, FPR
2, O
R
10H
4, O
R
4C
13, O
R
4S2, O
R
4Q
3, XC
R
1, O
R
4C
46, O
R
10P1, M
TN
R
1A 
O
R
2B6, O
R
4C
13, O
R
2A5, O
R
4S2, O
R
5M
10, O
R
1L6, C
ALM
3, O
R
4Q
3, O
R
10H
4, O
R
10P1, O
R
4C
46 
D
M
XL2, H
M
O
X1, AKAP8L, C
BX4, R
PH
3AL, C
STB, SER
PIN
A1, SKIL, C
D
H
2, AKA
P11, PTPR
N
, C
O
TL1, FG
D
3 
O
XT, G
R
IN
1 
O
XT, G
R
IN
1, M
TN
R
1A 
O
XT, G
R
IN
1, M
TN
R
1A 
O
XT, G
R
IN
1, M
TN
R
1A 
H
M
O
X1, TLR
1, IL1A, SYK 
H
M
O
X1, R
PH
3AL, TR
AF7, SYK 
C
O
L4A3BP, EIF2AK2, PPP1R
15A, O
S9 
ISL2, H
O
XA2, D
LX1, C
D
O
N
, D
SC
AM
L1, PR
D
M
1 
C
AD
PS, A
R
FG
AP3, FAM
3B, R
PH
3AL, EXO
C
3, EXO
C
1, SYK
 
M
YD
88, H
M
O
X1, G
ATA4, TLR
1, C
ASP1, IL1A, SYK
 
H
M
O
X1, O
XT, R
PH
3AL, TR
AF7, C
ASP1, N
M
U
, IL1A, SYK
 
H
M
O
X1, O
XT, R
PH
3AL, C
ALM
3, TR
AF7, C
ASP1, N
M
U
, IL1A, SYK
 
C
AD
PS, A
R
FG
AP3, H
M
O
X1, O
XT, FAM
3B, R
PH
3AL, EXO
C
3, N
M
U
, EXO
C
1, SY
K 
N
M
I, M
YD
88, H
M
O
X1, TLR
1, C
H
ST2, PR
D
X2, SER
PIN
A1, FPR
2, XC
R
1, O
R
M
2, IL1A 
IL1R
1, N
M
I, D
EFB125, TLR
1, C
H
ST2, PR
D
X2, FPR
2, C
O
TL1, M
YD
88, SAR
M
1, H
M
O
X1, SER
PIN
A1, XC
R
1, O
R
M
2, IL1A 
C
O
L18A1, PH
B, G
R
IN
1, C
BX4, AC
TN
1, PR
D
X2, D
LX1, M
YD
88, SAR
M
1, N
M
E3, H
M
O
X1, C
STB, FAIM
, TR
AF7, C
ASP1, IL1A, FG
D
3, FG
F4 
C
O
L18A1, PH
B, G
R
IN
1, C
BX4, AC
TN
1, PR
D
X2, D
LX1, M
YD
88, SAR
M
1, N
M
E3, H
M
O
X1, C
STB, FAIM
, TR
AF7, C
ASP1, IL1A, FG
D
3, FG
F4 
C
O
L18A1, PH
B, G
R
IN
1, C
BX4, AC
TN
1, PR
D
X2, D
LX1, M
YD
88, SAR
M
1, N
M
E3, H
M
O
X1, C
STB, FAIM
, TR
AF7, C
ASP1, IL1A, FG
D
3, FG
F4 
G
enes 
PR
X, C
D
9 
PR
X, C
D
9, KC
N
Q
3 
C
D
9, SM
AD
3 
PR
X, C
D
9 
SM
AD
3, SYN
PO 
PR
X, C
D
9, O
R
10A3, KC
N
Q
3, O
R
13H
1, O
R
4N
5 
SM
AD
3, SYN
PO 
SM
AD
3, SYN
PO 
G
enes 
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PATH
W
AY
 
MOLECULAR 
FUNCTION 
BIOLOGICAL 
PROCESS 
 
H
istone M
odifications (A
nnotated G
enom
ic R
egions, TSS ± 10 kb): H
3K
27ac_T_no_R
epX (Enrichm
ent in H
3K
27ac in endotoxin tolerant m
onocytes; no co-localization w
ith repressive histone m
odifications) 
M
F  
H
istone M
odifications (A
nnotated G
enom
ic R
egions, TSS ± 10 kb): H
4ac_T_no_R
epX (Enrichm
ent in H
4ac in endotoxin tolerant m
onocytes; no co-localization w
ith repressive histone m
odifications) 
 
hsa04060:C
ytokine-cytokine receptor interaction 
G
O
:0046870~cadm
ium
 ion binding 
G
O
:0005507~copper ion binding 
G
O
:0008083~grow
th factor activity 
G
O
:0005509~calcium
 ion binding 
G
O
:0000041~transition m
etal ion transport 
G
O
:0006979~response to oxidative stress 
G
O
:0032101~regulation of response to external stim
ulus 
G
O
:0006955~im
m
une response 
Term 
G
O
:0005507~copper ion binding 
G
O
:0046870~cadm
ium
 ion binding 
Term 
5 2 3 5 10 3 4 4 10 Count 
4 4 Count 
5.75 
2.30 
3.45 
5.75 
11.49 
3.46 
4.60 
4.60 
11.49 
% 1.62 
1.62 
% 
4.21E-02 
4.45E-02 
3.92E-02 
6.11E-03 
2.20E-02 
4.83E-02 
4.77E-02 
4.42E-02 
6.70E-03 
P value 
2.06E-04 
5.03E-07 
P value 
C
XC
L1, TN
FR
SF6B, C
SF3, IL2R
A, C
XC
L5 
M
T1L, M
T1E, M
T1F 
STEAP3, M
T1L, M
T1E, M
T1F 
C
XC
L1, C
SF3, G
PI, W
ISP3, N
D
P 
FKBP8, R
AB11FIP3, BEST1, M
ASP2, TG
M
3, TR
PV6, M
M
P14, C
D
H
4, SYT17, TR
PM
2 
STEAP3, SLC
39A11, TR
PM
2 
D
H
R
S2, PTG
S2, M
M
P14, TR
PM
2 
M
YO
D
1, N
PC
1, IL2R
A, PTG
S2 
C
XC
L1, C
SF3, G
PI, IL2R
A, C
XC
L5, M
ASP2, LILR
B4, M
S4A1, FC
G
R
T, PAG
1 
G
enes 
M
T1L, M
T1M
, M
T1A, M
T1G 
M
T1L, M
T1M
, M
T1A, M
T1G 
G
enes 
 
124 
Appendix 
 
 
MOLECULAR FUNCTION BIOLOGICAL FUNCTION  DN
A
 M
ethylation (A
nnotated G
enom
ic R
egions (TSS ± 10 kb)): Enrichm
ent in D
N
A
 m
ethylation in endotoxin tolerant m
onocytes 
G
O
:0008066~glutam
ate receptor activity 
G
O
:0005234~extracellular-glutam
ate-gated ion channel activity 
G
O
:0004970~ionotropic glutam
ate receptor activity 
G
O
:0003777~m
icrotubule m
otor activity 
G
O
:0004714~transm
em
brane receptor protein tyrosine kinase activity 
G
O
:0032403~protein com
plex binding 
G
O
:0004713~protein tyrosine kinase activity 
G
O
:0004713~protein tyrosine kinase activity 
G
O
:0019904~protein dom
ain specific binding 
G
O
:0004672~protein kinase activity 
G
O
:0032559~adenyl ribonucleotide binding 
G
O
:0005524~A
TP
 binding 
G
O
:0001882~nucleoside binding 
G
O
:0001883~purine nucleoside binding 
G
O
:0030554~adenyl nucleotide binding 
G
O
:0032555~purine ribonucleotide binding 
G
O
:0017076~purine nucleotide binding 
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Appendix 
 
BIOLOGICAL FUNCTION 
 m
R
N
A
 Expression: G
enes U
p-R
egulated in Endotoxin Tolerance  
G
O
:0007243~protein 
kinase cascade  
G
O
:0040012~regulation of 
locom
otion 
G
O
:0010033~response to 
organic substance  
G
O
:0000271~polysaccharid
e biosynthetic process  
G
O
:0006816~calcium
 ion 
transport  
G
O
:0000165~M
A
PK
KK
 
cascade  
G
O
:0006006~glucose 
m
etabolic process  
G
O
:0007242~intracellular 
signaling cascade  
G
O
:0015674~di-, tri-valent 
inorganic cation transport  
G
O
:0006909~phagocytosis 
G
O
:0009611~response to 
w
ounding  
G
O
:0006468~protein am
ino 
acid phosphorylation  
G
O
:0032318~regulation of 
R
as G
TP
ase activity 
G
O
:0019318~hexose 
m
etabolic process  
G
O
:0046578~regulation of 
R
as protein signal 
transduction 
G
O
:0016051~carbohydrate 
 
 
G
O
:0005996~m
onosacchar
ide m
etabolic process  
G
O
:0051056~regulation of 
sm
all G
TPase m
ediated 
signal transduction  
G
O
:0010324~m
em
brane 
invagination  
G
O
:0006897~endocytosis 
Term
 
54 33 93 13 27 33 29 151 
32 14 74 90 23 35 39 25 41 45 41 41 Count 
3.01 
1.84 
5.19 
0.73 
1.51 
1.84 
1.62 
8.43 
1.79 
0.78 
4.13 
5.02 
1.28 
1.95 
2.18 
1.40 
2.29 
2.51 
2.29 
2.29 
%
 
6.64E
-04 
6.13E
-04 
5.68E
-04 
5.38E
-04 
4.54E
-04 
2.83E
-04 
2.82E
-04 
2.80E
-04 
2.78E
-04 
2.70E
-04 
2.39E
-04 
1.59E
-04 
1.49E
-04 
1.29E
-04 
3.27E
-05 
2.78E
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2.04E
-05 
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